Määrus kehtestatakse „Ravikindlustuse seaduse“ paragrahvi 43 lõike 1 alusel.
§ 1. Reguleerimisala
Määrus kehtestab Eesti Haigekassa ravimite loetelu, mis on toodud käesoleva määruse lisas.
§ 2. Ravimite piirhind
Kuni ravimite piirhinna kehtestamiseni loetakse piirhinnaks jaemüügi hind.
§ 3. [käesolevast tekstist välja jäetud]
| Ravimikood | Toimeained | ATC kood | Ravim | Müügiloa hoidja | 50% soodustus | Märkused | 75% soodustus | Diagnoosid | Märkused | 100% soodustus | Diagnoosid | Märkused |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1011430 | adapaleen | D10AD03 | DIFFERIN 0,1% CREAM kreem 0,1% 30g | GALDERMA INTERNATIONAL | 50% | |||||||
| 1062492 | adapaleen | D10AD03 | DIFFERIN 0,1% CREAM kreem 0,1% 5g | GALDERMA INTERNATIONAL | 50% | |||||||
| 1011429 | adapaleen | D10AD03 | DIFFERIN 0,1% GEL geel 0,1% 30g | GALDERMA INTERNATIONAL | 50% | |||||||
| 1062504 | adapaleen | D10AD03 | DIFFERIN 0,1% GEL geel 0,1% 5g | GALDERMA INTERNATIONAL | 50% | |||||||
| 1011272 | alendroonhape | M05BA04 | FOSAMAX ÜKS KORD NÄDALAS 70MG tablett 70mg N2 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1074350 | alendroonhape | M05BA04 | FOSAMAX ÜKS KORD NÄDALAS 70 MG tablett 70mg N4 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1074349 | alendroonhape | M05BA04 | FOSAMAX tablett 10mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | M80* | *rev ortopeedil alla 16- aastastele lastele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1213344 [RTL 2006, 26, 482 – jõust. 1.04.2006] | alendroonhape+ kolekaltsiferool | M05XX80 | FOSAVANCE 70 mg/70 mcg tablett N2 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1213355 [RTL 2006, 26, 482 – jõust. 1.04.2006] | alendroonhape+ kolekaltsiferool | M05XX80 | FOSAVANCE 70 mg/70 mcg tablett N4 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1083899 [RTL 2006, 26, 482 – jõust. 1.04.2006] | alfakaltsidool | A11CC03 | ALPHA D3-TEVA kapsel 0,25mcg N30 | TEVA PHARMACEUTICAL INDUSTRIES Ltd | 50% | 75% | N18* | *rv nefroloogil ja pediaatril, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1031038 [RTL 2006, 26, 482 – jõust. 1.04.2006] | alfakaltsidool | A11CC03 | ALPHA D3-TEVA kapsel 1mcg N10 | TEVA PHARMACEUTICAL INDUSTRIES Ltd | 50% | 75% | N18* | *rv nefroloogil ja pediaatril, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1111341 | alfa-lipoehape | A16AX01 | THIOCTACID 600 HR kaetud tablett 600 mg N30 | VIATRIS GmbH & Co.KG | 50% | |||||||
| 1011632 | alfusosiin | G04CA01 | XATRAL SR retardtablett 10mg N10 | SANOFI- SYNTHELABO FRANCE | 50% | |||||||
| 1064247 | alfusosiin | G04CA01 | XATRAL SR retardtablett 10mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | |||||||
| 1001686 | allopurinool | M04AA01 | ALLOPURINOL NYCOMED tablett 300mg N50 | Nycomed Sefa AS | 50% | 75% | M10; N20- N23 | |||||
| 1090044 | allopurinool | M04AA01 | ALLOPURINOL ALPHARMA TABLETS 100 MG tablett 100mg N50 | ALPHARMA Limited | 50% | 75% | M10; N20- N23 | |||||
| 1001619 | allopurinool | M04AA01 | ALLOPURINOL NYCOMED tablett 100mg N50 | Nycomed Sefa AS | 50% | 75% | M10; N20- N23 | |||||
| 1039531 | alumiiniumkloriid-hüdroksiid kompleks | A12CX81 | PHOSPHONORM kapsel 300mg N100 | MEDICE Chem.- pharm. Fabrik Pütter GmbH & Co. | 50% | |||||||
| 1064517 | amantadiin | N04BB01 | AMANTADIN- RATIOPHARM TABLETTEN tablett 100mg N100 | ratiopharm GmbH | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1005185 | amantadiin | N04BB01 | PK-MERZ TABLETS tablett 100mg N30 | Merz Pharmaceuticals GmbH | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1064472 | amantadiin | N04BB01 | PK-MERZ TABLETS tablett 100mg N90 | Merz Pharmaceuticals GmbH | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1084238 | amiodaroon | C01BD01 | AMIODARONE ALPHARMA TABLETS 200 MG tablett 200 mg N30 | ALPHARMA Limited | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | ||||
| 1016244 | amiodaroon | C01BD01 | CORDARONE 200 MG tablett 200mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | ||||
| 1044616 | amiodaroon | C01BD01 | AMIOKORDIN tablett 200 mg N60 | KRKA, d.d. | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | ||||
| 1012093 | amisulpiriid | N05AL05 | SOLIAN tablett 100mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1067497 | amisulpiriid | N05AL05 | SOLIAN tablett 200mg N150 | SANOFI- SYNTHELABO FRANCE | 50% | |||||||
| 1041141 | amisulpiriid | N05AL05 | SOLIAN tablett 200mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1012105 | amisulpiriid | N05AL05 | SOLIAN tablett 400mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1041130 | amisulpiriid | N05AL05 | SOLIAN tablett 50mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | |||||||
| 1008683 | amitriptüliin | N06AA09 | AMITRIPTYLIN NYCOMED 25 MG tablett 25mg N50 | Nycomed Sefa AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1005848 | amitriptüliin | N06AA09 | SAROTEN RETARD retardkapsel 50mg N100 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1107391 | amitriptüliin | N06AA09 | AMITRIPTILINS-GRINDEKS 10 MG tablett 10mg N50 | Grindeks | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1005860 | amitriptüliin | N06AA09 | SAROTEN tablett 10mg N100 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1012475 | amitriptüliin | N06AA09 | AMITRIPTILINS-GRINDEKS 25 MG tablett 25mg N50 | Grindeks | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1008661 | amitriptüliin | N06AA09 | AMITRIPTYLIN NYCOMED 10 MG tablett 10mg N50 | Nycomed Sefa AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1068634 | amitriptüliin | N06AA09 | AMITRIPTYLIN NYCOMED 25 MG tablett 25mg N100 | Nycomed Sefa AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- | *rev psühhiaatril | ||||
| 3); F60.3; (F70-F79)* | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1005893 | amitriptüliin | N06AA09 | SAROTEN tablett 25mg N100 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1157105 [RTL 2006, 26, 482 – jõust. 1.04.2006] | amlodipiin | C08CA01 | AMLODIPIN ACTAVIS tablett 10 mg N30 | Actavis Nordic A/S | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1157037 [RTL 2006, 26, 482 – jõust. 1.04.2006] | amlodipiin | C08CA01 | AMLODIPIN ACTAVIS tablett 5 mg N30 | Actavis Nordic A/S | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1012363 | amlodipiin | C08CA01 | NORMODIPINE tablett 10mg N30 | GEDEON RICHTER Ltd. | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1012352 | amlodipiin | C08CA01 | NORMODIPINE tablett 5mg N30 | GEDEON RICHTER Ltd. | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1018527 | amlodipiin | C08CA01 | NORVASC tablett 10mg N30 | Pfizer H.C.P. Corporation | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1018538 | amlodipiin | C08CA01 | NORVASC tablett 5mg N30 | Pfizer H.C.P. Corporation | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1087871 | amlodipiin | C08CA01 | AMLOCARD 5 tablett 5mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1087905 | amlodipiin | C08CA01 | AMLOCARD 10 tablett 10mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1109887 | amlodipiin | C08CA01 | AGEN tablett 5 mg N30 | Leciva a.s. | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1109900 | amlodipiin | C08CA01 | AGEN tablett 10 mg N30 | Leciva a.s. | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1109775 | amlodipiin | C08CA01 | AMLODIPIN-RATIOPHARM 5 MG tablett 5 mg N30 | ratiopharm GmbH | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1147003 | amlodipiin | C08CA01 | AMLODIPIN-RATIOPHARM 10 MG tablett 10 mg N30 | ratiopharm GmbH | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1122961 | amlodipiin | C08CA01 | HIPRES tablett 5 mg N30 | KRKA d.d. | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1122972 | amlodipiin | C08CA01 | HIPRES tablett 10 mg N30 | KRKA d.d. | 50% | 75% | (I10-I13); I15; I20 | |||||
| 1008919 | amoksitsilliin | J01CA04 | AMOXICILLIN- RATIOPHARM 1000 tablett 1000mg N10 | ratiopharm GmbH | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1000382 | amoksitsilliin | J01CA04 | AMOXICILLIN- RATIOPHARM 250 TS suspensioonigraanulid 50mgml 100ml | ratiopharm GmbH | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1000551 | amoksitsilliin | J01CA04 | AMOXICILLIN- RATIOPHARM 500 tablett 500mg N10 | ratiopharm GmbH | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1000450 | amoksitsilliin | J01CA04 | AMOXICILLIN- RATIOPHARM 750 tablett 750mg N10 | ratiopharm GmbH | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1022487 | amoksitsilliin | J01CA04 | BACTOX 125MG/5ML pulber peroraalseks suspensiooniks 25mgml 60ml | LABORATOIRE INNOTECH INTERNATIONAL | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1022498 | amoksitsilliin | J01CA04 | BACTOX 250MG/5ML pulber peroraalseks suspensiooniks 50mgml 60ml | LABORATOIRE INNOTECH INTERNATIONAL | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1088872 | amoksitsilliin | J01CA04 | BACTOX 500MG/5ML pulber peroraalseks suspensiooniks 100mgml 60ml | LABORATOIRE INNOTECH INTERNATIONAL | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1042939 [RTL 2006, 26, 482 – jõust. 1.04.2006] | amoksitsilliin | J01CA04 | BACTOX pulber suspensiooniks 1g N6 | LABORATOIRE INNOTECH INTERNATIONAL | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1020654 | amoksitsilliin | J01CA04 | FLEMOXIN SOLUTAB lahustuv tablett 250mg N14 | YAMANOUCHI EUROPE B.V. | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1066452 | amoksitsilliin | J01CA04 | FLEMOXIN SOLUTAB lahustuv tablett 250mg N20 | YAMANOUCHI EUROPE B.V. | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1020643 | amoksitsilliin | J01CA04 | FLEMOXIN SOLUTAB lahustuv tablett 500mg N14 | YAMANOUCHI EUROPE B.V. | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1066429 | amoksitsilliin | J01CA04 | FLEMOXIN SOLUTAB lahustuv tablett 500mg N20 | YAMANOUCHI EUROPE B.V. | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1066430 | amoksitsilliin | J01CA04 | FLEMOXIN SOLUTAB lahustuv tablett 500mg N30 | YAMANOUCHI EUROPE B.V. | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1028067 | amoksitsilliin | J01CA04 | HICONCIL 100 MG/ML | KRKA, d.d. | 50% | 75% | J13-J15*; | *rv alla 16-aastastele | ||||
| graanulid 100mgml 10ml | H66* | lastele | ||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1028056 | amoksitsilliin | J01CA04 | HICONCIL 125 MG/5 ML suspensioonigraanulid 25mgml 60ml | KRKA, d.d. | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1028078 | amoksitsilliin | J01CA04 | HICONCIL 250 MG/5 ML suspensioonigraanulid 50mgml 100ml | KRKA, d.d. | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1019461 | amoksitsilliin | J01CA04 | OSPAMOX 250 MG/5 ML suspensioonigraanulid 50mgml 60ml N1 | Sandoz GmbH | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1066058 | amoksitsilliin | J01CA04 | OSPAMOX tablett 1000mg N12 | Sandoz GmbH | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1066047 | amoksitsilliin | J01CA04 | OSPAMOX tablett 500mg N12 | Sandoz GmbH | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1032387 | amoksitsilliin | J01CA04 | UPSAMOX kapsel 250mg N12 | Bristol-Myers Squibb Eesti AS | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1032398 | amoksitsilliin | J01CA04 | UPSAMOX kapsel 500mg N12 | Bristol-Myers Squibb Eesti AS | 50% | 75% | J13-J15; H66 | *rv alla 16-aastastele lastele | ||||
| 1011047 | amoksitsilliin+klavulaanhape | J01CR02 | AMOKSIKLAV 2X tablett 875mg+125mg N10 | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1066700 | amoksitsilliin+klavulaanhape | J01CR02 | AMOKSIKLAV 2X tablett 875mg+125mg N14 | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1011069 | amoksitsilliin+klavulaanhape | J01CR02 | AMOKSIKLAV 2X pulber peroraalse suspensiooni valmistamiseks 400mg+57mg 5ml 35ml | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1066711 | amoksitsilliin+klavulaanhape | J01CR02 | AMOKSIKLAV 2X pulber peroraalse suspensiooni valmistamiseks 400mg+57mg 5ml 70ml | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1011058 | amoksitsilliin+klavulaanhape | J01CR02 | AMOKSIKLAV 2X tablett 500mg+125mg N10 | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1066722 | amoksitsilliin+klavulaanhape | J01CR02 | AMOKSIKLAV 2X tablett 500mg+125mg N14 | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1028685 | amoksitsilliin+klavulaanhape | J01CR02 | AUGMENTIN suspensioonigraanulid 80mg+11,4mgml 70ml | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1028630 | amoksitsilliin+klavulaanhape | J01CR02 | AUGMENTIN tablett 500mg+125mg N14 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1091012 | amoksitsilliin+klavulaanhape | J01CR02 | AUGMENTIN kaetud tablett 875mg+125mg N12 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1066733 | amoksitsilliin+klavulaanhape | J01CR02 | AUGMENTIN kaetud tablett 875mg+125mg N14 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1028641 | amoksitsilliin+klavulaanhape | J01CR02 | AUGMENTIN kaetud tablett 875mg+125mg N2 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1046359 | amoksitsilliin+klavulaanhape | J01CR02 | BETAKLAV tablett 500 mg+125 mg N14 | KRKA, d.d. | 50% | |||||||
| 1046360 | amoksitsilliin+klavulaanhape | J01CR02 | BETAKLAV tablett 500 mg+125 mg N21 | KRKA, d.d. | 50% | |||||||
| 1046371 | amoksitsilliin+klavulaanhape | J01CR02 | BETAKLAV pulber suspensiooni valmistamiseks 250 mg+62,5 mg/5 ml 13,16 g | KRKA, d.d. | 50% | |||||||
| 1045875 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 156,25 MG/5 ML pulber suspensiooniks 25mg+6,25mg/ml 100ml | Biochemie GmbH | 50% | |||||||
| 1043132 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 156,25 MG/5 ML pulber suspensiooniks 25mg+6,25mg/ml 60ml | Biochemie GmbH | 50% | |||||||
| 1045864 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 156,25 MG/5 ML pulber suspensiooniks 25mg+6,25mg/ml 75ml | Biochemie GmbH | 50% | |||||||
| 1046427 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 312,5 MG/5ML pulber suspensiooniks 50mg+12,5mg/ml 100ml | Biochemie GmbH | 50% | |||||||
| 1043143 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 312,5 MG/5ML pulber suspensiooniks 50mg+12,5mg/ml 60ml | Biochemie GmbH | 50% | |||||||
| 1046416 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 312,5 MG/5ML pulber suspensiooniks 50mg+12,5mg/ml 75ml | Biochemie GmbH | 50% | |||||||
| 1043154 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 625 MG tablett 500mg+125mg N10 | Biochemie GmbH | 50% | |||||||
| 1045921 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 625 MG tablett 500mg+125mg N100 | Biochemie GmbH | 50% | |||||||
| 1045886 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 625 MG tablett 500mg+125mg N12 | Biochemie GmbH | 50% | |||||||
| 1068959 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 625 MG tablett 500mg+125mg N14 | Biochemie GmbH | 50% | |||||||
| 1045897 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 625 MG tablett 500mg+125mg N15 | Biochemie GmbH | 50% | |||||||
| 1045909 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 625 MG tablett 500mg+125mg N16 | Biochemie GmbH | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1045910 | amoksitsilliin+klavulaanhape | J01CR02 | CURAM 625 MG tablett 500mg+125mg N20 | Biochemie GmbH | 50% | |||||||
| 1009842 | amorolfiin | D01AE16 | LOCERYL kreem 0,25% 20g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1061042 | amorolfiin | D01AE16 | LOCERYL küünelakk 5% 5ml N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1009572 | amorolfiin | D01AE16 | LOCERYL küünelakk 5% 2.5ml N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1065978 | ampitsilliin | J01CA01 | STANDACILLIN kapsel 500mg N12 | Biochemie GmbH | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1033546 | anastrosool | L02BG03 | ARIMIDEX tablett 1mg N28 | AstraZeneca UK Ltd. | 50% | 100% | (C00-D48)* | *rv onkoloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1203523 [RTL 2006, 26, 482 – jõust. 1.04.2006] | aripiprasool | N05AX12 | ABILIFY tablett 10 mg N28 | Bristol-Myers Squibb Eesti AS | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhistele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1203578 [RTL 2006, 26, 482 – jõust. 1.04.2006] | aripiprasool | N05AX12 | ABILIFY tablett 15 mg N28 | Bristol-Myers Squibb Eesti AS | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhistele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1203624 [RTL 2006, 26, 482 – jõust. 1.04.2006] | aripiprasool | N05AX12 | ABILIFY tablett 30 mg N28 | Bristol-Myers Squibb Eesti AS | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhistele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1004500 [RTL 2006, 26, 482 – jõust. 1.04.2006] | asatiopriin | L04AX01 | IMURAN TABLETS 50 MG kaetud tablett 50mg N100 | Glaxo Wellcome Operations | 50% | 75% | K50; K51; K73; K74; L10; L12; L13.0; L40; M07; M05; M06; M08; M45; M46; (M30- M33); M35; (N00- N08)*** | rv gastroenteroloogil ja pediaatril; rv dermatoveneroloogil; rv dermatoveneroloogil ja reumatoloogil; rv reumatoloogil ja pediaatril; ***rv nefroloogil ja pediaatril | 100% | G70*; T86 | *rev neuroloogil | |
| 1121869 [RTL 2006, 26, 482 – jõust. 1.04.2006] | asatiopriin | L04AX01 | AZAREKHEXAL 50 tablett 50 mg N100 | Hexal AG | 50% | 75% | K50; K51; K73; K74; L10; L12; L13.0; L40; M07; M05; M06; M08; M45; M46; (M30- M33); M35; (N00- N08)*** | rv gastroenteroloogil ja pediaatril; rv dermatoveneroloogil; rv dermatoveneroloogil ja reumatoloogil; rv reumatoloogil ja pediaatril; ***rv nefroloogil ja pediaatril | 100% | G70*; T86 | *rev neuroloogil | |
| 1005736 | aselaiinhape | D10AX03 | SKINOREN kreem 20% 30g | Schering AG | 50% | |||||||
| 1036358 | aselastiin | S01GX80 | ALLERGODIL silmatilgad 0,05% 6ml | VIATRIS GmbH & Co.KG | 50% | |||||||
| 1019775 | asitromütsiin | J01FA10 | SUMAMED kapsel 250mg N6 | AWD Pharma Ltd. | 50% | |||||||
| 1019809 | asitromütsiin | J01FA10 | SUMAMED suspensioonigraanulid 20mg/ml 20ml | AWD Pharma Ltd. | 50% | |||||||
| 1019797 | asitromütsiin | J01FA10 | SUMAMED tablett 500mg N3 | AWD Pharma Ltd. | 50% | |||||||
| 1019810 | asitromütsiin | J01FA10 | SUMAMED FORTE suspensioonigraanulid 40mg/ml 20ml | AWD Pharma Ltd. | 50% | |||||||
| 1127955 | asitromütsiin | J01FA10 | AZATRIL caps 250 mg N6 | Actavis AB | 50% | |||||||
| 1113400 | asitromütsiin | J01FA10 | AZITROX tablett 250 mg N3 | Leciva a.s. | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1113411 | asitromütsiin | J01FA10 | AZITROX tablett 250 mg N6 | Leciva a.s. | 50% | |||||||
| 1113398 | asitromütsiin | J01FA10 | AZITROX tablett 500 mg N3 | Leciva a.s. | 50% | |||||||
| 1008144 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1009516 | atenolool | C07AB03 | ATENOLOL ALPHARMA TABLETS 50 MG tablett 50mg N30 | ALPHARMA Limited | 50% | 75% | I10-I13; I15; I20 | |||||
| 1007895 | atenolool | C07AB03 | ATENOLOL-RATIOPHARM 25 tablett 25mg N30 | ratiopharm GmbH | 50% | 75% | I10-I13; I15; I20 | |||||
| 1007851 | atenolool | C07AB03 | ATENOLOL-RATIOPHARM 100 tablett 100mg N30 | ratiopharm GmbH | 50% | 75% | I10-I13; I15; I20 | |||||
| 1007873 | atenolool | C07AB03 | ATENOLOL-RATIOPHARM 50 tablett 50mg N30 | ratiopharm GmbH | 50% | 75% | I10-I13; I15; I20 | |||||
| 1008166 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1143548 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1030521 | atorvastatiin | C10AA05 | SORTIS kaetud tablett 10mg N30 | Pfizer Limited | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1030532 | atorvastatiin | C10AA05 | SORTIS kaetud tablett 20mg N30 | Pfizer Limited | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1030543 | atorvastatiin | C10AA05 | SORTIS kaetud tablett 40mg N30 | Pfizer Limited | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1138047 | atorvastatiin | C10AA05 | ATORIS tablett 10 mg N30 | KRKA, d.d. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1138058 | atorvastatiin | C10AA05 | ATORIS tablett 20 mg N30 | KRKA, d.d. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1180213 | atorvastatiin | C10AA05 | TORVACARD 10 tablett 10 mg N30 | Zentiva a. s. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1180235 | atorvastatiin | C10AA05 | TORVACARD 20 tablett 20 mg N30 | Zentiva a. s. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1180257 | atorvastatiin | C10AA05 | TORVACARD 40 tablett 40 mg N30 | Zentiva a. s. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1039250 | atsetüültsüsteiin | R05CB01 | ACC LONG lahustuv tablett 600mg N10 | Hexal AG | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1039238 | atsetüültsüsteiin | R05CB01 | ACC 200 graanulid lahuse valmistamiseks 200 mg N20 | Hexal AG | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1112500 | atsetüültsüsteiin | R05CB01 | ACC 100 lahustuv tablett 100 mg N20 | Hexal AG | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1039249 | atsetüültsüsteiin | R05CB01 | ACC 100 graanulid lahuse valmistamiseks 100 mg N20 | Hexal AG | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1112465 | atsetüültsüsteiin | R05CB01 | ACC 200 lahustuv tablett 200 mg N20 | Hexal AG | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1034738 | atsetüültsüsteiin | R05CB01 | ACC 200 HOT graanulid lahuse valmistamiseks 200 mg N20 | Hexal AG | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1034750 | atsetüültsüsteiin | R05CB01 | ACETYLCYSTEIN NYCOMED 200 MG graanulid lahuse valmistamiseks 200 mg N20 | Nycomed Sefa AS | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1036156 | atsetüültsüsteiin | R05CB01 | ACETYLCYSTEIN NYCOMED 100 MG graanulid lahuse valmistamiseks 100 mg N20 | Nycomed Sefa AS | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1122635 | atsetüültsüsteiin | R05CB01 | MUCOFLUID lahustuv tablett 200 mg N30 | Spirig Baltikum Lithuanian-Swiss Ltd. | 100% | E84* | *rev pulmonoloogil ja pediaatril | |||||
| 1000731 | atsitretiin | D05BB02 | NEOTIGASON kapsel 10mg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 75% | L40; L86; M07; Q80; Q82.8* | *rv dermatoveneroloogil | ||||
| 1061716 | atsükloviir | D06BB03 | ACYCLOVIR STADA, CREAM kreem 5% 20g | STADA ARZNEIMITTEL AG | 50% | |||||||
| 1013623 [RTL 2006, 26, 482 – jõust. 1.04.2006] | atsükloviir | J05AB01 | ACIC 200 tablett 200mg N25 | Hexal AG | 50% | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | ||||
| 1086274 [RTL 2006, 26, 482 – | atsükloviir | J05AB01 | ACICLOVIR tablett 200 mg N20 | Actavis AB | 50% | 100% | (D60- | *rv hematoloogil ja pediaatril | ||||
| jõust. 1.04.2006] | D64)*; T86 | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1086285 [RTL 2006, 26, 482 – jõust. 1.04.2006] | atsükloviir | J05AB01 | ACICLOVIR tablett 400 mg N10 | Actavis AB | 50% | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | ||||
| 1041657 [RTL 2006, 26, 482 – jõust. 1.04.2006] | atsükloviir | J05AB01 | ACICLOVIR ALPHARMA TABLETS 200 MG tablett 200mg N30 | ALPHARMA Limited | 50% | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | ||||
| 1041679 [RTL 2006, 26, 482 – jõust. 1.04.2006] | atsükloviir | J05AB01 | ACICLOVIR ALPHARMA TABLETS 800 MG tablett 800mg N35 | ALPHARMA Limited | 50% | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | ||||
| 1006625 | atsükloviir | S01AD03 | ZOVIRAX OPHTHALMIC OINTMENT 3% silmasalv 3% 4.5g | Glaxo Wellcome Operations | 50% | |||||||
| 1165384 [RTL 2006, 26, 482 – jõust. 1.04.2006] | atsükloviir | J05AB01 | ACIC 400 MG TABLETID tablett 400 mg N35 | Hexal AG | 50% | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | ||||
| 1165395 [RTL 2006, 26, 482 – jõust. 1.04.2006] | atsükloviir | J05AB01 | ACIC 800 MG TABLETID tablett 800 mg N35 | Hexal AG | 50% | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | ||||
| 1036145 | auranofiin | M01CB03 | RIDAURA tablett 3mg N100 | Goldshield Pharmaceuticals Ltd. | 50% | 75% | M05; M06; M08; M45; M46* | *rv reumatoloogil ja pediaatril | ||||
| 1019483 | batsiratsiin+neomütsiin | D06AX80 | BANEOCIN OINTMENT salv 250+5000TÜ/g 20g | Sandoz GmbH | 50% | |||||||
| 1019494 | batsiratsiin+neomütsiin | D06AX80 | BANEOCIN POWDER puistepulber 250TÜ+5mg/g 10g | Biochemie GmbH | 50% | |||||||
| 1115738 | beetahistiin | N07CA01 | BETASERC tablett 24mg N50 | Solvay Pharmaceuticals B.V. | 50% | |||||||
| 1008458 | beetahistiin | N07CA01 | BETASERC tablett 16mg N60 | Solvay Pharmaceuticals B.V. | 50% | |||||||
| 1008436 | beetahistiin | N07CA01 | BETASERC tablett 8mg N100 | Solvay Pharmaceuticals B.V. | 50% | |||||||
| 1004870 | beetametasoon | D07AC01 | BETNOVATE CREAM kreem 0,1% 15g | Glaxo Wellcome Operations | 50% | |||||||
| 1004263 | beetametasoon | D07AC01 | BETNOVATE OINTMENT salv 0,1% 15g | Glaxo Wellcome Operations | 50% | |||||||
| 1018448 | beetametasoon | D07AC01 | CELESTODERM-V kreem 1mgg 30g | Schering Plough Europe | 50% | |||||||
| 1061884 | beetametasoon | D07AC01 | CELESTODERM-V kreem 1mgg 50g | Schering Plough Europe | 50% | |||||||
| 1018459 | beetametasoon | D07AC01 | CELESTODERM-V salv 1mgg 30g | Schering Plough Europe | 50% | |||||||
| 1007514 | beetametasoon+fusiidhape | D07CC80 | FUCICORT kreem 0,1%+2% 15g | Leo Pharmaceutical Products | 50% | |||||||
| 1004320 | beetametasoon+neomütsiin | D07CC81 | BETNOVATE N CREAM kreem 0,1%+0,5% 15g | Glaxo Wellcome Operations | 50% | |||||||
| 1006041 | beetametasoon+salitsüülhape | D07BC80 | DIPROSALIC lahus 0,05%+2% 30ml | Schering Plough Europe | 50% | |||||||
| 1062403 | beetametasoon+salitsüülhape | D07BC80 | DIPROSALIC lahus 0,05%+2% 50ml | Schering Plough Europe | 50% | |||||||
| 1006074 | beetametasoon+salitsüülhape | D07BC80 | DIPROSALIC salv 0,05%+3% 20g | Schering Plough Europe | 50% | |||||||
| 1062425 | beetametasoon+salitsüülhape | D07BC80 | DIPROSALIC salv 0,05%+3% 30g | Schering Plough Europe | 50% | |||||||
| 1062436 | beetametasoon+salitsüülhape | D07BC80 | DIPROSALIC salv 0,05%+3% 50g | Schering Plough Europe | 50% | |||||||
| 1197109 [RTL 2006, 26, 482 – jõust. 1.04.2006] | bekaplermiin | D03AX06 | REGRANEX geel 0,01% 15g N1 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1034851 | beklometasoon | R03BA01 | BECLOMET EASYHALER inhalatsioonipulber 200mcg/annuses 200annust (kasutuspakend) | ORION CORPORATION ORION PHARMA | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1000337 | beklometasoon | R03BA01 | BECOTIDE BECODISKS inhalatsioonipulber 0,2mg/annuses 120annust N1 | Glaxo Group Ltd. | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1093261 | beklometasoon | R03BA01 | ECOBEC 100 MCG EASI- BREATHE inhal aeros 100mcg/annus 200annust N1 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1001103 | beklometasoon | R01AD01 | BECONASE AQUEOUS NASAL SPRAY 50 MCG ninasprei 50mcg/annuses 200annust | Glaxo Wellcome Operations | 50% | 75% | J30* | *rv alla 16-aastastele lastele | ||||
| 1152201 | beklometasoon | R03BA01 | BECLOFORTE INHALER inhal aeros, lahus 0,25mg N200 | Glaxo Group Ltd. | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1045538 | beklometasoon | R03BA01 | ECOBEC 100 MCG inhal aeros 100mcg/annus 200annust | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1045561 | beklometasoon | R03BA01 | ECOBEC 250 MCG EASI- BREATHE inhal aeros 250mcg/annus 200 annust N1 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1045550 | beklometasoon | R03BA01 | ECOBEC 250 MCG inhal aeros 250mcg/annus 200annust | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1013128 [RTL 2006, 26, 482 – jõust. 1.04.2006] | beklometasoon | R01AD01 | NASOBEC sprei 50 mcg/1 annuses 200 annust 30 ml | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J30* | *rv alla 16-aastastele lastele | ||||
| 1190326 [RTL 2006, 26, 482 – jõust. 1.04.2006] | beklometasoon | R03BA01 | BECLOMET EASYHALER inhalatsioonipulber 200mcg/annuses 200annust (alustuspakend) | ORION CORPORATION ORION PHARMA | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1134818 | beklometasoon | R03BA01 | ECOBEC 250 MCG EASI- BREATHE inhal aeros 250mcg/annus 200 annust N3 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil | ||||
| 1034042 | betaksolool | S01ED02 | BETOPTIC S silmatilgad, suspensioon 0,25% 5ml | s.a. ALCON- COUVREUR n.v. | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1124299 | betaksolool | S01ED02 | BETOPTIC lahus, silmatilgad 0,5% 5 ml | s.a. ALCON- COUVREUR n.v. | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1012194 | bikalutamiid | L02BB03 | CASODEX 150 tablett 150mg N28 | AstraZeneca UK Ltd. | 50% | |||||||
| 1026560 | bikalutamiid | L02BB03 | CASODEX tablett 50mg N28 | AstraZeneca UK Ltd. | 50% | |||||||
| 1077005 | biperideen | N04AA02 | AKINETON tablett 2mg N100 | Abbott GmbH & Co. KG | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1017223 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1225662 [RTL 2006, 26, 482 – jõust. 1.04.2006] | bisoprolool | C07AB07 | CONCOR COR 2,5 MG kaetud tablett 2,5 mg N30 | MERCK KgaA | 50% | |||||||
| 1137923 [RTL 2006, 26, 482 – jõust. 1.04.2006] | bisoprolool+ hüdroklorotiasiid | C07BB07 | LODOZ 2,5/6,25 mg tablett N30 | MERCK KgaA | 50% | |||||||
| 1137934 [RTL 2006, 26, 482 – jõust. 1.04.2006] | bisoprolool+ hüdroklorotiasiid | C07BB07 | LODOZ 5/6,25 mg tablett N30 | MERCK KgaA | 50% | |||||||
| 1137945 [RTL 2006, 26, 482 – jõust. 1.04.2006] | bisoprolool+ hüdroklorotiasiid | C07BB07 | LODOZ 10/6,25 mg tablett N30 | MERCK KgaA | 50% | |||||||
| 1042782 | brinsolamiid | S01EC04 | AZOPT silmatilgad 1% 5ml | ALCON LABORATORIES Inc. | 50% | 100% | (H40-H42)* | *rv oftalmoloogil juhul, kui ravi beeta-adrenoblokaatoriga ei ole langetanud piisavalt silma siserõhku või beeta- adrenoblokaator on vastunäidustatud | ||||
| 1085565 | brivudiin | J05AB82 | BRIVUMEN tablett 125 mg N1 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1085554 | brivudiin | J05AB82 | BRIVUMEN tablett 125 mg N7 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1111318 | brivudiin | J05AB82 | BRIVUMEN tablett 125 mg N35 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1008098 | bromokriptiin | G02CB01 | BROMOCRIPTIN-RICHTER tablett 2,5mg N30 | GEDEON RICHTER Ltd. | 50% | 100% | E22; E24; G20** | rev endokrinoloogil; *rev neuroloogil | ||||
| 1003497 | bromokriptiin | G02CB01 | PARLODEL tablett 2,5mg N30 | Novartis Finland OY | 50% | 100% | E22; E24; G20** | rev endokrinoloogil; *rev neuroloogil | ||||
| 1043389 | budesoniid | R01AD05 | RHINOCORT AQUA 64 MCG/DOSE ninasprei 64mcg/annuses 10ml N120 | AstraZeneca AB | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1011070 | budesoniid | R01AD05 | TAFEN NASAL ninasprei 50mcg/annuses 200annust | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1013050 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1013061 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1111138 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1013072 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1111149 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1111150 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1088322 | budesoniid | R03BA02 | PULMICORT inhal aeros 50mcg/annuses 200annust N1 | AstraZeneca AB | 50% | 75% | J45* | *rv alla 18-aastasele lapsele ning rev pediaatril ja pulmonoloogil | ||||
| 1038316 | budesoniid | R03BA02 | PULMICORT SUSPENSION FOR NEBULISATION 0,25 MG/ML nebulisaatori susp. 0,25mg/ml 2ml N20 | AstraZeneca AB | 50% | 75% | J45* | *rv alla 18-aastasele lapsele ning rev pediaatril ja pulmonoloogil | ||||
| 1057542 | budesoniid | R03BA02 | PULMICORT TURBUHALER inhalatsioonipulber 0,1mg/annuses 200annust N1 | AstraZeneca AB | 50% | 75% | J45* | *rv alla 18-aastasele lapsele ning rev pediaatril ja pulmonoloogil | ||||
| 1114827 | budesoniid | R03BA02 | PULMICORT TURBUHALER inhalatsioonipulber 0,2mg/annuses 100annust N1 | AstraZeneca AB | 50% | 75% | J45* | *rv alla 18-aastasele lapsele ning rev pediaatril ja pulmonoloogil | ||||
| 1124390 | budesoniid | R03BA02 | MIFLONIDE 200 mcg inhal.pulber kapslis 200 mcg N60 | Novartis Finland OY | 50% | 75% | J45* | *rv alla 18-aastasele lapsele ning rev pediaatril ja pulmonoloogil | ||||
| 1124413 | budesoniid | R03BA02 | MIFLONIDE 400 mcg inhal.pulber kapslis 400 mcg N60 | Novartis Finland OY | 50% | 75% | J45* | *rv alla 18-aastasele lapsele ning rev pediaatril ja pulmonoloogil | ||||
| 1068443 | budesoniid+formoterool | R03AK83 | SYMBICORT TURBUHALER inhalatsioonipulber 160mcg+4,5mcg/annus 120annust N1 | AstraZeneca AB | 50% | 75% | J45* | *rev pulmonoloogil ja pediaatril vastavalt Eesti ravijuhisele | ||||
| 1013724 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1072505 | budesoniid+formoterool | R03AK83 | SYMBICORT TURBUHALER inhalatsioonipulber 80mcg+4,5mcgannus 120annus N1 | AstraZeneca AB | 50% | 75% | J45,* | rev pediaatril ja pulmonoloogil *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1072493 | budesoniid+formoterool | R03AK83 | SYMBICORT TURBUHALER inhalatsioonipulber 80mcg+4,5mcgannus 60annus N1 | AstraZeneca AB | 50% | |||||||
| 1113545 | bupropioon | N06AX81 | WELLBUTRIN SR TABLETS tablett 150 mg N30 | Glaxo Group Ltd. | 50% | |||||||
| 1113556 | bupropioon | N06AX81 | WELLBUTRIN SR TABLETS tablett 150 mg N60 | Glaxo Group Ltd. | 50% | |||||||
| 1005006 | busulfaan | L01AB01 | MYLERAN TABLETS tablett 2mg N100 | Glaxo Wellcome Operations | 50% | 100% | (C00-D48)* | *rv onkoloogil, hematoloogil ja pediaatril | ||||
| 1099874 | butenafiin | D01AE82 | MENTAX kreem 1% 10g | MediNet International Ltd. | 50% | |||||||
| 1012598 | daltepariin | B01AB04 | FRAGMIN inj 10000TÜ 0.4ml täidetud süstal N5 | Pfizer Enterprises Sarl | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1012600 | daltepariin | B01AB04 | FRAGMIN inj 12500TÜ 0.5ml täidetud süstal N5 | Pfizer Enterprises Sarl | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1003914 | daltepariin | B01AB04 | FRAGMIN inj 12500TÜ anti Xa/ml 0.2ml täidetud süstal N10 | Pfizer Enterprises Sarl | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1003969 | daltepariin | B01AB04 | FRAGMIN inj 25000TÜ anti Xa/ml 0.2ml täidetud süstal N10 | Pfizer Enterprises Sarl | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1012587 | daltepariin | B01AB04 | FRAGMIN inj 7500TÜ 0.3ml täidetud süstal N10 | Pfizer Enterprises Sarl | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1008414 | deksametasoon | H02AB02 | DEXAMETHASON 4 MG/ML süstelahus 4mgml amp 1ml N25 | KRKA, d.d. | 50% | 100% | (C00-D48)* | *rv onkoloogil, hematoloogil ja pediaatril. | ||||
| 1014972 [RTL 2006, 26, 482 – jõust. | deksametasoon | H02AB02 | DEXAMETHASON KRKA tablett 0,5mg N10 | KRKA, d.d. | 50% | 75% | L10; L12; L13.0* | *rv dermatoveneroloogil ja pediaatril | 100% | (C00- D48); E23; E25; E27*; | rv onkoloogil, hematoloogil ja pediaatril; *rev endokrinoloogil ja pediaatril | |
| 1.04.2006] | E89.3; E89.6; T86 | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1090932 | deksametasoon | S01BA01 | MAXIDEX OINTMENT silmasalv 1mg/g 3.5g | s.a. ALCON COUVREUR n.v. | 50% | |||||||
| 1124288 | deksametasoon | S01BA01 | MAXIDEX silmatilgad, suspensioon 0,1% 5 ml | s.a. ALCON COUVREUR n.v. | 50% | |||||||
| 1007479 | deksametasoon | S01BA01 | OFTAN DEXA silmatilgad, lahus 0,1% 5 ml | Santen OY | 50% | |||||||
| 1044379 | deksametasoon+klooramfenikool | S01CA82 | OFTAN DEXA-CHLORA silmasalv 0,1%+0,2% 3.5g | Santen OY | 50% | |||||||
| 1044368 | deksametasoon+klooramfenikool | S01CA82 | OFTAN DEXA-CHLORA silmatilgad 0,1%+0,2% 10 ml | Santen OY | 50% | |||||||
| 1124301 | deksametasoon+neomütsiin+polümüksiin B | S01CA80 | MAXITROL silmatilgad, suspensioon 1mg+3500TÜ +6000TÜ/ml 5 ml | s.a. ALCON COUVREUR n.v. | 50% | |||||||
| 1124266 | deksametasoon+tobramütsiin | S01CA81 | TOBRADEX silmatilgad, suspensioon 0,1%+0,3% 5 ml | s.a. ALCON COUVREUR n.v. | 50% | |||||||
| 1150276 | deksametasoon+tobramütsiin | S01CA81 | TOBRADEX EYE OINTMENT silmasalv 0,1 %+0,3% 3,5 g N1 | s.a. ALCON COUVREUR n.v. | 50% | |||||||
| 1011979 | deksketoprofeen | M01AE17 | DOLMEN tablett 25mg N10 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1087275 | deksketoprofeen | M01AE17 | DOLMEN tablett 25mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1087286 | deksketoprofeen | M01AE17 | DOLMEN tablett 25mg N50 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1107492 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 30 ml | Schering Plough Europe | 50% | |||||||
| 1107504 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 50 ml | Schering Plough Europe | 50% | |||||||
| 1107515 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 60 ml | Schering Plough Europe | 50% | |||||||
| 1107526 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 100 ml | Schering Plough Europe | 50% | |||||||
| 1107537 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 120 ml | Schering Plough Europe | 50% | |||||||
| 1107548 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 150 ml | Schering Plough Europe | 50% | |||||||
| 1107559 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 225 ml | Schering Plough Europe | 50% | |||||||
| 1107560 | Desloratadiin | R06AX27 | AERIUS siirup 0,5 mg/ml 300 ml | Schering Plough Europe | 50% | |||||||
| 1077971 | Desloratadiin | R06AX27 | AERIUS tablett 5mg N10 | Schering Plough Europe | 50% | |||||||
| 1012396 | Desloratadiin | R06AX27 | AERIUS tablett 5mg N2 | Schering Plough Europe | 50% | |||||||
| 1077982 | Desloratadiin | R06AX27 | AERIUS tablett 5mg N30 | Schering Plough Europe | 50% | |||||||
| 1064348 | desmopressiin | H01BA02 | MINIRIN ninasprei 10mcg/annuses 2.5ml | Ferring AB | 50% | 100% | E23.2* | *rev endokrinoloogil ja pediaatril | ||||
| 1064360 | desmopressiin | H01BA02 | MINIRIN tablett 0,1mg N30 | Ferring AB | 50% | 100% | E23.2* | *rev endokrinoloogil ja pediaatril | ||||
| 1064382 | desmopressiin | H01BA02 | MINIRIN tablett 0,2mg N30 | Ferring AB | 50% | 100% | E23.2* | *rev endokrinoloogil ja pediaatril | ||||
| 1063314 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1010675 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1063303 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1062863 | desogestreel+etünüülöstradiool | G03AA09 | MARVELON tablett 0,15mg+0,03mg N21x3 | N.V. ORGANON | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1062908 | desogestreel+etünüülöstradiool | G03AA09 | MERCILON tablett 0,15mg+0,02mg N21x3 | N.V. ORGANON | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1062920 | desogestreel+etünüülöstradiool | G03AA09 | NOVYNETTE kaetud tablett 0,15mg+0,02mg N63 | GEDEON RICHTER Ltd. | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast | ||||||||||||
| 1062931 | desogestreel+etünüülöstradiool | G03AA09 | REGULON kaetud tablett 0,15mg+0,03mg N21x3 | GEDEON RICHTER Ltd. | 50% | 75% | Z30* | aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1038495 | desogestreel+etünüülöstradiool | G03AB05 | GRACIAL tabl 25mcg+40mcg N7;125mcg+30mcg N15 | N.V. ORGANON | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1010686 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1161458 | desogestreel+etünüülöstradiool | G03AB05 | GRACIAL tabl (25mcg+40mcg N7;125mcg+30mcg N15)x3 | N.V. ORGANON | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1007682 | diasepaam | N05BA01 | DIAZEPAM DESITIN rektaalne lahus 5mg/2,5 ml N5 | Desitin Arzneimittel GmbH | 50% | |||||||
| 1007659 [RTL 2006, 26, 482 – jõust. 1.04.2006] | diasepaam | N05BA01 | DIAZEPAM DESITIN rektaalne lahus 10mg/2,5 ml N5 | Desitin Arzneimittel GmbH | 50% | |||||||
| 1160839 [RTL 2006, 26, 482 – jõust. 1.04.2006] | didanosiin | J05AF02 | VIDEX EC 250 MG gastroresistentne kapsel 250mg N30 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1160840 [RTL 2006, 26, 482 – jõust. 1.04.2006] | didanosiin | J05AF02 | VIDEX EC 400 MG gastroresistentne kapsel 400mg N30 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1160828 [RTL 2006, 26, 482 – jõust. 1.04.2006] | didanosiin | J05AF02 | VIDEX dispergeeritav/närimistablett 100mg N60 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1160817 [RTL 2006, 26, 482 – jõust. 1.04.2006] | didanosiin | J05AF02 | VIDEX dispergeeritav/närimistablett 25mg N60 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1066834 | dienogest+etünüülöstradiool | G03AA81 | JEANINE tablett 2mg+0,03mg N21 | JENAPHARM GmbH & Co.KG | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1190427 | dienogest+östradiool | G03FA15 | KLIMODIEN tablett 2mg+2mg N3x28 | Schering AG | 50% | |||||||
| 1012385 | dienogest+östradiool | G03FA15 | KLIMODIEN tablett 2mg+2mg N28 | Schering AG | 50% | |||||||
| 1000786 | difenhüdramiin | R06AA02 | DIMEDROL tablett 50mg tabl N10 | Tallinna Farmaatsiatehase AS | 50% | |||||||
| 1222209 [RTL 2006, 26, 482 – jõust. 1.04.2006] | digoksiin | C01AA05 | DIGOXIN NYCOMED 0,25 MG tablett 0,25mg N60 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1222197 [RTL 2006, 26, 482 – jõust. 1.04.2006] | digoksiin | C01AA05 | DIGOXIN NYCOMED 62,5 MCG tablett 62,5mcg N60 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1009291 | digoksiin | C01AA05 | DIGOXIN NYCOMED 0,25 MG tablett 0,25mg N50 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1009314 | digoksiin | C01AA05 | DIGOXIN NYCOMED 62,5 MCG tablett 62,5mcg N100 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1070592 | digoksiin | C01AA05 | DIGOXIN tablett 0,25mg N50 | Grindex | 50% | 75% | I50 | |||||
| 1026728 | dihüdrokodeiin | N02AA08 | DHC CONTINUS retardtablett 120mg N56 | Mundipharma Ges.m.b.H | 50% | |||||||
| 1026706 | dihüdrokodeiin | N02AA08 | DHC CONTINUS retardtablett 60mg N56 | Mundipharma Ges.m.b.H | 50% | |||||||
| 1108303 | dihüdrokodeiin | N02AA08 | DHC CONTINUS retardtablett 90mg N56 | Mundipharma Ges.m.b.H | 50% | |||||||
| 1019090 | dihüdrotahhüsterool | A11CC02 | TACHYSTIN LIQUIDUM suukaudne lahus 1mg/ml 20ml | Chauvin ankerpharm GmbH | 50% | 100% | E20; E89.2 | *rv endokrinoloogil ja pediaatril | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1002520 | diklofenak | M01AB05 | CATAFLAM tablett 50mg N20 | Novartis Finland OY | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1040320 | diklofenak | M01AB05 | DICLAC 100 suposiit 100mg N10 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1071942 | diklofenak | M01AB05 | DICLAC 150 ID retardtablett 150mg N100 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1071920 | diklofenak | M01AB05 | DICLAC 150 ID retardtablett 150mg N20 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1083507 | diklofenak | M01AB05 | DICLAC 50 TABL tablett 50mg N50 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1071986 | diklofenak | M01AB05 | DICLAC 75 ID retardtablett 75mg N100 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1071964 | diklofenak | M01AB05 | DICLAC 75 ID retardtablett 75mg N20 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1012307 | diklofenak | M01AB05 | DICLAC RETARD retardtablett 100mg N20 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1078163 | diklofenak | M01AB05 | DICLAC RETARD retardtablett 100mg N50 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1016109 | diklofenak | M01AB05 | DICLOBERL RETARD retardkapsel 100mg N50 | Berlin-Chemie | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1143605 | diklofenak | M01AB05 | DICLOFENAC- RATIOPHARM 25 enterotablett 25mg N20 | ratiopharm GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1001372 | diklofenak | M01AB05 | DICLOFENAC- RATIOPHARM 50 enterotablett 50mg N20 | ratiopharm GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1072213 | diklofenak | M01AB05 | DICLOFENAC- RATIOPHARM 50 enterotablett 50mg N50 | ratiopharm GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| L40; M07; M05; M06; | ||||||||||||
| 1017133 | diklofenak | M01AB05 | DICLOFENAC-RATIOPHARM 100 suposiit 100mg N10 | ratiopharm GmbH | 50% | 75% | M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1007356 | diklofenak | M01AB05 | DICLOFENAC-RATIOPHARM 50 suposiit 50mg N10 | ratiopharm GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1041602 | diklofenak | M01AB05 | DICLOFENAC-RATIOPHARM UNO modif tablett 150mg N10 | ratiopharm GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1072279 | diklofenak | M01AB05 | DICLOFENAC-RATIOPHARM UNO modif tablett 150mg N20 | ratiopharm GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1072280 | diklofenak | M01AB05 | DICLOFENAC-RATIOPHARM UNO modif tablett 150mg N50 | ratiopharm GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1032590 | diklofenak | M01AB05 | DICLOMELAN 50 mg tablett 50mg N10 | LANNACHER HEILMITTEL GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1032589 | diklofenak | M01AB05 | DICLOMELAN RETARD 100 mg retardtablett 100mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1032613 | diklofenak | M01AB05 | DICLOMELAN suposiit 100mg N6 | LANNACHER HEILMITTEL GmbH | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1024030 | diklofenak | M01AB05 | INFLAMAC 50 gastroresistentne kapsel 50mg N20 | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1024041 | diklofenak | M01AB05 | INFLAMAC 75 SR retardkapsel 75mg N20 | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1022993 | diklofenak | M01AB05 | NAKLOFEN DUO modif kapsel 75mg N20 | KRKA, d.d. | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1005613 | diklofenak | M01AB05 | NAKLOFEN RETARD retardtablett 100mg N20 | KRKA, d.d. | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1005567 | diklofenak | M01AB05 | NAKLOFEN SUPOSIIT suposiit 50mg N10 | KRKA, d.d. | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1039621 | diklofenak | M01AB05 | OLFEN-100 RECTOCAPS rektaalkapsel 100 mg N 5 | Mepha LDA | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1039632 | diklofenak | M01AB05 | OLFEN-100 SR DEPOCAPS retardkapsel 100mg N20 | Mepha LDA | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1039609 | diklofenak | M01AB05 | OLFEN-25 LACTAB enterotablett 25mg N30 | Mepha LDA | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1039665 | diklofenak | M01AB05 | OLFEN-50 LACTAB enterotablett 50mg N20 | Mepha LDA | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1039610 | diklofenak | M01AB05 | OLFEN-50 RECTOCAPS rektaalkapsel 50 mg N10 | Mepha LDA | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1012048 | diklofenak | M01AB05 | OLFEN-75 SR DEPOTABS retardtablett 75mg N30 | Mepha LDA | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1143324 | diklofenak | M01AB05 | VOLTAREN 100 suposiit 100mg N5 | Novartis Finland OY | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1002924 | diklofenak | M01AB05 | VOLTAREN 25 enterotablett 25mg N30 | Novartis Finland OY | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1125605 [RTL 2006, 26, 482 – jõust. 1.04.2006] | diklofenak | M01AB05 | VOLTAREN 50 enterotablett 50mg N20 | Novartis Finland OY | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1003341 | diklofenak | M01AB05 | VOLTAREN 50 suposiit 50mg N10 | Novartis Finland OY | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1072730 | diklofenak | M01AB05 | VOLTAREN RETARD retardtablett 100mg N30 | Novartis Finland OY | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1073999 | diklofenak | M02AA15 | DICLAC 5% GEL geel 5% 100g N1 | Hexal AG | 50% | |||||||
| 1040364 | diklofenak | M02AA15 | DICLAC 5% GEL geel 5% 50g N1 | Hexal AG | 50% | |||||||
| 1024715 | diklofenak | M02AA15 | ORTOFEN salv 2% 30g | Tallinna Farmaatsiatehase AS | 50% | |||||||
| 1023691 | diklofenak | S01BC03 | VOLTAREN OPHTHA silmatilgad 0,1% 5 ml N1 | Novartis Pharma France | 50% | |||||||
| 1163089 | diklofenak | M01AB05 | DICLAC gastroresistentne tablett 25 mg N100 | Hexal AG | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1163078 | diklofenak | M01AB05 | DICLAC gastroresistentne tablett 25 mg N30 | Hexal AG | 50% | |||||||
| 1115121 | diklofenak | M01AB05 | INFLAMAC 50 gastroresistentne kapsel 50mg N100 | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; | *rv üle 63-aastastele | ||||
| M45; M46; | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1115132 | diklofenak | M01AB05 | INFLAMAC 75 SR retardkapsel 75mg N60 | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1134166 | diklofenak | M01AB05 | DICLOBERL RETARD retardkapsel 100mg N20 | Berlin-Chemie | 50% | 75% | L40; M07; M05; M06; M08; M15- M19*; M30- M33; M35; M45; M46; | *rv üle 63-aastastele | ||||
| 1088401 | diklofenak+misoprostool | M01AB80 | ARTHROTEC tablett 50mg+0,2mg N100 | Pfizer Enterprises Sarl | 50% | |||||||
| 1082865 | diklofenak+misoprostool | M01AB80 | ARTHROTEC tablett 50mg+0,2mg N20 | Pfizer Enterprises Sarl | 50% | |||||||
| 1088399 | diklofenak+misoprostool | M01AB80 | ARTHROTEC tablett 50mg+0,2mg N60 | Pfizer Enterprises Sarl | 50% | |||||||
| 1014556 | diltiaseem | C08DB01 | ALTIAZEM RR retardkapsel 180mg N20 | INSTITUTO LUSOFARMACO d ´Italia S.p.A | 50% | |||||||
| 1019753 | diltiaseem | C08DB01 | DILTIAZEM tablett 60mg N30 | AWD Pharma Ltd. | 50% | |||||||
| 1019764 | diltiaseem | C08DB01 | DILTIAZEM tablett 90mg N30 | AWD Pharma Ltd. | 50% | |||||||
| 1031645 | diltiaseem | C08DB01 | DILTIAZEM LANNACHER prolongeeritud tablett 90 mg N20 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1031634 | diltiaseem | C08DB01 | DILTIAZEM LANNACHER prolongeeritud tablett 180 mg N30 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1028203 | doksasosiin | C02CA04 | CARDURA tablett 1mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1028214 | doksasosiin | C02CA04 | CARDURA tablett 2mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1028225 | doksasosiin | C02CA04 | CARDURA tablett 4mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1045077 | doksasosiin | C02CA04 | KAMIREN tablett 1mg N20 | KRKA, d.d. | 50% | |||||||
| 1071380 | doksasosiin | C02CA04 | KAMIREN tablett 1mg N30 | KRKA, d.d. | 50% | |||||||
| 1045066 | doksasosiin | C02CA04 | KAMIREN tablett 2mg N20 | KRKA, d.d. | 50% | |||||||
| 1071391 | doksasosiin | C02CA04 | KAMIREN tablett 2mg N30 | KRKA, d.d. | 50% | |||||||
| 1045088 | doksasosiin | C02CA04 | KAMIREN tablett 4mg N20 | KRKA, d.d. | 50% | |||||||
| 1071379 | doksasosiin | C02CA04 | KAMIREN tablett 4mg N30 | KRKA, d.d. | 50% | |||||||
| 1011597 | doksasosiin | C02CA04 | ZOXON 1 tablett 1mg N15 | Zentiva a.s. | 50% | |||||||
| 1083574 | doksasosiin | C02CA04 | ZOXON 1 tablett 1mg N30 | Zentiva a.s. | 50% | |||||||
| 1011609 | doksasosiin | C02CA04 | ZOXON 2 tablett 2mg N10 | Zentiva a.s. | 50% | |||||||
| 1083585 | doksasosiin | C02CA04 | ZOXON 2 tablett 2mg N30 | Zentiva a.s. | 50% | |||||||
| 1011610 | doksasosiin | C02CA04 | ZOXON 4 tablett 4mg N30 | Zentiva a.s. | 50% | |||||||
| 1065877 | doksütsükliin | J01AA02 | DOXITIN tablett 100mg N10 | Vitabalans OY | 50% | 100% | (A50-A53)* | *rv dermatoveneroloogil | ||||
| 1144976 | doksütsükliin | J01AA02 | DOXY M-RATIOPHARM 100 tablett 100mg N10 | ratiopharm GmbH | 50% | 100% | (A50-A53)* | *rv dermatoveneroloogil | ||||
| 1018303 | doksütsükliin | J01AA02 | DOXYCYCLIN 100 STADA TABS tablett 100mg N10 | STADA ARZNEIMITTEL AG | 50% | 100% | (A50-A53)* | *rv dermatoveneroloogil | ||||
| 1065934 | doksütsükliin | J01AA02 | DOXYCYCLIN 100 STADA TABS tablett 100mg N20 | STADA ARZNEIMITTEL AG | 50% | 100% | (A50-A53)* | *rv dermatoveneroloogil | ||||
| 1035357 | doksütsükliin | J01AA02 | DOXYHEXAL 100 tablett 100mg N10 | Hexal AG | 50% | 100% | (A50-A53)* | *rv dermatoveneroloogil | ||||
| 1065899 | doksütsükliin | J01AA02 | DOXYLAN tablett 100mg N10 | LANNACHER HEILMITTEL GmbH | 50% | 100% | (A50-A53)* | *rv dermatoveneroloogil | ||||
| 1018156 | domperidoon | A03FA03 | MOTILIUM tablett 10mg N10 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1063055 | domperidoon | A03FA03 | MOTILIUM tablett 10mg N30 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1030385 | donepesiil | N06DA02 | ARICEPT tablett 10mg N28 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1030374 | donepesiil | N06DA02 | ARICEPT tablett 5mg N28 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1022960 | dornaas alfa | R05CB13 | PULMOZYME inhalatsioonilahus 1mg/ml 2.5ml N6 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1014961 | dorsolamiid | S01EC03 | TRUSOPT silmatilgad 2% 5 ml | Merck Sharp & Dohme OÜ | 50% | 100% | (H40-H42)* | *rv oftalmoloogil oftalmoloogil juhul, kui ravi beeta- adrenoblokaatoriga ei ole langetanud piisavalt silma siserõhku või beeta- adrenoblokaator on vastunäidustatud | ||||
| 1043536 | drospirenoon+etünüülöstradiool | G03AA12 | YARINA tablett 3mg+0,03mg | Schering AG | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning | ||||
| N21 | sünnitamisele meditsiinilise vastunäidustuse korral | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1165711 [RTL 2006, 26, 482 – jõust. 1.04.2006] | drospirenoon+ östradiool | G03FA17 | ANGELIQ tablett 2 mg+1 mg N28 | Schering AG | 50% | |||||||
| 1062885 | drotaveriin | A03AD02 | NO-SPA tablett 40mg N100 | Chinoin | 50% | |||||||
| 1015467 | drotaveriin | A03AD02 | NO-SPA tablett 40mg N20 | Chinoin | 50% | |||||||
| 1195624 | duloksetiin | N06AX21 | CYMBALTA gastroresistentne kõvakapsel 30 mg N28 | Eli Lilly Netherland B.V. | 50% | |||||||
| 1195635 | duloksetiin | N06AX21 | CYMBALTA gastroresistentne kõvakapsel 60 mg N28 | Eli Lilly Netherland B.V. | 50% | |||||||
| 1155440 | dutasteriid | G04CB02 | AVODART kapsel 0,5 mg N30 | GlaxoSmithKline Eesti OÜ | 50% | |||||||
| 1054752 | düdrogesteroon | G03DB01 | DUPHASTON tablett 10mg N20 | Solvay Pharmaceuticals BV | 50% | |||||||
| 1081617 | ebastiin | R06AX22 | KESTINE 10 mg tablett 10mg N30 | Nycomed Sefa AS | 50% | |||||||
| 1009976 | ebastiin | R06AX22 | KESTINE tablett 20mg N10 | Nycomed Sefa AS | 50% | |||||||
| 1077948 | ebastiin | R06AX22 | KESTINE tablett 20mg N100 | Nycomed Sefa AS | 50% | |||||||
| 1077937 | ebastiin | R06AX22 | KESTINE tablett 20mg N30 | Nycomed Sefa AS | 50% | |||||||
| 1044032 | Efavirenzum | J05AG03 | STOCRIN kapsel 200 mg N90 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1044021 | Efavirenzum | J05AG03 | STOCRIN kapsel 100mg N30 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1044010 | Efavirenzum | J05AG03 | STOCRIN kapsel 50mg N30 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1107368 | Efavirenzum | J05AG03 | STOCRIN suukaudne lahus 30mg/ml 180ml | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1028540 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1062548 | ekonasool | G01AF05 | GYNO-PEVARYL 150 COMBIPACK vagin suposiit 150mg N3 + vagin kreem 1%15g | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1039036 | ekonasool | G01AF05 | GYNO-PEVARYL 50 vaginaaloovul 50mg N15 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1020373 | ekonasool | G01AF05 | GYNO-PEVARYL oovul 150mg N3 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1011148 | eksemestaan | L02BG06 | AROMASIN tablett 25mg N30 | Pfizer Enterprises Sarl | 50% | |||||||
| 1078107 | Emedastiin | S01GX06 | EMADINE silmatilgad 0,05% 10ml | ALCON LABORATORIES (UK) Ltd. | 50% | |||||||
| 1042850 | Emedastiin | S01GX06 | EMADINE silmatilgad 0,05% 5ml | ALCON LABORATORIES (UK) Ltd. | 50% | |||||||
| 1074091 | enalapriil | C09AA02 | BERLIPRIL 5 tablett 5mg N100 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1017470 | enalapriil | C09AA02 | BERLIPRIL 5 tablett 5mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074080 | enalapriil | C09AA02 | BERLIPRIL 5 tablett 5mg N50 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1087501 | enalapriil | C09AA02 | EDNYT tablett 10mg N30 | GEDEON RICHTER Ltd. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1060186 | enalapriil | C09AA02 | EDNYT tablett 2,5mg N30 | GEDEON RICHTER Ltd. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1087512 | enalapriil | C09AA02 | EDNYT tablett 20mg N30 | GEDEON RICHTER Ltd. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1087499 | enalapriil | C09AA02 | EDNYT tablett 5mg N30 | GEDEON RICHTER Ltd. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074181 | enalapriil | C09AA02 | ENAHEXAL 10 MG tablett 10mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1010620 | enalapriil | C09AA02 | ENAHEXAL 10 MG tablett 10mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074125 | enalapriil | C09AA02 | ENAHEXAL 20 MG tablett 20mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1010631 | enalapriil | C09AA02 | ENAHEXAL 20 MG tablett 20mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074147 | enalapriil | C09AA02 | ENAHEXAL 5 MG tablett 5mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1010619 | enalapriil | C09AA02 | ENAHEXAL 5 MG tablett 5mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1010013 | enalapriil | C09AA02 | ENALAPRIL- RATIOPHARM 10MG tablett 10mg N30 | ratiopharm GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1010024 | enalapriil | C09AA02 | ENALAPRIL- RATIOPHARM 20MG tablett 20mg N30 | ratiopharm GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1010002 | enalapriil | C09AA02 | ENALAPRIL- RATIOPHARM 5MG tablett 5mg N30 | ratiopharm GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1005174 | enalapriil | C09AA02 | ENAP 10 tablett 10mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1030408 | enalapriil | C09AA02 | ENAP 2,5 tablett 2,5mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1005219 | enalapriil | C09AA02 | ENAP 20 tablett 20mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1016929 | enalapriil | C09AA02 | ENAP 5 tablett 5mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1101070 | enalapriil | C09AA02 | INVORIL tablett 10mg N30 | Ranbaxy UK Ltd | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1101069 | enalapriil | C09AA02 | INVORIL tablett 5mg N30 | Ranbaxy UK Ltd | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074215 | enalapriil | C09AA02 | RENITEC 10 MG tablett 10mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1111307 | enalapriil | C09AA02 | RENITEC 10 MG tablett 10mg N100 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074226 | enalapriil | C09AA02 | RENITEC 5 MG tablett 5mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074259 | enalapriil | C09AA02 | RENITEC FORTE tablett 20mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1111295 | enalapriil | C09AA02 | RENITEC FORTE tablett 20mg N100 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1013599 | enalapriil | C09AA02 | BERLIPRIL 10 tablett 10mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1013601 | enalapriil | C09AA02 | BERLIPRIL 20 tablett 20mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1133895 | enalapriil | C09AA02 | ENAP 5 tablett 5mg N60 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1133929 | enalapriil | C09AA02 | ENAP 10 tablett 10 mg N60 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1133952 | enalapriil | C09AA02 | ENAP 20 tablett 20mg N60 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1012004 | enalapriil | C09AA02 | ENALAPRILUM - 5 MG MEPHA tablett 5 mg N30 | Mepha LDA | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1012015 | enalapriil | C09AA02 | ENALAPRILUM - 10 MG MEPHA tablett 10 mg N28 | Mepha LDA | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1012026 | enalapriil | C09AA02 | ENALAPRILUM - 20 MG MEPHA tablett 20 mg N28 | Mepha LDA | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074899 | enalapriil+hüdroklorotiasiid | C09BA02 | CO-RENITEC tablett 10mg+25mg N30 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074888 | enalapriil+hüdroklorotiasiid | C09BA02 | CO-RENITEC tablett 20mg+12,5mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1016918 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAP-H tablett 10mg+25mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1016907 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAP-HL tablett 10mg+12,5mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1147597 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAP-H tablett 10mg+25mg N30 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1147609 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAP-H tablett 10mg+25mg N60 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1147564 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAP-HL tablett 10mg+12,5mg N30 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1147575 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAP-HL tablett 10mg+12,5mg N60 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1151389 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAP-HL 20 tablett 20mg+12,5mg N30 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074901 | enalapriil+hüdroklorotiasiid | C09BA02 | RENITEC PLUS tablett 20mg+6mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1129159 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAHEXAL COMP 20/12,5 tablett 20mg + 12,5mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1129160 | enalapriil+hüdroklorotiasiid | C09BA02 | ENAHEXAL COMP 10/25 tablett 10mg + 25mg N20 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1065529 | enoksapariin | B01AB05 | CLEXANE inj 100 mg/ml amp või süstel 0,2ml N10 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1020081 | enoksapariin | B01AB05 | CLEXANE inj 100 mg/ml amp või süstel 0,2ml N2 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065541 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 0,4ml N10 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065530 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 0,4ml N2 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065563 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 0,6ml N10 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065552 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 0,6ml N2 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1065585 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 0,8ml N10 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065574 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 0,8ml N2 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065608 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 1ml N10 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065596 | enoksapariin | B01AB05 | CLEXANE inj100 mg/ml amp või süstel 1ml N2 | LABORATOIRE AVENTIS | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1064607 | entakapoon | N04BX02 | COMTESS tablett 200mg N100 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1030273 | entakapoon | N04BX02 | COMTESS tablett 200mg N30 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1064618 | entakapoon | N04BX02 | COMTESS tablett 200mg N350 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1064595 | entakapoon | N04BX02 | COMTESS tablett 200mg N60 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1084250 | Epoetin beta | B03XA80 | NEORECORMON 50 000 MULTIDOSE injektsioonisubstants 50000TÜ viaal N1+lahusti | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1044212 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 10000TÜ 0.3ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1066340 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 10000TÜ 0.3ml N6 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1044199 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 2000TÜ 0.3ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1066384 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 2000TÜ 0.3ml N6 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1061378 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 4000TÜ 0.3ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1061389 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 4000TÜ 0.3ml N6 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1044201 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 5000TÜ 0.3ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1066418 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 5000TÜ 0.3ml N6 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1044188 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 500TÜ 0.3ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1066407 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 500TÜ 0.3ml N6 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1061356 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 6000TÜ 0.3ml 0.3ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1061367 | Epoetin beta | B03XA80 | NEORECORMON süstelahus 6000TÜ 0.3ml 0.3ml N6 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1010844 | eprosartaan | C09CA02 | TEVETEN tablett 400mgTabl N14 | Solvay Pharmaceuticals BV | 50% | |||||||
| 1081123 | eprosartaan | C09CA02 | TEVETEN tablett 400mgTabl N28 | Solvay Pharmaceuticals BV | 50% | |||||||
| 1081134 | eprosartaan | C09CA02 | TEVETEN tablett 400mgTabl N56 | Solvay Pharmaceuticals BV | 50% | |||||||
| 1010855 | eprosartaan | C09CA02 | TEVETEN tablett 600mg 1Tabl N14 | Solvay Pharmaceuticals BV | 50% | |||||||
| 1081101 | eprosartaan | C09CA02 | TEVETEN tablett 600mg 1Tabl N28 | Solvay Pharmaceuticals BV | 50% | |||||||
| 1081112 | eprosartaan | C09CA02 | TEVETEN tablett 600mg 1Tabl N56 | Solvay Pharmaceuticals BV | 50% | |||||||
| 1163720 | erütromütsiin | D10AF02 | AKNEFUG EL lahus paikseks kasut. 10mgml 50ml | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1024142 | erütromütsiin | J01FA01 | ERYTHROMYCIN NYCOMED tablett 500mg N10 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | 100% | (A50-A53)* | *rv dermatoveneroloogil | |
| 1083990 | erütropoetiin | B03XA01 | EPREX 10 000 inj 10000TÜ/ml eeltäidetud süstal 1ml N6 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1084137 | erütropoetiin | B03XA01 | EPREX 2000 inj 4000TÜ/ml eeltäidetud süstlad 0,5ml N6 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1084148 | erütropoetiin | B03XA01 | EPREX 4000 inj 10000TÜ/1ml eeltäidetud süstlad 0,4ml N6 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1088355 | erütropoetiin | B03XA01 | EPREX 5000 inj 5000TÜ/0,5ml täidetud süstal 0,5 ml N6 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| 1088366 | erütropoetiin | B03XA01 | EPREX 6000 inj 6000TÜ/0,6ml täidetud süstal 0,6 ml N6 | JANSSEN-CILAG INTERNATIONAL NV | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1162943 | esetimiib | C10AX09 | EZETROL 10 mg N14 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1162965 | esetimiib | C10AX09 | EZETROL 10 mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1087949 | Esomeprasool | A02BC05 | NEXIUM tablett 20mg N14 | AstraZeneca AB | 50% | |||||||
| 1087961 | Esomeprasool | A02BC05 | NEXIUM tablett 20mg N140 | AstraZeneca AB | 50% | |||||||
| 1087950 | Esomeprasool | A02BC05 | NEXIUM tablett 20mg N28 | AstraZeneca AB | 50% | |||||||
| 1012442 | Esomeprasool | A02BC05 | NEXIUM tablett 20mg N3 | AstraZeneca AB | 50% | |||||||
| 1087938 | Esomeprasool | A02BC05 | NEXIUM tablett 20mg N7 | AstraZeneca AB | 50% | |||||||
| 1087972 | Esomeprasool | A02BC05 | NEXIUM tablett 40mg N14 | AstraZeneca AB | 50% | |||||||
| 1087994 | Esomeprasool | A02BC05 | NEXIUM tablett 40mg N140 | AstraZeneca AB | 50% | |||||||
| 1087983 | Esomeprasool | A02BC05 | NEXIUM tablett 40mg N28 | AstraZeneca AB | 50% | |||||||
| 1012677 | Esomeprasool | A02BC05 | NEXIUM tablett 40mg N7 | AstraZeneca AB | 50% | |||||||
| 1102509 | estsitalopraam | N06AB10 | CIPRALEX tablett 5 mg N14 | H. Lundbeck AS | 50% | |||||||
| 1102510 | estsitalopraam | N06AB10 | CIPRALEX tablett 5 mg N28 | H. Lundbeck AS | 50% | |||||||
| 1102521 | estsitalopraam | N06AB10 | CIPRALEX tablett 10 mg N14 | H. Lundbeck AS | 50% | |||||||
| 1102543 | estsitalopraam | N06AB10 | CIPRALEX tablett 10 mg N28 | H. Lundbeck AS | 50% | |||||||
| 1102565 | estsitalopraam | N06AB10 | CIPRALEX tablett 15 mg N28 | H. Lundbeck AS | 50% | |||||||
| 1102598 | estsitalopraam | N06AB10 | CIPRALEX tablett 20 mg N28 | H. Lundbeck AS | 50% | |||||||
| 1138621 | etonogestreel + etinüülöstradiool | G02BB01 | NUVARING vaginaalrõngas 11,7mg+2,7mg N1 | N.V. ORGANON | 50% | |||||||
| 1138632 | etonogestreel + etinüülöstradiool | G02BB01 | NUVARING vaginaalrõngas 11,7mg+2,7mg N3 | N.V. ORGANON | 50% | |||||||
| 1036213 | etoposiid | L01CB01 | VEPESID kapsel 100mg N10 | Bristol-Myers Squibb Eesti AS | 50% | 100% | (C00-D48)* | *rv onkoloogil, hematoloogil ja pediaatril | ||||
| 1085318 | etorikoksiib | M01AH80 | ARCOXIA tablett 60 mg N14 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1085307 | etorikoksiib | M01AH80 | ARCOXIA tablett 60 mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1085330 | etorikoksiib | M01AH80 | ARCOXIA tablett 90 mg N14 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1085329 | etorikoksiib | M01AH80 | ARCOXIA tablett 90 mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1085352 | etorikoksiib | M01AH80 | ARCOXIA tablett 120 mg N14 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1085341 | etorikoksiib | M01AH80 | ARCOXIA tablett120 mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1127865 | etorikoksiib | M01AH80 | ARCOXIA tablett 60 mg N7 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1127854 | etorikoksiib | M01AH80 | ARCOXIA tablett 90 mg N7 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1127843 | etorikoksiib | M01AH80 | ARCOXIA tablett 120 mg N7 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1038361 | famotidiin | A02BA03 | FAMOSAN tablett 20mg N20 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1038350 | famotidiin | A02BA03 | FAMOSAN tablett 40mg N10 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1014714 | famotidiin | A02BA03 | QUAMATEL tablett 20mg N28 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1014725 | famotidiin | A02BA03 | QUAMATEL tablett 40mg N14 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1077959 | feksofenadiin | R06AX26 | TELFAST 120MG tablett 120mg N100 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1009819 | feksofenadiin | R06AX26 | TELFAST 120MG tablett 120mg N30 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1077960 | feksofenadiin | R06AX26 | TELFAST 180MG tablett 180mg N100 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1009820 | feksofenadiin | R06AX26 | TELFAST 180MG tablett 180mg N30 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1019708 | felodipiin | C08CA02 | PLENDIL retardtablett 10mg N30 | AstraZeneca AB | 50% | 75% | (I10-I13); I15 | |||||
| 1028135 | felodipiin | C08CA02 | PLENDIL retardtablett 2,5mg N30 | AstraZeneca AB | 50% | 75% | (I10-I13); I15 | |||||
| 1019696 | felodipiin | C08CA02 | PLENDIL retardtablett 5mg N30 | AstraZeneca AB | 50% | 75% | (I10-I13); I15 | |||||
| 1078028 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1012330 | felodipiin | C08CA02 | PRESID retardtablett 10mg N30 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | (I10-I13); I15 | |||||
| 1077780 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1012318 | felodipiin | C08CA02 | PRESID retardtablett 2,5mg N30 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | (I10-I13); I15 | |||||
| 1078017 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1012329 | felodipiin | C08CA02 | PRESID retardtablett 5mg N30 | IVAX Pharmaceuticals | 50% | 75% | (I10-I13); | |||||
| s.r.o. | I15 | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1174373 [RTL 2006, 26, 482 – jõust. 1.04.2006] | felodipiin | C08CA02 | FELODIPINHEXAL 5 prol tablett 5 mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15 | |||||
| 1174474 | felodipiin | C08CA02 | FELODIPINHEXAL 10 prol tablett 10 mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15 | |||||
| 1105647 | felodipiin | C08CA02 | FELODIPINE ALPHARMA TABLETS 5 MG prol tablett 5 mg N30 | Alpharma Limited | 50% | 75% | (I10-I13); I15 | |||||
| 1029495 | fenobarbitaal | N03AA02 | PHENAEMAL 0,1 tablett 100mg N50 | Desitin Arzneimittel GmbH | 50% | 100% | G40* | *rev neuroloogil | ||||
| 1026593 | fenofibraat | C10AB05 | LIPANTHYL kapsel 200mg N30 | LABORATOIRES FOURNIER S.A | 50% | |||||||
| 1020272 | fenoksümetüülpenitsilliin | J01CE02 | OSPEN 500 tablett 500 000 TÜ N12 | Biochemie GmbH | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1020340 | fenoksümetüülpenitsilliin | J01CE02 | OSPEN 1000 tablett 1 000 000 TÜ N12 | Biochemie GmbH | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1105951 | fenoksümetüülpenitsilliin | J01CE02 | OSPEN 400 000 IU/5 ml Oral Suspension siirup 400 000 TÜ/5 ml 60 ml | Biochemie GmbH | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1013645 | fenoksümetüülpenitsilliin | J01CE02 | VEPICOMBIN NOVUM 1 000 000 TÜ tablett 1000000TÜ N10 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1106558 | fenoksümetüülpenitsilliin | J01CE02 | VEPICOMBIN NOVUM 1 000 000 TÜ tablett 1000000TÜ N100 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1106536 | fenoksümetüülpenitsilliin | J01CE02 | VEPICOMBIN NOVUM 1 000 000 TÜ tablett 1000000TÜ N20 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1106547 | fenoksümetüülpenitsilliin | J01CE02 | VEPICOMBIN NOVUM 1 000 000 TÜ tablett 1000000TÜ N30 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1013634 | fenoksümetüülpenitsilliin | J01CE02 | VEPICOMBIN NOVUM 500 000 TÜ tablett 500000TÜ N20 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1106525 | fenoksümetüülpenitsilliin | J01CE02 | VEPICOMBIN NOVUM 500 000 TÜ tablett 500000TÜ N30 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1013656 | fenoksümetüülpenitsilliin | J01CE02 | VEPICOMBIN NOVUM 85 000TÜ/ML graanulid lahuseks 85000TÜ/ml 100ml N1 | Nycomed Sefa AS | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1031207 | fenoksümetüülpenitsilliin | J01CE02 | V-PENICILIN 250MG SLOVAKOFARMA tablett 250mg N30 | Slovakofarma | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1031218 | fenoksümetüülpenitsilliin | J01CE02 | V-PENICILIN 500MG SLOVAKOFARMA tablett 500mg N30 | Slovakofarma | 50% | 75% | J13-J15* | *rv alla 16-aastastele lastele | ||||
| 1044223 | fenoterool | R03AC04 | BEROTEC N 100 MCG inhal aeros 100mcg/annuses 200annust 10 ml | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1001169 | fenoterool+ipratroopiumbromiid | R03AK80 | BERODUAL inhalatsioonilahus 0,5mg+0,25mg/ml 20ml | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1009651 | fenoterool+ipratroopiumbromiid | R03AK80 | BERODUAL N annustatud aerosool 50mcg+20mcgannus 200annus | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1028168 | fentanüül | N02AB03 | DUROGESIC TTS 100mcg/h N5 | Janssen Pharmaceutica N.V. | 50% | 100% | (C00-D48)* | *rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kelle valutustamiseks ei saa kasutada suukaudset morfiini kõrvaltoimete või ravimvormi sobimatuse tõttu või kui suukaudne morfiin ei taga valutustamist. | ||||
| 1022218 | fentanüül | N02AB03 | DUROGESIC TTS 25mcg/h N5 | Janssen Pharmaceutica N.V. | 50% | 100% | (C00-D48)* | *rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kelle valutustamiseks ei saa kasutada suukaudset morfiini kõrvaltoimete või ravimvormi sobimatuse tõttu või kui suukaudne morfiin ei taga valutustamist. | ||||
| *rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kelle | ||||||||||||
| 1028146 | fentanüül | N02AB03 | DUROGESIC TTS 50mcg/h N5 | Janssen Pharmaceutica N.V. | 50% | 100% | (C00-D48)* | valutustamiseks ei saa kasutada suukaudset morfiini kõrvaltoimete või ravimvormi sobimatuse tõttu või kui suukaudne morfiin ei taga valutustamist. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1129137 | fentanüül | N02AB03 | DUROGESIC TTS 75mcg/h N5 | Janssen Pharmaceutica N.V. | 50% | 100% | (C00- D48),* | rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kelle valutustamiseks ei saa kasutada suukaudset morfiini kõrvaltoimete või ravimvormi sobimatuse tõttu või kui suukaudne morfiin ei taga valutustamist, *soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1077050 | fenütoiin | N03AB02 | PHENHYDAN tablett 100mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | G40* | *rev neuroloogil | ||||
| 1013487 | finasteriid | G04CB01 | PENESTER tablett 5mg N30 | LÉCIVA a.s. | 50% | |||||||
| 1007042 | finasteriid | G04CB01 | PROSCAR 5 MG tablett 5mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1070637 | flekainiidatsetaat | C01BC04 | TAMBOCOR tablett 100mg N100 | 3M HEALTH CARE Ltd. | 50% | |||||||
| 1032242 | flekainiidatsetaat | C01BC04 | TAMBOCOR tablett 100mg N20 | 3M HEALTH CARE Ltd. | 50% | |||||||
| 1070626 | flekainiidatsetaat | C01BC04 | TAMBOCOR tablett 50mg N100 | 3M HEALTH CARE Ltd. | 50% | |||||||
| 1032231 | flekainiidatsetaat | C01BC04 | TAMBOCOR tablett 50mg N20 | 3M HEALTH CARE Ltd. | 50% | |||||||
| 1060344 | fludarabiin | L01BB05 | FLUDARA ORAL tablett 10mg N15 | Schering AG | 50% | |||||||
| 1060355 | fludarabiin | L01BB05 | FLUDARA ORAL tablett 10mg N20 | Schering AG | 50% | |||||||
| 1036943 | flukonasool | J02AC01 | DIFLAZON 100 kapsel 100mg N28 | KRKA, d.d. | 50% | |||||||
| 1036954 | flukonasool | J02AC01 | DIFLAZON 150 kapsel 150mg N1 | KRKA, d.d. | 50% | |||||||
| 1071504 | flukonasool | J02AC01 | DIFLAZON 200 kapsel 200mg N20 | KRKA, d.d. | 50% | |||||||
| 1036965 | flukonasool | J02AC01 | DIFLAZON 200 kapsel 200mg N7 | KRKA, d.d. | 50% | |||||||
| 1036932 | flukonasool | J02AC01 | DIFLAZON 50 kapsel 50mg N7 | KRKA, d.d. | 50% | |||||||
| 1007154 | flukonasool | J02AC01 | DIFLUCAN 100MG kapsel 100mg N7 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1007187 | flukonasool | J02AC01 | DIFLUCAN 150MG kapsel 150mg N1 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1007132 | flukonasool | J02AC01 | DIFLUCAN 50MG kapsel 50mg N7 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1083620 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1011722 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1083631 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1011733 | flukonasool | J02AC01 | MYCOMAX kapsel 150mg N1 | LÉCIVA a.s. | 50% | |||||||
| 1009718 | flukonasool | J02AC01 | MYCOSYST 150 MG kapsel 150mg N1 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1082999 | flukonasool | J02AC01 | MYCOSYST 150 MG kapsel 150mg N2 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1009707 | flukonasool | J02AC01 | MYCOSYST 50 MG kapsel 50mg N7 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1144662 | flukonasool | J02AC01 | FLUCOHEXAL 50 kapsel 50 mg N7 | Hexal AG | 50% | |||||||
| 1144774 | flukonasool | J02AC01 | FLUCOHEXAL 100 kapsel 100 mg N7 | Hexal AG | 50% | |||||||
| 1144831 | flukonasool | J02AC01 | FLUCOHEXAL 150 kapsel 150 mg N1 | Hexal AG | 50% | |||||||
| 1144842 | flukonasool | J02AC01 | FLUCOHEXAL 150 kapsel 150 mg N2 | Hexal AG | 50% | |||||||
| 1144875 | flukonasool | J02AC01 | FLUCOHEXAL 200 kapsel 200 mg N7 | Hexal AG | 50% | |||||||
| 1140275 | flukonasool | J02AC01 | FLUCONAZOL NYCOMED 150 MG kõvakapsel 150 mg N1 | Nycomed Sefa AS | 50% | |||||||
| 1140286 | flukonasool | J02AC01 | FLUCONAZOL NYCOMED 150 MG kõvakapsel 150 mg N2 | Nycomed Sefa AS | 50% | |||||||
| 1154944 | flukonasool | J02AC01 | FLUCORIC kõvakapsel 150 mg N1 | Ranbaxy UK Ltd | 50% | |||||||
| 1038664 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1107111 | fluoksetiin | N06AB03 | FLUX kapsel 20mg N14 | Hexal AG | 50% | |||||||
| 1107122 | fluoksetiin | N06AB03 | FLUX kapsel 20mg N28 | Hexal AG | 50% | |||||||
| 1044784 | fluoksetiin | N06AB03 | FLUOXETIN MEDOCHEMIE kapslid 20 mg N30 | Medochemie Ltd. | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1030420 | fluoksetiin | N06AB03 | NYCOFLOX kapsel 20mg N30 | Nycomed Sefa AS | 50% | |||||||
| 1070390 | fluoksetiin | N06AB03 | PROZAC kapsel 20mg N14 | Eli Lilly Holding Limited | 50% | |||||||
| 1070402 | fluoksetiin | N06AB03 | PROZAC kapsel 20mg N28 | Eli Lilly Holding Limited | 50% | |||||||
| 1007839 | fluoksetiin | N06AB03 | PROZAC kapsel 20mg N7 | Eli Lilly Holding Limited | 50% | |||||||
| 1006142 | flupentiksool | N05AF01 | FLUANXOL DEPOT süstelahus 100mg/ml 1ml N1 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1006175 | flupentiksool | N05AF01 | FLUANXOL DEPOT süstelahus 20mg/ml amp 1ml N1 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1005972 | flupentiksool | N05AF01 | FLUANXOL tablett 1mg N50 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1107201 | flupirtiin | N02BG07 | KATADOLON kapsel 100 mg N10 | AWD.Pharma GmbH&Co.KG | 50% | |||||||
| 1115244 | flupirtiin | N02BG07 | KATADOLON kapsel 100 mg N30 | AWD.Pharma GmbH&Co.KG | 50% | |||||||
| 1115255 | flupirtiin | N02BG07 | KATADOLON kapsel 100 mg N 50 | AWD.Pharma GmbH&Co.KG | 50% | |||||||
| 1006344 | flutikasoonpropionaat | D07AC17 | CUTIVATE CREAM 0,05% kreem 0,05% 15g N1 | Glaxo Wellcome Operations | 50% | 75% | L20; L23; L40** | rv dermatoveneroloogil ja pediaatril; *rv dermatoveneroloogil; | ||||
| 1004847 | flutikasoonpropionaat | D07AC17 | CUTIVATE OINTMENT 0,005% salv 0,005% 15g N1 | Glaxo Wellcome Operations | 50% | |||||||
| 1007233 | flutikasoonpropionaat | R01AD08 | FLIXONASE AQUEOUS NASAL SPRAY 50 MCG ninasprei 50mcg/annuses 120annust N1 | Glaxo Wellcome Operations | 50% | |||||||
| 1007840 | flutikasoonpropionaat | R03BA05 | FLIXOTIDE DISKUS 100 MCG inhalatsioonipulber 100mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil, rv alla 18-aastasele lapsele | ||||
| 1007884 | flutikasoonpropionaat | R03BA05 | FLIXOTIDE DISKUS 250 MCG inhalatsioonipulber 250mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil, rv alla 18-aastasele lapsele | ||||
| 1007862 | flutikasoonpropionaat | R03BA05 | FLIXOTIDE DISKUS 50 MCG inhalatsioonipulber 50mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil, rv alla 18-aastasele lapsele | ||||
| 1006467 | flutikasoonpropionaat | R03BA05 | FLIXOTIDE INHALER inhal aeros 50mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil, rv alla 18-aastasele lapsele | ||||
| 1130690 | flutikasoonpropionaat | R03BA05 | FLIXOTIDE INHALER inhal aeros 50mcg/annuses 120annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45* | *rev pediaatril ja pulmonoloogil, rv alla 18-aastasele lapsele | ||||
| 1008302 | fluvastatiin | C10AA04 | LESCOL 40 MG kapsel 40mg N28 | Novartis Finland OY | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1011126 | fluvastatiin | C10AA04 | LESCOL XL tablett 80mg N28 | Novartis Finland OY | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1039564 | fluvoksamiin | N06AB08 | FEVARIN kaetud tablett 100mg N30 | Solvay Pharmaceuticals B.V | 50% | |||||||
| 1070569 | fluvoksamiin | N06AB08 | FEVARIN kaetud tablett 100mg N50 | Solvay Pharmaceuticals B.V | 50% | |||||||
| 1149791 | fluvoksamiin | N06AB08 | FEVARIN kaetud tablett 50mg N30 | Solvay Pharmaceuticals B.V | 50% | |||||||
| 1070570 | fluvoksamiin | N06AB08 | FEVARIN kaetudtablett 50mg N50 | Solvay Pharmaceuticals B.V | 50% | |||||||
| 1149803 | fluvoksamiin | N06AB08 | FEVARIN kaetud tablett 50mg N60 | Solvay Pharmaceuticals B.V | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1115503 | fluvoksamiin | N06AB08 | FEVARIN kaetud tablett 50mg N20 | Solvay Pharmaceuticals B.V | 50% | |||||||
| 1035784 | follitropiin alfa | G03GA05 | GONAL-F injektsioonisubstants 75TÜ+1 ml lahustit N1 | ARES TRADING SA | 50% | |||||||
| 1107414 | follitropiin alfa | G03GA05 | GONAL-f 1050 IU/1,75 ML injektsioonisubstants 70 mcg/1,75 ml N1 | Serono Europe Ltd. | 50% | |||||||
| 1107403 | follitropiin alfa | G03GA05 | GONAL-f 450 IU/0,75 ML injektsioonisubstants 30 mcg N1 | Serono Europe Ltd. | 50% | |||||||
| 1173855 | follitropiin alfa | G03GA05 | GONAL-F 300 IU/0,5 ml (22 mcg/0,5 ml) süstelahus pensüstelis N1 | Serono Europe Ltd. | 50% | |||||||
| 1213513 | follitropiin alfa | G03GA05 | GONAL-F 450 IU/0,75 ml (33 mcg/0,75 ml) süstelahus pensüstelis N1 | Serono Europe Ltd. | 50% | |||||||
| 1173866 | follitropiin alfa | G03GA05 | GONAL-F 900 IU/1,5 ml (66 mcg/1,5 ml) süstelahus pensüstelis N1 | Serono Europe Ltd. | 50% | |||||||
| 1034198 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 100TÜ viaal+lahusti N1 | N.V. ORGANON | 50% | |||||||
| 1064001 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 100TÜ viaal+lahusti N10 | N.V. ORGANON | 50% | |||||||
| 1063987 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 100TÜ viaal+lahusti N3 | N.V. ORGANON | 50% | |||||||
| 1063998 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 100TÜ viaal+lahusti N5 | N.V. ORGANON | 50% | |||||||
| 1034200 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 150TÜ+lahusti N1 | N.V. ORGANON | 50% | |||||||
| 1064034 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 150TÜ+lahusti N10 | N.V. ORGANON | 50% | |||||||
| 1064012 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 150TÜ+lahusti N3 | N.V. ORGANON | 50% | |||||||
| 1064023 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 150TÜ+lahusti N5 | N.V. ORGANON | 50% | |||||||
| 1034176 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 50TÜ viaal+lahusti N1 | N.V. ORGANON | 50% | |||||||
| 1063943 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 50TÜ viaal+lahusti N10 | N.V. ORGANON | 50% | |||||||
| 1063921 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 50TÜ viaal+lahusti N3 | N.V. ORGANON | 50% | |||||||
| 1063932 | follitropiin beeta | G03GA06 | PUREGON injektsioonisubstants 50TÜ viaal+lahusti N5 | N.V. ORGANON | 50% | |||||||
| 1011924 | follitropiin beeta | G03GA06 | PUREGON süstelahus 100TÜ 0.5ml viaal 0.5ml N1 | N.V. ORGANON | 50% | |||||||
| 1064078 | follitropiin beeta | G03GA06 | PUREGON süstelahus 100TÜ 0.5ml viaal 0.5ml N10 | N.V. ORGANON | 50% | |||||||
| 1064067 | follitropiin beeta | G03GA06 | PUREGON süstelahus 100TÜ 0.5ml viaal 0.5ml N5 | N.V. ORGANON | 50% | |||||||
| 1011935 | follitropiin beeta | G03GA06 | PUREGON süstelahus 150TÜ 0.5ml viaal 0.5ml N1 | N.V. ORGANON | 50% | |||||||
| 1064090 | follitropiin beeta | G03GA06 | PUREGON süstelahus 150TÜ 0.5ml viaal 0.5ml N10 | N.V. ORGANON | 50% | |||||||
| 1064089 | follitropiin beeta | G03GA06 | PUREGON süstelahus 150TÜ 0.5ml viaal 0.5ml N5 | N.V. ORGANON | 50% | |||||||
| 1099403 | follitropiin beeta | G03GA06 | PUREGON süstelahus 300IU 0.36ml N1 | N.V. ORGANON | 50% | |||||||
| 1011913 | follitropiin beeta | G03GA06 | PUREGON süstelahus 50TÜ 0.5ml viaal 0.5ml N1 | N.V. ORGANON | 50% | |||||||
| 1064056 | follitropiin beeta | G03GA06 | PUREGON süstelahus 50TÜ 0.5ml viaal 0.5ml N10 | N.V. ORGANON | 50% | |||||||
| 1064045 | follitropiin beeta | G03GA06 | PUREGON süstelahus 50TÜ 0.5ml viaal 0.5ml N5 | N.V. ORGANON | 50% | |||||||
| 1099335 | follitropiin beeta | G03GA06 | PUREGON süstelahus 600IU 0.72ml kolbampull N1 | N.V. ORGANON | 50% | |||||||
| 1087152 | formoterool | R03AC13 | FORADIL inhalatsioonipulber kapslis 12mcg N60 | Novartis Finland OY | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1034064 | formoterool | R03AC13 | OXIS TURBUHALER inhalatsioonipulber 4,5mcg/annuses 60annust N1 | AstraZeneca UK Ltd. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1034075 | formoterool | R03AC13 | OXIS TURBUHALER inhalatsioonipulber 9mcg/annuses 60annust N1 | AstraZeneca UK Ltd. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1027145 | fosinopriil | C09AA09 | MONOPRIL tablett 10mg N28 | Bristol-Myers Squibb Eesti AS | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1027336 | fosinopriil | C09AA09 | MONOPRIL tablett 20mg N28 | Bristol-Myers Squibb | 50% | 75% | (I10-I13); | |||||
| Eesti AS | I15; I50 | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1107021 | fosinopriil+hüdroklorotiasiid | C09BA09 | MONOZIDE tablett 20 mg/12,5 mg N28 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1060399 | furosemiid | C03CA01 | Furosemid Nycomed 40 MG tablett 40mg N100 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1000258 | furosemiid | C03CA01 | Furosemid Nycomed 40 MG tablett 40mg N20 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1039362 | furosemiid | C03CA01 | LASIX RETARD retardkapsel 60mg N30 | Aventis-Pharma Deutchland GmbH | 50% | 75% | I50 | |||||
| 1112511 | furosemiid | C03CA01 | FUROGAMMA 500 tablett 500 mg N20 | Wörwag Pharma GmbH | 50% | |||||||
| 1112522 | furosemiid | C03CA01 | FUROGAMMA 500 tablett 500 mg N50 | Wörwag Pharma GmbH | 50% | |||||||
| 1112533 | furosemiid | C03CA01 | FUROGAMMA 500 tablett 500 mg N100 | Wörwag Pharma GmbH | 50% | |||||||
| 1212758 [RTL 2006, 26, 482 – jõust. 1.04.2006] | fusafungiin | R02AB03 | BIOPAROX sprei 0.125mg/annuses 10ml | Les Laboratories Servier | 50% | |||||||
| 1007750 | fusiidhape | D06AX01 | FUCIDIN kreem 2% 15g | Leo Pharmaceutical Products | 50% | |||||||
| 1007727 | fusiidhape | D06AX01 | FUCIDIN salv 2% 15g | Leo Pharmaceutical Products | 50% | |||||||
| 1018606 | fusiidhape | S01AA13 | FUCITHALMIC viskoossed silmatilgad 1% 5g N1 | Leo Pharmaceutical Products | 50% | |||||||
| 1076947 | gabapentiin | N03AX12 | NEURONTIN kapsel 100mg N100 | Pfizer Limited | 50% | |||||||
| 1033030 | gabapentiin | N03AX12 | NEURONTIN kapsel 100mg N20 | Pfizer Limited | 50% | |||||||
| 1076969 | gabapentiin | N03AX12 | NEURONTIN kapsel 300mg N100 | Pfizer Limited | 50% | |||||||
| 1032815 | gabapentiin | N03AX12 | NEURONTIN kapsel 300mg N50 | Pfizer Limited | 50% | |||||||
| 1076958 | gabapentiin | N03AX12 | NEURONTIN kapsel 400mg N100 | Pfizer Limited | 50% | |||||||
| 1032826 | gabapentiin | N03AX12 | NEURONTIN kapsel 400mg N50 | Pfizer Limited | 50% | |||||||
| 1091427 | galantamiin | N06DA04 | REMINYL suukaudne lahus 4 mg/ml 100 ml | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1091348 | galantamiin | N06DA04 | REMINYL kaetud tablett 12 mg N56 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1091326 | galantamiin | N06DA04 | REMINYL kaetud tablett 8 mg N56 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1091337 | galantamiin | N06DA04 | REMINYL kaetud tablett 8 mg N14 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1091315 | galantamiin | N06DA04 | REMINYL kaetud tablett 4 mg N14 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1012059 | ganireliks | H01CC01 | ORGALUTRAN süstelahus 0,25mg 0.5ml täidetud süstal 0.5ml N1 | N.V. ORGANON | 50% | |||||||
| 1064685 | ganireliks | H01CC01 | ORGALUTRAN süstelahus 0,25mg 0.5ml täidetud süstal 0.5ml N5 | N.V. ORGANON | 50% | |||||||
| 1022263 | gantsükloviir | J05AB06 | CYMEVENE kapsel 250mg N84 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1023624 | gestodeen+etünüülöstradiool | G03AA10 | FEMODEN tablett 0,075mg+0,03mg N21 | Schering AG | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1027718 | gestodeen+etünüülöstradiool | G03AA10 | HARMONET tablett 0,075mg+0,02mg N21 | WYETH LEDERLE PHARMA GmbH | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1062953 | gestodeen+etünüülöstradiool | G03AA10 | HARMONET tablett 0,075mg+0,02mg N63 | WYETH LEDERLE PHARMA GmbH | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1035098 | gestodeen+etünüülöstradiool | G03AA10 | LOGEST tablett 0,075mg+0,02mg N21 | Schering AG | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise | ||||
| vastunäidustuse korral | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1005309 | gestodeen+etünüülöstradiool | G03AA10 | MINULET tablett 0,075mg+0,03mg N21 | WYETH LEDERLE PHARMA GmbH | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1062986 | gestodeen+etünüülöstradiool | G03AA10 | MINULET tablett 0,075mg+0,03mg N63 | WYETH LEDERLE PHARMA GmbH | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1012149 | gestodeen+etünüülöstradiool | G03AA10 | MIRELLE tablett 60mcg+15mcg N28 | Schering AG | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1027651 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1063156 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1115716 | gestodeen+etünüülöstradiool | G03AA10 | LINDYNETTE 20 tablett 0,075 mg+0,02 mg N3x21 | GEDEON RICHTER Ltd. | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1115693 | gestodeen+etünüülöstradiool | G03AA10 | LINDYNETTE 30 tablett 0,075 mg+0,03 mg N3x21 | GEDEON RICHTER Ltd. | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1006300 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1075182 | glibenklamiid | A10BB01 | MANINIL 3,5 tablett 3,5mg N120 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | E11; E14 | |||||
| 1001226 | glibenklamiid | A10BB01 | MANINIL 3,5 tablett 3,5mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | E11; E14 | |||||
| 1075171 | glibenklamiid | A10BB01 | MANINIL 3,5 tablett 3,5mg N60 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | E11; E14 | |||||
| 1016097 | glibenklamiid | A10BB01 | MANINIL 5 tablett 5mg N120 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | E11; E14 | |||||
| 1029439 | gliklasiid | A10BB09 | DIABREZIDE tablett 80mg N40 | L. MOLTENI & C.DEI FRATELLI ALITTI S.P.A. | 50% | 75% | E11; E14 | |||||
| 1161740 | gliklasiid | A10BB09 | DIAPREL MR tablett 30mg N60 | Les Laboratories Servier | 50% | 75% | E11; E14 | |||||
| 1046405 | gliklasiid | A10BB09 | DIAPREL tablett 80mg N60 | Les Laboratories Servier | 50% | 75% | E11; E14 | |||||
| 1084957 [RTL 2006, 26, 482 – jõust. 1.04.2006] | glimepiriid | A10BB12 | AMARYL tablett 1mg N30 | Aventis-Pharma Deutchland GmbH | 50% | 75% | E11; E14 | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1084968 | glimepiriid | A10BB12 | AMARYL tablett 1mg N90 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1110328 [RTL 2006, 26, 482 – jõust. 1.04.2006] | glimepiriid | A10BB12 | AMARYL tablett 2mg N30 | Aventis-Pharma Deutchland GmbH | 50% | 75% | E11; E14 | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1084979 | glimepiriid | A10BB12 | AMARYL tablett 2mg N90 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1110339 [RTL 2006, 26, 482 – jõust. 1.04.2006] | glimepiriid | A10BB12 | AMARYL tablett 3mg N30 | Aventis-Pharma Deutchland GmbH | 50% | 75% | E11; E14 | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1084980 | glimepiriid | A10BB12 | AMARYL tablett 3mg N90 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1125391 [RTL 2006, 26, 482 – jõust. 1.04.2006] | glimepiriid | A10BB12 | AMARYL tablett 4mg N30 | Aventis-Pharma Deutchland GmbH | 50% | 75% | E11; E14 | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| Berlin-Chemie AG | ||||||||||||
| 1176948 | glimepiriid | A10BB12 | OLTAR 1 MG tablett 1 mg N30 | (Menarini Group) | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1177039 | glimepiriid | A10BB12 | OLTAR 2 MG tablett 2 mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1177129 | glimepiriid | A10BB12 | OLTAR 3 MG tablett 3 mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1175015 | glimepiriid | A10BB12 | GLIMEPIRID HEXAL 1 MG TABLETID tablett 1 mg N30 | Hexal AG | 50% | |||||||
| 1175060 | glimepiriid | A10BB12 | GLIMEPIRID HEXAL 2 MG TABLETID tablett 2 mg N30 | Hexal AG | 50% | |||||||
| 1175116 | glimepiriid | A10BB12 | GLIMEPIRID HEXAL 3 MG TABLETID tablett 3 mg N30 | Hexal AG | 50% | |||||||
| 1175161 | glimepiriid | A10BB12 | GLIMEPIRID HEXAL 4 MG TABLETID tablett 4 mg N30 | Hexal AG | 50% | |||||||
| 1029338 | glipisiid | A10BB07 | GLIBENESE GITS tablett 10mg N30 | Pfizer H.C.P. Corporation | 50% | 75% | E11; E14 | |||||
| 1029349 | glipisiid | A10BB07 | GLIBENESE GITS tablett 5mg N30 | Pfizer H.C.P. Corporation | 50% | 75% | E11; E14 | |||||
| 1015625 | glipisiid | A10BB07 | MINIDIAB tablett 5mg N30 | Pfizer Enterprises Sarl | 50% | 75% | E11; E14 | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1165878 | glükagoon | H04AA01 | GLUCAGEN 1 MG HYPOKIT injektsioonisubstants 1mg viaal+lahusti täidetud süstlas N1 | Novo Nordisk A/S | 50% | |||||||
| 1029035 | glükoosamiin | M01AX05 | ARTHRYL pulber lahuse valmistamiseks 1500mg N20 | ROTTAPHARM S.r.I | 50% | |||||||
| 1073900 | glükoosamiin | M01AX05 | ARTHRYL pulber lahuse valmistamiseks 1500mg N30 | ROTTAPHARM S.r.I | 50% | |||||||
| 1137068 | glükoosamiin | M01AX05 | GLUCADOL kaetud tablett 500 mg N60 | Nycomed Sefa AS | 50% | |||||||
| 1137079 | glükoosamiin | M01AX05 | GLUCADOL kaetud tablett 500 mg N120 | Nycomed Sefa AS | 50% | |||||||
| 1220094 [RTL 2006, 26, 482 – jõust. 1.04.2006] | glükoosamiin | M01AX05 | GLUCADOL kaetud tablett 500 mg N180 | Nycomed Sefa AS | 50% | |||||||
| 1002621 | gosereliin | L02AE03 | ZOLADEX implantaat 3,6mg N1 | AstraZeneca UK Ltd. | 50% | 75% | N80* | *rv günekoloogil III-IV astme endometrioosi põdevatele patsientidele | ||||
| 1023859 | granisetroon | A04AA02 | KYTRIL süstelahus 1mg/ml 1ml N5 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1063088 | granisetroon | A04AA02 | KYTRIL süstelahus 1mg/ml 3ml N5 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1023950 [RTL 2006, 26, 482 – jõust. 1.04.2006] | granisetroon | A04AA02 | KYTRIL tablett 1mg N10 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil kõrge emetogeensusega tsütostaatilisest ravist põhjustatud iivelduse ja oksendamise profülaktikaks ja raviks, soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1014679 | haloperidool | N05AD01 | HALOPERIDOL TABLETS 5 MG tablett 5mg N50 | GEDEON RICHTER Ltd. | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1014680 | haloperidool | N05AD01 | HALOPERIDOL tablett 1,5mg N50 | GEDEON RICHTER Ltd. | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| 1014691 | haloperidool | N05AD01 | HALOPERIDOL peroraalsed tilgad 2mg/ml 10ml | GEDEON RICHTER Ltd. | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79)* | *rev psühhiaatril | ||||
| (F00-F09)*; (F10-F19.4- | ||||||||||||
| 1064674 | haloperidool | N05AD01 | HALOPERIDOL-DECANOATE- RICHTER süstelahus 50mg/ml amp 1ml N5 | GEDEON RICHTER Ltd. | 50% | 100% | 7); (F20- F29);(F30- F31); (F32/33.2- 3); F60.3; (F70-F79) | *rev psühhiaatril | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1062122 | haltsinoniid | D07AD02 | BETACORTON SOLUTION solution 0,1% 100ml | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | |||||||
| 1028742 | haltsinoniid | D07AD02 | BETACORTON SOLUTION solution 0,1% 25ml | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | |||||||
| 1024029 | haltsinoniid+karbamiid | D07XD80 | BETACORTON CREAM kreem 0,1%+5% 20g | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | |||||||
| 1062458 | haltsinoniid+karbamiid | D07XD80 | BETACORTON CREAM kreem 0,1%+5% 50g | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | |||||||
| 1080762 | haltsinoniid+salitsüülhape | D07XD81 | BETACORTON S SOLUTION nahalahus 0,1%+2% 100ml | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | |||||||
| 1028753 | haltsinoniid+salitsüülhape | D07XD81 | BETACORTON S SOLUTION nahalahus 0,1%+2% 25ml | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | |||||||
| 1035807 | Human menopausal gonadotrophin | G03GA02 | PERGONAL injektsioonisubstants 75TÜ+1 ml lahustit N1 | ARES TRADING SA | 50% | |||||||
| 1063808 | Human menopausal gonadotrophin | G03GA02 | PERGONAL injektsioonisubstants 75TÜ+1 ml lahustit N10 | ARES TRADING SA | 50% | |||||||
| 1015434 | hüdroklorotiasiid | C03AA03 | HYPOTHIAZID tablett 100mg N20 | Chinoin | 50% | 75% | I10-I13; I15; I50; O10- O16 | |||||
| 1015478 | hüdroklorotiasiid | C03AA03 | HYPOTHIAZID tablett 25mg N20 | Chinoin | 50% | 75% | I10-I13; I15; I50; O10- O16 | |||||
| 1008841 | hüdroklorotiasiid+amiloriid | C03EA81 | MODURETIC tablett 5mg+50mg N30 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1030172 | hüdroklorotiasiid+triamtereen | C03EA80 | TRIAMPUR COMPOSITUM tablett 12,5mg+25mg N50 | ARZNEIMITTELWERK DRESDEN GmbH | 50% | |||||||
| 1137013 | hüdrokortisoon | D07AA02 | HYDROCORTISON DAK salv 1% 30ml | Nycomed Sefa AS | 50% | |||||||
| 1018594 | hüdrokortisoon+fusiidhape | D07CA01 | FUCIDIN H kreem 10mg+20mgg 15g | Leo Pharmaceutical Products | 50% | |||||||
| 1035403 | hüdrokortisoon+kloorheksidiin | D07BA80 | SIBICORT kreem 1%+1% 20g | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1045145 | hüdrokortisoon+tsiprofloksatsiin | S02CA82 | CIPROBAY HC kõrvatilgad 1%+0,2% 10 ml | Alcon Cusi S.A. | 50% | |||||||
| 1020621 | hüdrokortisoonbutüraat | D07AB02 | LOCOID CRELO Nahaemulsioon 1mg/g 30g | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1020610 | hüdrokortisoonbutüraat | D07AB02 | LOCOID kreem 0,1% 30g | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1020632 | hüdrokortisoonbutüraat | D07AB02 | LOCOID LIPID kreem 0,1% 30g | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1036022 | hüdroksükarbamiid | L01XX05 | HYDREA kapsel 500mg N100 | Bristol-Myers Squibb Eesti AS | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | ||||
| 1027291 | hüdroksüklorokiin | P01BA02 | PLAQUENIL tablett 200mg N60 | Sanofi-Synthelabo Ltd | 50% | 75% | M05; M06; M08; (M30- M33); M35; M45; M46* | *rv reumatoloogil ja pediaatril | ||||
| 1213209 [RTL 2006, 26, 482 – jõust. 1.04.2006] | ibandroonhape | M05BA06 | BONVIVA tablett 150 mg N1 | Roche Registration Limited | 50% | |||||||
| 1213210 [RTL 2006, 26, 482 – jõust. 1.04.2006] | ibandroonhape | M05BA06 | BONVIVA tablet 150 mg N3 | Roche Registration Limited | 50% | |||||||
| 1145203 | ibuprofeen | M01AE01 | BURANA tablett 400mg N30 | ORION CORPORATION ORION PHARMA | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1073012 | ibuprofeen | M01AE01 | IBUMAX tablett 400mg N100 | Vitabalans OY | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1072987 | ibuprofeen | M01AE01 | IBUMAX tablett 400mg N30 | Vitabalans OY | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1085206 | ibuprofeen | M01AE01 | IBUMAX tablett 600mg N100 | Vitabalans OY | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1085194 | ibuprofeen | M01AE01 | IBUMAX tablett 600mg N30 | Vitabalans OY | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1073089 | ibuprofeen | M01AE01 | IBUMETIN 400 tablett 400mg N100 | Nycomed Sefa AS | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1073078 | ibuprofeen | M01AE01 | IBUMETIN 400 tablett 400mg N50 | Nycomed Sefa AS | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1073113 | ibuprofeen | M01AE01 | IBUMETIN 600 tablett 600mg N100 | Nycomed Sefa AS | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1008616 | ibuprofeen | M01AE01 | IBUMETIN 600 tablett 600mg N20 | Nycomed Sefa AS | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1073102 | ibuprofeen | M01AE01 | IBUMETIN 600 tablett 600mg N50 | Nycomed Sefa AS | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1031364 | ibuprofeen | M01AE01 | IBUPROFEN ALPHARMA TABLETS 400MG tablett 400mg N20 | ALPHARMA Limited | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1032208 | ibuprofeen | M01AE01 | IBUPROFEN ALPHARMA TABLETS 600MG tablett 600mg N20 | ALPHARMA Limited | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1032703 | ibuprofeen | M01AE01 | IBUPROFEN LANNACHER tablett 400mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1032714 | ibuprofeen | M01AE01 | IBUPROFEN LANNACHER tablett 600mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1111329 | ibuprofeen | M01AE01 | IBUMETIN 400 tablett 400mg N30 | Nycomed Sefa AS | 50% | 75% | M05; M06; M08; M15- M19*; M45; M46 | *rv üle 63-aastastele | 100% | C00-D48 | ||
| 1041231 | idarubitsiin | L01DB06 | ZAVEDOS kapsel 10mg N1 | Pfizer Enterprises Sarl | 50% | |||||||
| 1041220 | idarubitsiin | L01DB06 | ZAVEDOS kapsel 5mg N1 | Pfizer Enterprises Sarl | 50% | |||||||
| 1085712 | imatinib | L01XX28 | GLIVEC kapsel 100mg N120 | Novartis Pharma AG | 50% | |||||||
| 1085723 | imatinib | L01XX28 | GLIVEC kapsel 100mg N180 | Novartis Pharma AG | 50% | |||||||
| 1085688 | imatinib | L01XX28 | GLIVEC kapsel 100mg N24 | Novartis Pharma AG | 50% | |||||||
| 1085699 | imatinib | L01XX28 | GLIVEC kapsel 100mg N48 | Novartis Pharma AG | 50% | |||||||
| 1085701 | imatinib | L01XX28 | GLIVEC kapsel 100mg N96 | Novartis Pharma AG | 50% | |||||||
| 1085677 | imatinib | L01XX28 | GLIVEC kapsel 50mg N30 | Novartis Pharma AG | 50% | |||||||
| 1074877 | imidapriil | C09AA80 | TANATRIL tablett 10mg N100 | ALGOL OY | 50% | |||||||
| 1009875 | imidapriil | C09AA80 | TANATRIL tablett 10mg N30 | ALGOL OY | 50% | |||||||
| 1074866 | imidapriil | C09AA80 | TANATRIL tablett 5mg N100 | ALGOL OY | 50% | |||||||
| 1009864 | imidapriil | C09AA80 | TANATRIL tablett 5mg N30 | ALGOL OY | 50% | |||||||
| 7000018 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 7000029 | imikute toitesegu | ISOMIL 400 g (laktoosivaba) | Abbot | 75% | K52.2; K90.4; L20.8; L27.2 | *rv alla 1-aastastele lastele | ||||||
| 7000030 | imikute toitesegu | PEPTIDI TUTTELI 400 g | Valio | 75% | K52.2; K90.4; L20.8; L27.2 | *rv alla 1-aastastele lastele | ||||||
| 7000041 | imikute toitesegu | ALFARE (DS24) 400 g (vadaku) | Nestle | 75% | K52.2; K90.4; L20.8; L27.2 | *rv alla 1-aastastele lastele | ||||||
| K52.2*; | ||||||||||||
| 7000052 | imikute toitesegu | NUTRI JUNIOR 400 g | N.V. Nutricia | 75% | K90.4; L20.8; L27.2* | *rv alla 1-aastastele lastele | ||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 7000063 | imikute toitesegu | Neocate 400 g (aminohapete segu) | N.V. Nutricia | 75% | K52.2; K90.4; L20.8; L27.2 | *rv alla 1-aastastele lastele | ||||||
| 7000074 [RTL 2006, 26, 482 – jõust. 1.04.2006] | imikute toitesegu | Aptamil Pepti (Nutrilon Pepti) 450 g | Milupa | 75% | K52.2; K90.4; L20.8; L27.2 | *rv alla 1-aastastele lastele | ||||||
| 7000085 [RTL 2006, 26, 482 – jõust. 1.04.2006] | imikute toitesegu | Aptamil Pepti MCT (Pepti- Junior) 450 g | Milupa | 75% | K52.2; K90.4; L20.8; L27.2 | *rv alla 1-aastastele lastele | ||||||
| 7000096 [RTL 2006, 26, 482 – jõust. 1.04.2006] | imikute toitesegu | Aptamil Soya (Nutrilon Soya) 400 g | Milupa | 75% | K52.2; K90.4; L20.8; L27.2 | *rv alla 1-aastastele lastele | ||||||
| 1060322 | imikvimood | D06BB10 | ALDARA kreem 5% 250mg N12 | 3M HEALTH CARE Ltd. | 50% | |||||||
| 1144527 | imipramiin | N06AA02 | IMIPRAMINE ALPHARMA TABLETS 25 MG tablett 25mg N48 | ALPHARMA Limited | 50% | |||||||
| 1068308 | imipramiin | N06AA02 | IMIPRAMINE ALPHARMA TABLETS 25 MG tablett 25mg N50 | ALPHARMA Limited | 50% | |||||||
| 1038383 | indapamiid | C03BA11 | PRO-INDAP kapsel 2,5mg N30 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1167780 | indapamiid | C03BA11 | TERTENSIF SR retardtablett 1,5mg N30 | Les Laboratories Servier | 50% | |||||||
| 1019416 | indapamiid | C03BA11 | TERTENSIF tablett 2,5mg N30 | Les Laboratories Servier | 50% | |||||||
| 1010934 | indinaviir | J05AE02 | CRIXIVAN kapsel 333 mg N135 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1013476 | indinaviir | J05AE02 | CRIXIVAN kapsel 100mg N180 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1088276 | indinaviir | J05AE02 | CRIXIVAN kapsel 200mg N180 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1088287 | indinaviir | J05AE02 | CRIXIVAN kapsel 200mg N270 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1026650 | indinaviir | J05AE02 | CRIXIVAN kapsel 200mg N360 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1088300 | indinaviir | J05AE02 | CRIXIVAN kapsel 400mg N180 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1088311 | indinaviir | J05AE02 | CRIXIVAN kapsel 400mg N90 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1004904 | indometatsiin | M01AB01 | INDOMET- RATIOPHARM 50 kapsel 50mg N20 | ratiopharm GmbH | 50% | 100% | C00-D48 | |||||
| 1071841 | indometatsiin | M01AB01 | INDOMET- RATIOPHARM 50 kapsel 50mg N50 | ratiopharm GmbH | 50% | 100% | C00-D48 | |||||
| 1074103 | indometatsiin | M02AA23 | INDOMET-RATIOPHARM GEL geel 1% 100g | ratiopharm GmbH | 50% | |||||||
| 1001697 | indometatsiin | M02AA23 | INDOMET-RATIOPHARM GEL geel 1% 50g | ratiopharm GmbH | 50% | |||||||
| 1029204 | indometatsiin | M02AA23 | ELMETACIN SPRAY lahus paikseks kasut. 8mg/ml 50ml N1 | SANKYO PHARMA GmbH | 50% | |||||||
| 1084788 | insuliin aspart | A10AB05 | NOVOMIX 30 FLEXPEN süstesuspensioon 100/TÜml eeltäidetud süstevahend 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1084823 | insuliin aspart | A10AB05 | NOVOMIX 30 PENFILL süstesuspensioon 100IU/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1092541 | insuliin aspart | A10AB05 | NOVORAPID FLEXPEN süstelahus 100IU/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1045785 | insuliin aspart | A10AB05 | NOVORAPID NOVOLET 3 ML süstelahus 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; | |||||
| P70.2 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | |||||
| 1045796 | insuliin aspart | A10AB05 | NOVORAPID PENFILL süstelahus 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1040409 | Insuliin lispro | A10AB04 | HUMALOG PEN süstelahus 100TÜ/ml 3ml N5 | Eli Lilly Export S.A. | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1111284 | Insuliin lispro | A10AB04 | HUMALOG süstelahus 100TÜ/ml kolbampull 3ml N5 | Eli Lilly Export S.A. | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1043019 | Insuliin lispro | A10AD04 | HUMALOG MIX25 PEN süstesuspensioon 100TÜ/ml pen-injektor 3ml N5 | Eli Lilly Export S.A. | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1064562 | insuliin, humaan, keskmise toimeajaga | A10AC01 | PROTAPHANE PENFILL süstesuspensioon 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1037449 | insuliin, humaan, keskmise toimeajaga | A10AC01 | PROTAPHANE NOVOLET süstesuspensioon 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1115637 | insuliin, humaan, keskmise toimeajaga | A10AC01 | HUMULIN N PEN inj 100TÜ/ml kolbampull pen-injektoris 3ml N5 | Eli Lilly Holding Limited | 50% | 100% | E10-E11; E13-E14; E89.1; O24; P70.2 | |||||
| 1115615 | insuliin, humaan, keskmise toimeajaga | A10AC01 | HUMULIN NPH süstesuspensioon 100TÜ/ml 3ml N5 | Eli Lilly Holding Limited | 50% | 100% | E10-E11; E13-E14; E89.1; O24; P70.2 | |||||
| 1112342 | insuliin, humaan, keskmise toimeajaga | A10AC01 | PROTAPHANE FLEXPEN süstesuspensioon 100 TÜ/ml pensüstel 3 ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1029428 | insuliin, humaan, lühikese ja keskmise toimeajaga insuliinide segu | A10AD01 | HUMULIN M3 (30/70) süstelahus 100TÜ/ml kolbampull 3ml N5 | Eli Lilly Holding Limited | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1064629 | insuliin, humaan, lühikese ja keskmise toimeajaga insuliinide segu | A10AD01 | MIXTARD 30 PENFILL süstesuspensioon 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1037450 | insuliin, humaan, lühikese ja keskmise toimeajaga insuliinide segu | A10AD01 | MIXTARD NOVOLET süstelahus 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1121218 | insuliin, humaan, lühikese ja keskmise toimeajaga insuliinide segu | A10AD01 | HUMULIN M3 (30/70) PEN inj 100 TÜ/1 ml pensüstel 3 ml N5 | Eli Lilly Holding Limited | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1006355 | insuliin, humaan, lühikese toimeajaga | A10AB01 | ACTRAPID PENFILL süstelahus 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1037438 | insuliin, humaan, lühikese toimeajaga | A10AB01 | ACTRAPID NOVOLET süstelahus 100TÜ/ml 3ml N5 | Novo Nordisk A/S | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1029417 | insuliin, humaan, lühikese toimeajaga | A10AB01 | HUMULIN REGULAR süstelahus 100TÜ/ml 3ml kolbampull N5 | Eli Lilly Holding Limited | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1083383 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1061345 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1083394 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1061323 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1061334 | insuliinglargiin | A10AE04 | LANTUS süstelahus 100TÜ/ml 3ml kolbampull N5 | Aventis-Pharma Deutchland GmbH | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1061288 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1061312 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1061299 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1061301 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1195792 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1195804 | insuliinglargiin | A10AE04 | LANTUS süstelahus 100TÜ/ml 3ml Optiset N5 | Aventis-Pharma Deutchland GmbH | 50% | 100% | E10-E11; E13-14; E89.1; O24; P70.2 | |||||
| 1195815 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1163854 | interferoon alfa | L03AB04 | ROFERON-A süstelahus 3000000TÜ 0.5ml 0.5ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | B18.2; C64; (C82- C85); (C91- C92); D45; D47* | rv gastroenteroloogil ja infektsionistil vastavalt Eesti ravijuhisele *rv onkoloogil ja hematoloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1163797 | interferoon alfa | L03AB04 | ROFERON-A süstelahus 9000000TÜ 0.5ml 0.5ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | B18.2; (C00- D48)* | rv gastroenteroloogil ja infektsionistil vastavalt Eesti ravijuhisele *rv onkoloogil ja hematoloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1040049 | interferoon alfa-2b | L03AB05 | INTRON A injektsioonisubstants 10milj TÜ N1+lahusti N1 | Schering Plough Europe | 50% | |||||||
| 1040027 | interferoon alfa-2b | L03AB05 | INTRON A injektsioonisubstants 3milj TÜ N1+ lahusti N1 | Schering Plough Europe | 50% | |||||||
| 1040038 | interferoon alfa-2b | L03AB05 | INTRON A injektsioonisubstants 5milj TÜ N1+lahusti N1 | Schering Plough Europe | 50% | |||||||
| 1040050 | interferoon alfa-2b | L03AB05 | INTRON A süstelahus 15miljTÜ/ml N1 | Schering Plough Europe | 50% | |||||||
| 1040061 | interferoon alfa-2b | L03AB05 | INTRON A süstelahus 25miljTÜ/ml N1 | Schering Plough Europe | 50% | |||||||
| 1040072 | interferoon alfa-2b | L03AB05 | INTRON A süstelahus 50miljTÜ/ml N1 | Schering Plough Europe | 50% | |||||||
| 1036369 | interferoon beeta | L03AB02 | AVONEX injektsioonisubstants 30mcg N4+lahusti 1 ml N4 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1071256 | interferoon beeta | L03AB02 | BETAFERON injektsioonisubstants 9600000TÜ N15+lahusti N15 | Schering AG | 50% | 100% | G35,* | rev neuroloogil konsiiliumi (kolme neuroloogi ühise) otsuse alusel hulgiskleroosi raviks patsiendile, kellel on eelneva kahe aasta vältel esinenud vähemalt kaks haiguse ägenemisperioodi neuroloogilise düsfunktsiooniga, *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1000595 | interferoon beeta | L03AB02 | BETAFERON injektsioonisubstants 9600000TÜ N5+lahusti N5 | Schering AG | 50% | 100% | G35,* | rev neuroloogil konsiiliumi (kolme neuroloogi ühise) otsuse alusel hulgiskleroosi raviks patsiendile, kellel on eelneva kahe aasta vältel esinenud vähemalt kaks haiguse ägenemisperioodi neuroloogilise düsfunktsiooniga, *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1010866 | interferoon beta-1a | L03AB07 | REBIF 44 MCG süstelahus 44mcg 0.5ml 0.5ml N1 | Serono Europe Ltd. | 50% | |||||||
| 1117640 | interferoon beta-1a | L03AB07 | REBIF 44 MCG süstelahus 44mcg 0.5ml 0.5ml N12 | Serono Europe Ltd. | 50% | 100% | G35,* | rev neuroloogil konsiiliumi (kolme neuroloogi ühise) otsuse alusel hulgiskleroosi raviks patsiendile, kellel on eelneva kahe aasta vältel esinenud vähemalt kaks haiguse ägenemisperioodi neuroloogilise düsfunktsiooniga,*soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| *rev neuroloogil konsiiliumi (kolme neuroloogi ühise) otsuse alusel hulgiskleroosi raviks | ||||||||||||
| 1071683 | interferoon beta-1a | L03AB07 | REBIF 44 MCG süstelahus 44mcg 0.5ml 0.5ml N3 | Serono Europe Ltd. | 50% | 100% | G35,* | patsiendile, kellel on eelneva kahe aasta vältel esinenud vähemalt kaks haiguse ägenemisperioodi neuroloogilise düsfunktsiooniga,**soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1035931 | interferoon beta-1a | L03AB07 | REBIF süstelahus 22mcg 0.5ml 0.5ml N1 | Serono Europe Ltd. | 50% | |||||||
| 1117639 | interferoon beta-1a | L03AB07 | REBIF süstelahus 22mcg 0.5ml 0.5ml N12 | Serono Europe Ltd. | 50% | 100% | G35,* | rev neuroloogil konsiiliumi (kolme neuroloogi ühise) otsuse alusel hulgiskleroosi raviks patsiendile, kellel on eelneva kahe aasta vältel esinenud vähemalt kaks haiguse ägenemisperioodi neuroloogilise düsfunktsiooniga,*soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1071638 | interferoon beta-1a | L03AB07 | REBIF süstelahus 22mcg 0.5ml 0.5ml N3 | Serono Europe Ltd. | 50% | 100% | G35,* | rev neuroloogil konsiiliumi (kolme neuroloogi ühise) otsuse alusel hulgiskleroosi raviks patsiendile, kellel on eelneva kahe aasta vältel esinenud vähemalt kaks haiguse ägenemisperioodi neuroloogilise düsfunktsiooniga,*soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1057700 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1105940 | ipratroopiumbromiid | R03BB01 | ATROVENT N inhal aeros, 0,021 mg/annuses 200 annust | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | 75% | J45,; J43,; J44*,* | rev pediaatril ja pulmonoloogil; rev pulmonoloogil; **soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1057711 | ipratroopiumbromiid | R03BB01 | ATROVENT inhalatsioonilahus 0,25mg/ml 20ml N1 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1034389 | irbesartaan | C09CA04 | APROVEL tablett 150mg N14 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060467 | irbesartaan | C09CA04 | APROVEL tablett 150mg N28 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060478 | irbesartaan | C09CA04 | APROVEL tablett 150mg N56 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060489 | irbesartaan | C09CA04 | APROVEL tablett 150mg N98 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1034390 | irbesartaan | C09CA04 | APROVEL tablett 300mg N14 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060490 | irbesartaan | C09CA04 | APROVEL tablett 300mg N28 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060502 | irbesartaan | C09CA04 | APROVEL tablett 300mg N56 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060513 | irbesartaan | C09CA04 | APROVEL tablett 300mg N98 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1034378 | irbesartaan | C09CA04 | APROVEL tablett 75mg N28 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1045347 | irbesartaan+hüdroklorotiasiid | C09DA04 | COAPROVEL tablett 150mg+12,5mg N28 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060670 | irbesartaan+hüdroklorotiasiid | C09DA04 | COAPROVEL tablett 150mg+12,5mg N56 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060681 | irbesartaan+hüdroklorotiasiid | C09DA04 | COAPROVEL tablett 150mg+12,5mg N98 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1045358 | irbesartaan+hüdroklorotiasiid | C09DA04 | COAPROVEL tablett 300mg+12,5mg N28 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1060692 | irbesartaan+hüdroklorotiasiid | C09DA04 | COAPROVEL tablett 300mg+12,5mg N56 | Sanofi Pharma Bristol Myers Squibb | 50% | |||||||
| SNC | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1060704 | irbesartaan+hüdroklorotiasiid | C09DA04 | COAPROVEL tablett 300mg+12,5mg N98 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1000348 | isokonasool | D01AC05 | TRAVOGEN kreem 1%/g 20g N1 | Schering AG | 50% | |||||||
| 1060928 | isokonasool | D01AC05 | TRAVOGEN kreem 1%/g 50g N1 | Schering AG | 50% | |||||||
| 1000416 | isokonasool+diflukortoloon | D01AC80 | TRAVOCORT kreem 1%+0,1%/g 15g N1 | Schering AG | 50% | |||||||
| 1061008 | isokonasool+diflukortoloon | D01AC80 | TRAVOCORT kreem 1%+0,1%/g 30g N1 | Schering AG | 50% | |||||||
| 1015074 | isosorbiiddinitraat | C01DA08 | ISDN-RATIOPHARM 20 retardkapsel 20mg N50 | ratiopharm GmbH | 50% | 75% | I20 | |||||
| 1008964 | isosorbiiddinitraat | C01DA08 | ISDN-RATIOPHARM 40 RETARDKAPSELN retardkapsel 40mg N50 | ratiopharm GmbH | 50% | 75% | I20 | |||||
| 1005028 | isosorbiiddinitraat | C01DA08 | ISDN-RATIOPHARM 5 tablett 5mg N50 | ratiopharm GmbH | 50% | 75% | I20 | |||||
| 1037371 | isosorbiiddinitraat | C01DA08 | ISOKET 20 retardtablett 20mg N50 | Schwarz Pharma AG | 50% | 75% | I20 | |||||
| 1037382 | isosorbiiddinitraat | C01DA08 | ISOKET 40 retardtablett 40mg N50 | Schwarz Pharma AG | 50% | 75% | I20 | |||||
| 1037416 | isosorbiidmononitraat | C01DA14 | ELANTAN 20 tablett 20mg N50 | Schwarz Pharma AG | 50% | 75% | I20 | |||||
| 1037405 | isosorbiidmononitraat | C01DA14 | ELANTAN 40 tablett 40mg N50 | Schwarz Pharma AG | 50% | 75% | I20 | |||||
| 1037427 | isosorbiidmononitraat | C01DA14 | ELANTAN LONG retardkapsel 50mg N20 | Schwarz Pharma AG | 50% | 75% | I20 | |||||
| 1046786 | isosorbiidmononitraat | C01DA14 | IMDUR retardtablett 60mg N30 | AstraZeneca AB | 50% | 75% | I20 | |||||
| 1001620 | isosorbiidmononitraat | C01DA14 | IS-5-MONO- RATIOPHARM 20 tablett 20mg N20 | ratiopharm GmbH | 50% | 75% | I20 | |||||
| 1006197 | isosorbiidmononitraat | C01DA14 | MONO MACK 20 MG tablett 20mg N50 | HEINRICH MACK NACHF. | 50% | 75% | I20 | |||||
| 1006221 | isosorbiidmononitraat | C01DA14 | MONO MACK 40 MG tablett 40mg N50 | HEINRICH MACK NACHF. | 50% | 75% | I20 | |||||
| 1003712 | isosorbiidmononitraat | C01DA14 | MONO MACK DEPOT retardtablett 100mg N20 | HEINRICH MACK NACHF. | 50% | 75% | I20 | |||||
| 1101913 | isosorbiidmononitraat | C01DA14 | OLICARD 40 RETARD retardkapsel 40mg N50 | Solvay Pharmaceuticals GmbH | 50% | 75% | I20 | |||||
| 1101924 | isosorbiidmononitraat | C01DA14 | OLICARD 60 RETARD retardkapsel 60mg N50 | Solvay Pharmaceuticals GmbH | 50% | 75% | I20 | |||||
| 1127540 | isosorbiidmononitraat | C01DA14 | ISOMONIT 20 tablett 20 mg N30 | Hexal AG | 50% | 75% | I20 | |||||
| 1127551 | isosorbiidmononitraat | C01DA14 | ISOMONIT 20 tablett 20 mg N100 | Hexal AG | 50% | 75% | I20 | |||||
| 1127562 | isosorbiidmononitraat | C01DA14 | ISOMONIT 40 tablett 40 mg N30 | Hexal AG | 50% | 75% | I20 | |||||
| 1127573 | isosorbiidmononitraat | C01DA14 | ISOMONIT 40 tablett 40 mg N100 | Hexal AG | 50% | 75% | I20 | |||||
| 1127584 | isosorbiidmononitraat | C01DA14 | ISOMONIT 60 RETARD modif tablett 60 mg N30 | Hexal AG | 50% | 75% | I20 | |||||
| 1127595 | isosorbiidmononitraat | C01DA14 | ISOMONIT 60 RETARD modifitseeritud tablett 60 mg N100 | Hexal AG | 50% | 75% | I20 | |||||
| 1043547 | isosorbiidmononitraat | C01DA14 | MONOSAN tablett 20 mg N30 | PRO. MED. CS. PRAHA a.s. | 50% | 75% | I20 | |||||
| 1017010 | isosorbiidmononitraat | C01DA14 | MONOSAN tablett 40 mg N30 | PRO. MED. CS. PRAHA a.s. | 50% | 75% | I20 | |||||
| 1004364 | isotretinoiin | D10BA01 | ROACCUTANE kapsel 10mg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 75% | L70.1; L70.2 | *rv dermatoveneroloogil | ||||
| 1112230 | isotretinoiin | D10BA01 | ROACCUTANE kapsel 20mg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 75% | L70.1; L70.2 | *rv dermatoveneroloogil | ||||
| 1178063 [RTL 2006, 26, 482 – jõust. 1.04.2006] | isotretinoiin | D10BA01 | ISOTRETINOIN SANDOZ 10 MG kapsel 10 mg N30 | Sandoz d.d. | 50% | 75% | L70.1; L70.2 | *rv dermatoveneroloogil | ||||
| 1178119 [RTL 2006, 26, 482 – jõust. 1.04.2006] | isotretinoiin | D10BA01 | ISOTRETINOIN SANDOZ 20 MG kapsel 20 mg N30 | Sandoz d.d. | 50% | 75% | L70.1; L70.2 | *rv dermatoveneroloogil | ||||
| 1071537 | itrakonasool | J02AC02 | ORUNGAL kapsel 100mg N15 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1071548 | itrakonasool | J02AC02 | ORUNGAL kapsel 100mg N28 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1021464 | itrakonasool | J02AC02 | ORUNGAL kapsel 100mg N4 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1041017 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1164035 | itrakonasool | J02AC02 | PROKANAZOL kapslid 100 mg N4 | Liconsa S.A. | 50% | |||||||
| 1164046 | itrakonasool | J02AC02 | PROKANAZOL kapslid 100 mg N14 | Liconsa S.A. | 50% | |||||||
| 1164057 | itrakonasool | J02AC02 | PROKANAZOL kapslid 100 mg N28 | Liconsa S.A. | 50% | |||||||
| 1018549 | kaltsipotriool | D05AX02 | DAIVONEX kreem 50mcgg 30g | Leo Pharmaceutical Products | 50% | 75% | L40; M07 | *rev dermatoveneroloogil | ||||
| 1018550 | kaltsipotriool | D05AX02 | DAIVONEX naha ravilahus 50mcgml 60ml | Leo Pharmaceutical Products | 50% | 75% | L40; M07 | *rev dermatoveneroloogil | ||||
| 1007693 | kaltsipotriool | D05AX02 | DAIVONEX salv 50 mcgg 30g N1 | Leo Pharmaceutical Products | 50% | 75% | L40; M07 | *rev dermatoveneroloogil | ||||
| 1093340 | kaltsipotriool+beetametasoon | D05AX80 | DAIVOBET salv 50 mcg+0,5 mg/g 30 g | Leo Pharmaceutical Products | 50% | 75% | L40;* | rv dermatoveneroloogil, *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1023613 | kaltsitoniin | H05BA01 | MIACALCIC NASAL 200 ninasprei 200TÜ/annuses 2ml | Novartis Finland OY | 50% | |||||||
| 1004599 | kaltsitriool | A11CC04 | ROCALTROL kapsel 0,25mcg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 75% | N18* | *rv nefroloogil ja pediaatril | 100% | E20; E89.2; N25 | *rv endokrinoloogil ja pediaatril | |
| 1044481 | kaltsiumatsetaat | A12AA12 | PHOS-EX 250 MG tablette 250 mg N180 | SUOMEEN SAIRAALAPALVELU OY | 50% | 75% | N18 | 100% | E20; E89.2 | *rv endokrinoloogil ja pediaatril | ||
| 1039553 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1065406 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1046337 | kaltsiumkarbonaat | A12AA04 | CALCIGRAN SINE närimistablett 1250 mg N100 | Nycomed Sefa AS | 75% | N18 | 100% | E20; E89.2 | *rv endokrinoloogil ja pediaatril | |||
| 1060647 | kandesartaan | C09CA06 | ATACAND tablett 16mg N100 | AstraZeneca AB | 50% | |||||||
| 1035908 | kandesartaan | C09CA06 | ATACAND tablett 16mg N28 | AstraZeneca AB | 50% | |||||||
| 1060658 | kandesartaan | C09CA06 | ATACAND tablett 8mg N100 | AstraZeneca AB | 50% | |||||||
| 1035919 | kandesartaan | C09CA06 | ATACAND tablett 8mg N28 | AstraZeneca AB | 50% | |||||||
| 1132591 | Kandesartaan+hüdroklorotiasiid | C09DA06 | ATACAND PLUS tablett 16mg+12,5mg N28 | AstraZeneca AB | 50% | |||||||
| 1013319 | kapetsitabiin | L01BC06 | XELODA tablett 150mg N60 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | (C18-C20)* | *rv onkoloogil metastaatilise kolorektaalvähi palliatiivseks kemoteraapiaks vastavalt Eesti Onkoloogide Seltsi kolorektaalvähi ravijuhisele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1013308 | kapetsitabiin | L01BC06 | XELODA tablett 500mg N120 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | (C18-C20)* | *rv onkoloogil metastaatilise kolorektaalvähi palliatiivseks kemoteraapiaks vastavalt Eesti Onkoloogide Seltsi kolorektaalvähi ravijuhisele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1036178 | kaptopriil | C09AA01 | CAPTOHEXAL 25 tablett 25mg N20 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1036167 | kaptopriil | C09AA01 | CAPTOHEXAL 50 tablett 50mg N20 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1036189 | kaptopriil | C09AA01 | CAPTOHEXAL 12,5 tablett 12,5mg N20 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1041691 | kaptopriil | C09AA01 | CAPTOPRIL ALPHARMA TABLETS 25 MG tablett 25mg N30 | ALPHARMA Limited | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1023062 | kaptopriil | C09AA01 | KAPTOPRIL 12,5 tablett 12,5mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1023073 | kaptopriil | C09AA01 | KAPTOPRIL 25 tablett 25mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1023084 | kaptopriil | C09AA01 | KAPTOPRIL 50 tablett 50mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1010350 | kaptopriil | C09AA01 | NYCAPRIL 25 MG tablett 25mg N40 | Nycomed Sefa AS | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1036550 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1042311 | karbamasepiin | N03AF01 | CARBALEX 200 MG TABLET tablett 200 mg N50 | GEROT PHARMAZEUTIKA GmbH | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79)*; | rev psühhiaatril; *rev neuroloogil | ||
| G40** | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1042322 | karbamasepiin | N03AF01 | CARBALEX 400 MG TABLET tablett 400 mg N50 | GEROT PHARMAZEUTIKA GmbH | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1008649 | karbamasepiin | N03AF01 | CARBAMAZEPIN NYCOMED 200 MG tablett 200mg N50 | Nycomed Sefa AS | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1035942 | karbamasepiin | N03AF01 | FINLEPSIN 200 RETARD retardtablett 200mg N50 | AWD.Pharma GmbH&Co.KG | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1035953 | karbamasepiin | N03AF01 | FINLEPSIN 400 RETARD retardtablett 400mg N50 | AWD.Pharma GmbH&Co.KG | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1036055 | karbamasepiin | N03AF01 | FINLEPSIN tablett 200mg N50 | AWD.Pharma GmbH&Co.KG | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1008009 | karbamasepiin | N03AF01 | TEGRETOL CR retardtablett 200mg N50 | Novartis Finland OY | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; | rev psühhiaatril; *rev neuroloogil | ||
| (F70-F79); G40* | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1009358 | karbamasepiin | N03AF01 | TEGRETOL CR retardtablett 400mg N30 | Novartis Finland OY | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1007974 | karbamasepiin | N03AF01 | TEGRETOL tablett 200mg N50 | Novartis Finland OY | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1019977 | karbamasepiin | N03AF01 | TEGRETOL tablett 400mg N30 | Novartis Finland OY | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1077117 | karbamasepiin | N03AF01 | TIMONIL 150 RETARD retardtablett 150mg N100 | Desitin Arzneimittel GmbH | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1077207 | karbamasepiin | N03AF01 | TIMONIL 300 RETARD retardtablett 300mg N100 | Desitin Arzneimittel GmbH | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-F79); G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1007716 | karbamasepiin | N03AF01 | TIMONIL 600 RETARD retardtablett 600mg N50 | Desitin Arzneimittel GmbH | 50% | 75% | G50.0 | 100% | (F00-F09); (F10-F19.4- 7); (F20-F29); (F30-F31); (F32/33.2- 3)*; | rev psühhiaatril; *rev neuroloogil | ||
| F60.3; (F70-F79); G40** | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1115592 | karbamasepiin | N03AF01 | CARBALEX 300 MG TABLET retardtablett 300 mg N50 | GEROT PHARMAZEUTIKA GmbH | 50% | 75% | G50.0 | 100% | F10; G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1042333 | karbamasepiin | N03AF01 | CARBALEX 600 MG TABLET retardtablett 600 mg N50 | GEROT PHARMAZEUTIKA GmbH | 50% | 75% | G50.0 | 100% | F10; G40* | rev psühhiaatril; *rev neuroloogil | ||
| 1022522 | karbotsüsteiin | R05CB03 | FLUDITEC siirup 20mg/ml 125 ml N1 | LABORATOIRE INNOTECH INTERNATIONAL | 50% | |||||||
| 1022533 | karbotsüsteiin | R05CB03 | FLUDITEC siirup 50mg/ml 125ml N1 | LABORATOIRE INNOTECH INTERNATIONAL | 50% | |||||||
| 1003576 | karbotsüsteiin | R05CB03 | MUCOPRONT kapsel 375mg N20 | HEINRICH MACK NACHF. | 50% | |||||||
| 1003958 | karbotsüsteiin | R05CB03 | MUCOPRONT siirup 50mg/g 200ml N1 | HEINRICH MACK NACHF. | 50% | |||||||
| 1077577 | karbotsüsteiin | R05CB03 | MUCOPRONT siirup 50mg/g 90ml N1 | HEINRICH MACK NACHF. | 50% | |||||||
| 1157543 | karvedilool | C07AG02 | CORYOL tablett 12,5mg N30 | KRKA, d.d. | 50% | 75% | I50* | *rev kardioloogil ja pediaatril | ||||
| 1157644 | karvedilool | C07AG02 | CORYOL tablett 25mg N30 | KRKA, d.d. | 50% | 75% | I50* | *rev kardioloogil ja pediaatril | ||||
| 1157341 [RTL 2006, 26, 482 – jõust. 1.04.2006] | karvedilool | C07AG02 | CORYOL tablett 3,125 mg N30 | KRKA, d.d. | 50% | 75% | I50* | *rev kardioloogil ja pediaatril | ||||
| 1029169 | karvedilool | C07AG02 | DILATREND tablett 12,5mg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1029158 | karvedilool | C07AG02 | DILATREND tablett 25mg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1029170 | karvedilool | C07AG02 | DILATREND tablett 6,25mg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1110609 | karvedilool | C07AG02 | CARVEDILOLHEXAL 6,25 tablett 6,25 mg N30 | Hexal AG | 50% | 75% | I50* | *rev kardioloogil ja pediaatril | ||||
| 1110564 | karvedilool | C07AG02 | CARVEDILOLHEXAL 12,5 tablett 12,5 mg N30 | Hexal AG | 50% | 75% | I50* | *rev kardioloogil ja pediaatril | ||||
| 1110520 | karvedilool | C07AG02 | CARVEDILOLHEXAL 25 tablett 25 mg N30 | Hexal AG | 50% | 75% | I50* | *rev kardioloogil ja pediaatril | ||||
| 1157442 | karvedilool | C07AG02 | CORYOL tablett 6,25mg N30 | KRKA, d.d. | 50% | 75% | I50* | *rev kardioloogil ja pediaatril | ||||
| 1018189 | ketokonasool | D01AC08 | NIZORAL kreem 2%/g 15g N1 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1060984 | ketokonasool | D01AC08 | NIZORAL kreem 2%/g 30g N1 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1071357 [RTL 2006, 26, 482 – jõust. 1.04.2006] | ketokonasool | J02AB02 | NIZORAL tablett 200 mg N30 | Janssen Pharmaceutica N.V. | 50% | 100% | T86 | |||||
| 1030026 [RTL 2006, 26, 482 – jõust. 1.04.2006] | ketokonasool | J02AB02 | ORONAZOL tablett 200mg N20 | KRKA, d.d. | 50% | 100% | T86 | |||||
| 1073483 | ketoprofeen | M01AE03 | KETO tablett 100mg N100 | Vitabalans OY | 50% | |||||||
| 1018921 | ketoprofeen | M01AE03 | KETO tablett 100mg N20 | Vitabalans OY | 50% | |||||||
| 1073461 | ketoprofeen | M01AE03 | KETO tablett 100mg N30 | Vitabalans OY | 50% | |||||||
| 1073517 | ketoprofeen | M01AE03 | KETO tablett 50mg N100 | Vitabalans OY | 50% | |||||||
| 1018910 | ketoprofeen | M01AE03 | KETO tablett 50mg N20 | Vitabalans OY | 50% | |||||||
| 1073506 | ketoprofeen | M01AE03 | KETO tablett 50mg N30 | Vitabalans OY | 50% | |||||||
| 1073562 | ketoprofeen | M01AE03 | KETOPROFEN- RATIOPHARM 100 tablett 100mg N100 | ratiopharm GmbH | 50% | |||||||
| 1112713 | ketoprofeen | M01AE03 | KETOPROFEN- RATIOPHARM 100 tablett 100mg N20 | ratiopharm GmbH | 50% | |||||||
| 1073551 | ketoprofeen | M01AE03 | KETOPROFEN- RATIOPHARM 100 tablett 100mg N50 | ratiopharm GmbH | 50% | |||||||
| 1073595 | ketoprofeen | M01AE03 | KETOPROFEN- RATIOPHARM 50 tablett 50mg N100 | ratiopharm GmbH | 50% | |||||||
| 1112689 | ketoprofeen | M01AE03 | KETOPROFEN- RATIOPHARM 50 tablett 50mg N20 | ratiopharm GmbH | 50% | |||||||
| 1073584 | ketoprofeen | M01AE03 | KETOPROFEN- RATIOPHARM 50 tablett 50mg N50 | ratiopharm GmbH | 50% | |||||||
| 1002609 | ketotifeen | R06AX17 | ZADITEN tablett 1mg N30 | Novartis Finland OY | 50% | |||||||
| 1028887 | klaritromütsiin | J01FA09 | FROMILID 250 tablett 250mg | KRKA, d.d. | 50% | |||||||
| N14 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1028876 | klaritromütsiin | J01FA09 | FROMILID 500 tablett 500mg N14 | KRKA, d.d. | 50% | |||||||
| 1011687 | klaritromütsiin | J01FA09 | FROMILID suspensioonigraanulid 125mg 5ml 25g N1 | KRKA, d.d. | 50% | |||||||
| 1032747 | klaritromütsiin | J01FA09 | KLACID 250 MG TABS tablett 250mg N10 | Abbott Laboratories S.A. | 50% | |||||||
| 1068870 | klaritromütsiin | J01FA09 | KLACID 250 MG TABS tablett 250mg N14 | Abbott Laboratories S.A. | 50% | |||||||
| 1068881 | klaritromütsiin | J01FA09 | KLACID PEDIATRIC SUSPENSION suspensioonigraanulid 25mgml 100ml N1 | Abbott Laboratories S.A. | 50% | |||||||
| 1032736 | klaritromütsiin | J01FA09 | KLACID PEDIATRIC SUSPENSION suspensioonigraanulid 25mgml 60ml N1 | Abbott Laboratories S.A. | 50% | |||||||
| 1068892 | klaritromütsiin | J01FA09 | KLACID PEDIATRIC SUSPENSION suspensioonigraanulid 50mgml 100ml N1 | Abbott Laboratories S.A. | 50% | |||||||
| 1032769 | klaritromütsiin | J01FA09 | KLACID PEDIATRIC SUSPENSION suspensioonigraanulid 50mgml 60ml N1 | Abbott Laboratories S.A. | 50% | |||||||
| 1032758 | klaritromütsiin | J01FA09 | KLACID SR retardtablett 500mg N5 | Abbott Laboratories S.A. | 50% | |||||||
| 1068904 | klaritromütsiin | J01FA09 | KLACID SR retardtablett 500mg N7 | Abbott Laboratories S.A. | 50% | |||||||
| 1141287 | klaritromütsiin | J01FA09 | FROMILID UNO modifitseeritud tablett 500 mg N7 | KRKA, d.d. | 50% | |||||||
| 1042670 | klaritromütsiin | J01FA09 | KLABAX kaetud tablett 500 mg N10 | Ranbaxy UK Ltd | 50% | |||||||
| 1040555 | klaritromütsiin | J01FA09 | KLABAX kaetud tablett 250 mg N12 | Ranbaxy UK Ltd | 50% | |||||||
| 1108718 | klaritromütsiin | J01FA09 | LEKOKLAR 500 MG tablett 500 mg N14 | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1108707 | klaritromütsiin | J01FA09 | LEKOKLAR 250 MG kaetud tablett 250 mg N14 | Lek Pharmaceuticals d.d. | 50% | |||||||
| 1166688 | klaritromütsiin | J01FA09 | KLABAX kaetud tablett 250 mg N14 | Ranbaxy UK Ltd | 50% | |||||||
| 1166677 | klaritromütsiin | J01FA09 | KLABAX kaetud tablett 500 mg N14 | Ranbaxy UK Ltd | 50% | |||||||
| 1006333 | klemastiin | R06AA04 | TAVEGYL tablett 1mg N20 | Novartis Finland OY | 50% | |||||||
| 1021914 | klindamütsiin | D10AF01 | DALACIN T lahus 10mgml 30ml N1 | Pfizer Enterprises Sarl | 50% | |||||||
| 1023938 | klindamütsiin | G01AA10 | DALACIN vaginaalkreem 20mgg 40g N1 | Pfizer Enterprises Sarl | 50% | |||||||
| 1011160 | klindamütsiin | G01AA10 | DALACIN VAGINAL OVULE oovul 100mg N3 | Pfizer Enterprises Sarl | 50% | |||||||
| 1068915 | klindamütsiin | J01FF01 | DALACIN C kapsel 150mg N100 | Pfizer Enterprises Sarl | 50% | |||||||
| 1007503 | klindamütsiin | J01FF01 | DALACIN C kapsel 150mg N16 | Pfizer Enterprises Sarl | 50% | |||||||
| 1007536 | klindamütsiin | J01FF01 | DALACIN C kapsel 300mg N16 | Pfizer Enterprises Sarl | 50% | |||||||
| 1005242 | klobetasool | D07AD01 | DERMOVATE kreem 0,05% 25g | Glaxo Group Ltd. | 50% | |||||||
| 1005286 | klobetasool | D07AD01 | DERMOVATE naha ravilahus 0,05% 25ml | Glaxo Group Ltd. | 50% | |||||||
| 1005208 | klobetasool | D07AD01 | DERMOVATE salv 0,05% 25g | Glaxo Group Ltd. | 50% | |||||||
| 1074327 | klodroonhape | M05BA02 | BONEFOS kapsel 400mg N100 | Schering OY | 50% | |||||||
| 1005691 | klodroonhape | M05BA02 | BONEFOS kapsel 400mg N30 | Schering OY | 50% | |||||||
| 1035469 | klodroonhape | M05BA02 | BONEFOS tablett 800mg N60 | Schering OY | 50% | |||||||
| 1011407 | klomipramiin | N06AA04 | ANAFRANIL 10 tablett 10mg N30 | Novartis Finland OY | 50% | |||||||
| 1011418 | klomipramiin | N06AA04 | ANAFRANIL SR retardtablett 75mg N20 | Novartis Finland OY | 50% | |||||||
| 1001462 | klomipramiin | N06AA04 | ANAFRANIL tablett 25mg N30 | Novartis Finland OY | 50% | |||||||
| 1004544 | klonasepaam | N03AE01 | RIVOTRIL tablett 2mg N30 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | G40* | *rev neuroloogil | ||||
| 1007345 | kloorambutsiil | L01AA02 | LEUKERAN TABLETS 2 MG tablett 2mg N25 | Glaxo Wellcome Operations | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | ||||
| 1044357 | klooramfenikool | S01AA01 | OFTAN AKVAKOL silmatilgad 0,5% 10 ml N1 | Santen OY | 50% | |||||||
| 1012880 | kloormadinoon+etünüülöstradiool | G03AA80 | BELARA filmtabletid 2 mg+30 | Grünenthal GmbH | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning | ||||
| mcg N21 | sünnitamisele meditsiinilise vastunäidustuse korral | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1094509 | kloormadinoon+etünüülöstradiool | G03AA80 | BELARA filmtabletid 2 mg+30 mcg N3X21 | Grünenthal GmbH | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1006119 | kloorprotikseen | N05AF03 | TRUXAL tablett 100mg N100 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1006063 | kloorprotikseen | N05AF03 | TRUXAL tablett 25mg N100 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1006096 | kloorprotikseen | N05AF03 | TRUXAL tablett 50mg N50 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1040588 | klopidogreel | B01AC04 | PLAVIX tablett 75mg N28 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1065732 | klopidogreel | B01AC04 | PLAVIX tablett 75mg N50 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1065743 | klopidogreel | B01AC04 | PLAVIX tablett 75mg N84 | Sanofi Pharma Bristol Myers Squibb SNC | 50% | |||||||
| 1004724 | klosapiin | N05AH02 | LEPONEX tablett 100mg N50 | Novartis Finland OY | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1004768 | klosapiin | N05AH02 | LEPONEX tablett 25mg N50 | Novartis Finland OY | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1010664 | klotrimasool | G01AF02 | ANTIFUNGOL 3 vagin. tablett 200mg N3 | Hexal AG | 50% | |||||||
| 1010642 | klotrimasool | G01AF02 | ANTIFUNGOL 3 VAGINAALKREEM vaginaalkreem 20mg/g 20g N1 | Hexal AG | 50% | |||||||
| 1010653 | klotrimasool | G01AF02 | ANTIFUNGOL COMBI vagin tabl 200 mg N3+vagin kreem 20mg/g 20g | Hexal AG | 50% | |||||||
| 1033692 | klotrimasool | G01AF02 | CANIFUG CREMOLUM 100 KOMBI vagin supp 100 mg N6+kreem 1% 20 g | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1033726 | klotrimasool | G01AF02 | CANIFUG CREMOLUM 100 vaginaalsuposiit 100mg N6 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1033737 | klotrimasool | G01AF02 | CANIFUG CREMOLUM 200 vaginaalsuposiit 200mg N3 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1033647 | klotrimasool | G01AF02 | CANIFUG VAGINALCREME 2% vaginaalkreem 2% 20g+3 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| aplikaatorit | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1045123 | klotrimasool | G01AF02 | KLOTRIMASOOL vagin. tablett 100mg N6 | GlaxoSmithkline Pharmaceuticals S.A. | 50% | |||||||
| 1003655 | kodeiin+fenüültoloksamiin | R05DA80 | CODIPRONT retardkapsel 30mg+10mg N10 | HEINRICH MACK NACHF. | 50% | |||||||
| 1003509 | kodeiin+fenüültoloksamiin | R05DA80 | CODIPRONT SIIRUP retardsuspensioon 2mg+0,66mg/g 100g N1 | HEINRICH MACK NACHF. | 50% | |||||||
| 1002676 | kolekaltsiferool+kaltsiumkarbonaat | A12AX80 | CALCIGRAN närimistablett 200 TÜ + 500 mg N30 | Nycomed Sefa AS | 75% | N18* | *rv nefroloogil ja pediaatril | |||||
| 1065394 | kolekaltsiferool+kaltsiumkarbonaat | A12AX80 | CALCIGRAN närimistablett 200 TÜ + 500 mg N100 | Nycomed Sefa AS | 75% | N18* | *rv nefroloogil ja pediaatril | |||||
| 1144336 | kolekaltsiferool+kaltsiumkarbonaat | A12AX80 | CALCIGRAN FORTE närimistablett 400 TÜ + 500 mg N60 | Nycomed Sefa AS | 75% | N18* | *rv nefroloogil ja pediaatril | |||||
| 1100923 | kolekaltsiferool+kaltsiumkarbonaat | A12AX80 | IDEOS närimistablett 400 TÜ + 500 mg N30 | LABORATOIRE INNOTECH INTERNATIONAL | 75% | N18* | *rv nefroloogil ja pediaatril | |||||
| 1143436 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1003352 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1027640 | Konjugeeritud östrogeenid | G03CA57 | PREMARIN tablett 0,625mg N28 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1063549 | Konjugeeritud östrogeenid | G03CA57 | PREMARIN tablett 0,625mg N28x3 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1022555 | kooriongonadotropiin | G03GA01 | PREGNYL injektsioonisubstants 5000TÜ viaal+1 ml lahustit N3 | N.V. ORGANON | 50% | |||||||
| 1035829 | kooriongonadotropiin | G03GA01 | PROFASI injektsioonisubstants 2000TÜ+1 ml lahustit N3 | ARES TRADING SA | 50% | |||||||
| 1035818 | kooriongonadotropiin | G03GA01 | PROFASI injektsioonisubstants 5000TÜ+1 ml lahustit N1 | ARES TRADING SA | 50% | |||||||
| 1063785 | kooriongonadotropiin | G03GA01 | PROFASI injektsioonisubstants 5000TÜ+1 ml lahustit N10 | ARES TRADING SA | 50% | |||||||
| 1116199 | kooriongonadotropiin | G03GA01 | OVITRELLE pulber ja lahusti süstelahuse valmistamiseks 250 mcg+1 ml (viaal+ampull) N1 | Serono Europe Ltd. | 50% | |||||||
| 1116201 | kooriongonadotropiin | G03GA01 | OVITRELLE pulber ja lahusti süstelahuse valmistamiseks 250 mcg+1 ml (viaal+ampull) N2 | Serono Europe Ltd. | 50% | |||||||
| 1116212 | kooriongonadotropiin | G03GA01 | OVITRELLE pulber ja lahusti süstelahuse valmistamiseks 250 mcg+1 ml (viaal+ampull) N10 | Serono Europe Ltd. | 50% | |||||||
| 1112128 | kromoglütsiinhape | R01AC01 | CROMO-RATIOPHARM NASENSPRAY ninasprei 2%/ml 15ml N1 | ratiopharm GmbH | 50% | 75% | J30* | *rv kuni 16-aastastele lastele | ||||
| 1001631 | kromoglütsiinhape | S01GX01 | LECROLYN silmatilgad 4% 5ml N1 | Santen OY | 50% | |||||||
| 1118955 | kromoglütsiinhape | S01GX01 | LECROLYN silmatilgad 4% 0.25ml N20 | Santen OY | 50% | |||||||
| 1115086 | kvetiapiin | N05AH04 | SEROQUEL kaetud tablett 200mg N60 | AstraZeneca UK Ltd. | 50% | 100% | (F20- F29),* | rv psühhiaatril skisofreenia spektri psühhooside raviks vastavalt Eesti ravijuhisele ning juhul kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid, *soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1038417 | kvetiapiin | N05AH04 | SEROQUEL kaetud tablett 200mg N30 | AstraZeneca UK Ltd. | 50% | |||||||
| 1067419 | kvetiapiin | N05AH04 | SEROQUEL kaetud tablett 25mg N6+tablett 100mg N3+tablett 200mg N1 | AstraZeneca UK Ltd. | 50% | |||||||
| 1120644 | kvetiapiin | N05AH04 | SEROQUEL kaetud tablett 100 mg N60 | AstraZeneca UK Ltd. | 50% | |||||||
| 1034457 | kvinapriil | C09AA06 | ACCUPRO 10 tablett 10mg N30 | Pfizer Limited | 50% | |||||||
| 1034468 | kvinapriil | C09AA06 | ACCUPRO 20 tablett 20mg N30 | Pfizer Limited | 50% | |||||||
| 1034446 | kvinapriil | C09AA06 | ACCUPRO 5 tablett 5mg N30 | Pfizer Limited | 50% | |||||||
| 1030105 | kvinapriil+hüdroklorotiasiid | C09BA06 | ACCUZIDE 20 tablett 20mg+12,5mg N30 | Pfizer Limited | 50% | |||||||
| 1031094 | kvinapriil+hüdroklorotiasiid | C09BA06 | ACCUZIDE tablett 10mg+12,5mg N30 | Pfizer Limited | 50% | |||||||
| 1007828 | labetalool | C07AG01 | TRANDATE TABLETS 100 MG tablett 100mg N50 | Glaxo Wellcome Operations | 50% | 75% | O10-O16 | |||||
| 1025873 | lamivudiin | J05AB10 | EPIVIR tablett 150mg N60 | Glaxo Wellcome Operations | 50% | |||||||
| 1043042 | lamivudiin | J05AF05 | ZEFFIX tablett 100mg N28 | Glaxo Wellcome Operations | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1036460 | lamivudiin+zidovudiin | J05AF81 | COMBIVIR tablett 150mg+300mg N60 | Glaxo Wellcome Operations | 50% | |||||||
| 1010080 | lamotrigiin | N03AX09 | LAMICTAL dispergeeritav 2mg N30 | Glaxo Wellcome Operations | 50% | 100% | G40,* | rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel; *soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1006546 | lamotrigiin | N03AX09 | LAMICTAL TABLETS 100 MG tablett 100mg N30 | Glaxo Wellcome Operations | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1006579 | lamotrigiin | N03AX09 | LAMICTAL TABLETS 25 MG tablett 25mg N30 | Glaxo Wellcome Operations | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1006748 | lamotrigiin | N03AX09 | LAMICTAL TABLETS 50 MG tablett 50mg N30 | Glaxo Wellcome Operations | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1141434 | lamotrigiin | N03AX09 | LAMICTAL DISPERSIBLE TABLETS 5 MG disp tablett 5 mg N30 | Glaxo Group Ltd. | 50% | 100% | G40*, ** | rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel; *soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1153897 | lamotrigiin | N03AX09 | LAMICTAL DISPERSIBLE TABLETS 25MG disp tablett 25 mg N30 | Glaxo Group Ltd. | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1122714 | lamotrigiin | N03AX09 | LAMICTAL DISPERSIBLE TABLETS 50MG disp tablett 50 mg N30 | Glaxo Group Ltd. | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1122691 | lamotrigiin | N03AX09 | LAMICTAL DISPERSIBLE TABLETS 100 MG disp tablett 100 mg N30 | Glaxo Group Ltd. | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1122736 | lamotrigiin | N03AX09 | LAMICTAL DISPERSIBLE TABLETS 200 MG disp tablett 200 mg N30 | Glaxo Group Ltd. | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1168680 | lamotrigiin | N03AX09 | LAMOTRIGIN SANDOZ 25 MG DISPERGEERITAV TABLETT N30 | Sandoz GmbH | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1168770 | lamotrigiin | N03AX09 | LAMOTRIGIN SANDOZ 50 MG DISPERGEERITAV TABLETT N30 | Sandoz GmbH | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1168860 | lamotrigiin | N03AX09 | LAMOTRIGIN SANDOZ 100 MG DISPERGEERITAV TABLETT N30 | Sandoz GmbH | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1168950 | lamotrigiin | N03AX09 | LAMOTRIGIN SANDOZ 200 MG DISPERGEERITAV TABLETT N30 | Sandoz GmbH | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1159916 | lamotrigiin | N03AX09 | LAMOTRIGIN HEXAL 25 MG TABLETID N30 | Hexal AG | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1160075 | lamotrigiin | N03AX09 | LAMOTRIGIN HEXAL 50 MG TABLETID N30 | Hexal AG | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele | ||||
| resistentse epilepsia näidustusel | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1160244 | lamotrigiin | N03AX09 | LAMOTRIGIN HEXAL 100 MG TABLETID N30 | Hexal AG | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1160402 | lamotrigiin | N03AX09 | LAMOTRIGIN HEXAL 200 MG TABLETID N30 | Hexal AG | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1167993 | lamotrigiin | N03AX09 | LAMEPIL 25 MG tablett 25 mg N30 | IVAX Pharmaceuticals s.r.o. | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1168028 | lamotrigiin | N03AX09 | LAMEPIL 100 MG tablett 100 mg N30 | IVAX Pharmaceuticals s.r.o. | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1172191 [RTL 2006, 26, 482 – jõust. 1.04.2006] | lamotrigiin | N03AX09 | LAMOTRIGIN ACTAVIS 50 MG dispergeeritav tablett 50 mg N 30 | Actavis Nordic A/S | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1172360 | lamotrigiin | N03AX09 | LAMOTRIGIN ACTAVIS 100 MG dispergeeritav tablett 100 mg N 30 | Actavis Nordic A/S | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustusel | ||||
| 1023679 | lansoprasool | A02BC03 | LANZUL kapsel 30mg N14 | KRKA, d.d. | 50% | |||||||
| 1041196 | latanoprost | S01EX03 | XALATAN silmatilgad 0,005% 2.5ml N1 | Pfizer Enterprises Sarl | 50% | 100% | (H40-H42)* | *rv oftalmoloogil, kui monoteraapia beeta- adrenoblokaatori ja karboanhüdraasi inhibiitoriga ei ole langetanud piisavalt silma siserõhku või mõlema rühma ravimid on vastunäidustatud | ||||
| 1088254 | latanoprost+timolool | S01ED51 | XALACOM silmatilgad 5 mg+50 mcg/ml 2,5 ml | Pfizer Enterprises Sarl | 50% | 100% | (H40- H42)*, ** | rv oftalmoloogil kui monoteraapia beeta- adrenoblokaatori, lokaalse karboanhüdraasi inhibiitori ja prostaglandiini analoogiga ning kombinatsioonteraapia beeta- adrenoblokaatori ja lokaalse karboanhüdraasi inhibiitoriga ei ole langetanud piisavalt silma siserõhku, *soodustus ei kehti enne hinnakokkuleppe sõlmimist. | ||||
| 1004454 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1073001 | latsidipiin | C08CA09 | LACIPIL tablett 4mg N28 | Glaxo Wellcome Operations | 50% | 75% | (I10-I13); I15 | |||||
| 1073023 | latsidipiin | C08CA09 | LACIPIL tablett 4mg N56 | Glaxo Wellcome Operations | 50% | 75% | (I10-I13); I15 | |||||
| 1122567 | latsidipiin | C08CA09 | LACIPIL FORTE 6 MG tablett 6 mg N28 | GlaxoSmithkline SpA | 50% | 75% | (I10-I13); I15 | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1122578 | latsidipiin | C08CA09 | LACIPIL FORTE 6 MG tablett 6 mg N56 | GlaxoSmithkline SpA | 50% | 75% | (I10-I13); I15 | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1071818 | leflunomiid | L04AA13 | ARAVA 10 MG tablett 10mg N100 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1009921 | leflunomiid | L04AA13 | ARAVA tabletid 10mg N30 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (M05; M06),* | rv reumatoloogil kui mono- või kombinatsioonteraapia metotreksaadi, sulfasalasiini ja hüdroksüklorokviiniga pole küllaldaselt efektiivne või põhjustab talumatuid kõrvaltoimeid, *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| *rv reumatoloogil kui mono- või kombinatsioonteraapia metotreksaadi, sulfasalasiini ja hüdroksüklorokviiniga | ||||||||||||
| 1009943 | leflunomiid | L04AA13 | ARAVA tabletid 100mg N3 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (M05; M06),* | pole küllaldaselt efektiivne või põhjustab talumatuid kõrvaltoimeid, **soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1071830 | leflunomiid | L04AA13 | ARAVA 20 MG tablett 20mg N100 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1009932 | leflunomiid | L04AA13 | ARAVA tabletid 20mg N30 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (M05; M06),* | rv reumatoloogil kui mono- või kombinatsioonteraapia metotreksaadi, sulfasalasiini ja hüdroksüklorokviiniga pole küllaldaselt efektiivne või põhjustab talumatuid kõrvaltoimeid, *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1095915 | lerkanidipiin | C08CA13 | LERCAPIN tablett 10mg N14 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1012295 | lerkanidipiin | C08CA13 | LERCAPIN tablett 10mg N28 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1095926 | lerkanidipiin | C08CA13 | LERCAPIN tablett 10mg N7 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1034334 | letrosool | L02BG04 | FEMARA tablett 2,5mg N30 | Novartis Finland OY | 50% | 100% | (C00-D48)* | *rv onkoloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1007176 | levamisool | P02CE01 | DECARIS 150 MG TABLET tablett 150mg N1 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1039519 | levocarnitiin | A16AA01 | NEFROCARNIT, SYRUP siirup 1g 3.3ml 50ml N1 | MEDICE Chem.- pharm. Fabrik Pütter GmbH & Co. | 50% | |||||||
| 1065439 | levocarnitiin | A16AA01 | NEFROCARNIT, SYRUP siirup 1g 3.3ml 50ml N3 | MEDICE Chem.- pharm. Fabrik Pütter GmbH & Co. | 50% | |||||||
| 1002014 | levodopa+benserasiid | N04BA80 | MADOPAR 250 tablett 200mg+50mg N100 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1077049 | levodopa+benserasiid | N04BA80 | MADOPAR DISPERSIBLE lahustuv tablett 100mg+25mg N100 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1085161 | levodopa+benserasiid | N04BA80 | MADOPAR HBS retardcaps 100mg+25mg N100 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1082922 | levodopa+benserasiid | N04BA80 | MADOPAR kapsel 100mg + 25mg N100 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1082517 | levodopa+karbidopa | N04BA81 | SINEMET 25/100 tablett 100mg+25mg N30 | Merck Sharp & Dohme OÜ | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1006894 | levodopa+karbidopa | N04BA81 | SINEMET CR 250 tablett 200mg+50mg N100 | Merck Sharp & Dohme OÜ | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1006861 | levodopa+karbidopa | N04BA81 | SINEMET tablett 250mg+25mg N100 | Merck Sharp & Dohme OÜ | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1017931 | levodopa+karbidopa | N04BA81 | NAKOM tablett 250 mg+25 mg N100 | Lek Pharmaceuticals d.d. | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1172810 | levodopa+karbidopa+entakapoon | N04BA03 | STALEVO tabletid 50/12,5/200 mg N100 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1172854 | levodopa+karbidopa+entakapoon | N04BA03 | STALEVO tabletid 100/25/200 mg N100 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1172898 | levodopa+karbidopa+entakapoon | N04BA03 | STALEVO tabletid 150/37,5/200 mg N100 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1077735 | Levodropropisiin | R05DB80 | LEVOPRONT siirup 6mg/ml 120ml | Dompe International S.A. | 50% | |||||||
| 1036921 | Levodropropisiin | R05DB80 | LEVOPRONT siirup 6mg/ml 60ml | Dompe International S.A. | 50% | |||||||
| 1021497 | levokabastiin | R01AC02 | LIVOSTIN ninasprei 0,05%/ml 10ml N1 | KRKA, d.d. | 50% | |||||||
| 1021486 | levokabastiin | S01GX02 | LIVOSTIN silmasuspensioon 0,05% 4ml | KRKA, d.d. | 50% | |||||||
| 1063291 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1042940 | levonorgestreel | G03AC03 | MIKRO-30 WYETH tablett 30mcg N35 | WYETH LEDERLE PHARMA GmbH | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise | ||||
| vastunäidustuse korral | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1088029 | levonorgestreel+etünüülöstradiool | G03AA07 | LOETTE tablett 0,1 mg + 0,02 mg N28 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1088030 | levonorgestreel+etünüülöstradiool | G03AA07 | LOETTE tablett 0,1 mg + 0,02 mg N84 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1008852 | levonorgestreel+östrogeen | G03AB03 | TRIQUILAR drazhee 0,05mg+0,03mgN6; 0,075mg+0,04mgN5; 0,125mg+0,03mgN10 (N21) | Schering AG | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1014815 | levonorgestreel+östrogeen | G03AB03 | TRI-REGOL kaetud tablett (0,05mg+0,03mgN6; 0,075mg+0,04mgN5; 0,125mg+0,03mgN10)x3 | GEDEON RICHTER Ltd. | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1113501 | levonorgestreel+östrogeen | G03FA11 | KLIMONORM tablett 2mg N9/0,15mg+2mgN12 | JENAPHARM GmbH & Co.KG | 50% | |||||||
| 1138126 | levotsetirisiin | R06AE09 | XYZAL kaetud tablett 5 mg N7 | UCB Pharma Oy Finland | 50% | |||||||
| 1138137 | levotsetirisiin | R06AE09 | XYZAL kaetud tablett 5 mg N28 | UCB Pharma Oy Finland | 50% | |||||||
| 1065822 | levotüroksiinnaatrium | H03AA01 | L-THYROXIN 100 BERLIN- CHEMIE tablett 100mcg N100 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E03; E89.0; E89.3 | |||||
| 1065866 | levotüroksiinnaatrium | H03AA01 | L-THYROXIN 50 BERLIN- CHEMIE tablett 50mcg N100 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E03; E89.0; E89.3 | |||||
| 1141917 [RTL 2006, 26, 482 – jõust. 1.04.2006] | levotüroksiinnaatrium | H03AA01 | EUTHYROX 100 MCG tablett 0,1 mg N50 | MERCK KgaA | 50% | 100% | E03; E89.0; E89.3 | |||||
| 1126583 [RTL 2006, 26, 482 – jõust. 1.04.2006] | levotüroksiinnaatrium | H03AA01 | L-THYROXHEXAL 100 tablett 100 mcg N100 | HEXAL AG | 50% | 100% | E03; E89.0; E89.3 | |||||
| 1126561[RTL 2006, 26, 482 – jõust. 1.04.2006] | levotüroksiinnaatrium | H03AA01 | L-THYROXHEXAL 50 tablett 50 mcg N100 | HEXAL AG | 50% | 100% | E03; E89.0; E89.3 | |||||
| 1013847 | linesoliid | J01XX08 | ZYVOXID tablett 400 mg N10 | Pfizer Enterprises Sarl | 50% | |||||||
| 1111576 | linesoliid | J01XX08 | ZYVOXID tablett 400 mg N20 | Pfizer Enterprises Sarl | 50% | |||||||
| 1111587 | linesoliid | J01XX08 | ZYVOXID tablett 400 mg N30 | Pfizer Enterprises Sarl | 50% | |||||||
| 1013858 | linesoliid | J01XX08 | ZYVOXID tablett 600 mg N10 | Pfizer Enterprises Sarl | 50% | |||||||
| 1111598 | linesoliid | J01XX08 | ZYVOXID tablett 600 mg N20 | Pfizer Enterprises Sarl | 50% | |||||||
| 1111600 | linesoliid | J01XX08 | ZYVOXID tablett 600 mg N30 | Pfizer Enterprises Sarl | 50% | |||||||
| 1030565 | lisinopriil | C09AA03 | DIROTON tablett 10mg N28 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1030576 | lisinopriil | C09AA03 | DIROTON tablett 20mg N28 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1030554 | lisinopriil | C09AA03 | DIROTON tablett 5mg N28 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1013331 | lisinopriil | C09AA03 | LIZINOPRILS-GRINDEKS tablett 10 mg N28 | Grindeks | 50% | |||||||
| 1013320 | lisinopriil | C09AA03 | LIZINOPRILS-GRINDEKS tablett 20 mg N28 | Grindeks | 50% | |||||||
| 1032118 | lomefloksatsiin | S01AX17 | OKACIN silmatilgad 0,3%/ml 5ml | Novartis Pharma SAS | 50% | |||||||
| 1063482 | loperamiid | A07DA03 | IMODIUM kapsel 2mg N20 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1083103 | loperamiid | A07DA03 | LOPEDIUM ISO kihisev tablett 2mg N20 | Hexal AG | 50% | |||||||
| 1083080 | loperamiid | A07DA03 | LOPEDIUM kapsel 2mg N30 | Hexal AG | 50% | |||||||
| 1083091 | loperamiid | A07DA03 | LOPEDIUM kapsel 2mg N50 | Hexal AG | 50% | |||||||
| 1063505 | loperamiid | A07DA03 | LOPERAMID-RATIOPHARM 2 MG tablett 2mg N20 | ratiopharm GmbH | 50% | |||||||
| 1063516 | loperamiid | A07DA03 | LOPERAMID-RATIOPHARM 2 MG tablett 2mg N50 | ratiopharm GmbH | 50% | |||||||
| KALETRA kapsel | ABBOTT | |||||||||||
| 1082483 | lopinaviir+ritonaviir | J05AE80 | 133,3mg+33,3mg N180 | LABORATORIES Ltd. | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1082472 | lopinaviir+ritonaviir | J05AE80 | KALETRA suukaudne lahus 80mg+20mg/ml 60ml N5 | ABBOTT LABORATORIES Ltd. | 50% | |||||||
| 1077915 | loratadiin | R06AX13 | CLARITINE FAST suukaudne lüofilisaat 10mg N100 | Schering Plough Europe | 50% | |||||||
| 1077904 | loratadiin | R06AX13 | CLARITINE FAST suukaudne lüofilisaat 10mg N30 | Schering Plough Europe | 50% | |||||||
| 1086577 | loratadiin | R06AX13 | CLARITINE siirup 1mg/ml 120ml N1 | Schering Plough Europe | 50% | |||||||
| 1086667 | loratadiin | R06AX13 | CLARITINE tablett 10mg N100 | Schering Plough Europe | 50% | |||||||
| 1086612 | loratadiin | R06AX13 | CLARITINE tablett 10mg N30 | Schering Plough Europe | 50% | |||||||
| 1088962 | loratadiin | R06AX13 | LORATIN tablett 10 mg N30 | Hexal AG | 50% | |||||||
| 1111521 | loratadiin | R06AX13 | RINOLAN siirup 1 mg/ml 100 ml | AWD Pharma Ltd. | 50% | |||||||
| 1111723 | loratadiin | R06AX13 | RINOLAN tablett 10 mg N30 | AWD Pharma Ltd. | 50% | |||||||
| 1024209 | lornoksikaam | M01AC05 | XEFO tablett 4 mg N20 | Nycomed Sefa AS | 50% | |||||||
| 1024210 | lornoksikaam | M01AC05 | XEFO tablett 8 mg N20 | Nycomed Sefa AS | 50% | |||||||
| 1134638 | lornoksikaam | M01AC05 | XEFO RAPID tablett 8 mg N20 | Nycomed Sefa AS | 50% | |||||||
| 1147339 | lornoksikaam | M01AC05 | XEFO RAPID tablett 8 mg N10 | Nycomed Sefa AS | 50% | |||||||
| 1082494 | losartaan | C09CA01 | COZAAR tablett 100mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1074978 | losartaan | C09CA01 | COZAAR tablett 12,5mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1074967 | losartaan | C09CA01 | COZAAR tablett 50mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1013735 | losartaan | C09CA01 | LORISTA tabletid 50 mg N28 | KRKA, d.d. | 50% | |||||||
| 1013005 | losartaan+hüdroklorotiasiid | C09DA01 | FORTZAAR tablett 100mg+25mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1027358 | losartaan+hüdroklorotiasiid | C09DA01 | HYZAAR tablett 50mg+12,5mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1166059 | losartaan+hüdroklorotiasiid | C09DA01 | LORISTA H kaetud tablett 50 mg+12,5 mg N28 | KRKA, d.d. | 50% | |||||||
| 1036011 | lovastatiin | C10AA02 | HOLETAR tablett 20mg N20 | KRKA, d.d. | 50% | |||||||
| 1012813 | lovastatiin | C10AA02 | HOLETAR tablett 40mg N30 | KRKA, d.d. | 50% | |||||||
| 1046810 | Lutropiin alfa | G03GA07 | LUVERIS 75 IU injektsioonisubstants 75TÜ viaal+lahusti (1ml) N1 | Serono Europe Ltd. | 50% | |||||||
| 1046832 | Lutropiin alfa | G03GA07 | LUVERIS 75 IU injektsioonisubstants 75TÜ viaal+lahusti (1ml) N10 | Serono Europe Ltd. | 50% | |||||||
| 1046821 | Lutropiin alfa | G03GA07 | LUVERIS 75 IU injektsioonisubstants 75TÜ viaal+lahusti (1ml) N3 | Serono Europe Ltd. | 50% | |||||||
| 1008245 | mebendasool | P02CA01 | MEBENDAZOLS 100 MG TABLETES tablett 100mg N6 | Grindeks | 50% | |||||||
| 1007222 | mebendasool | P02CA01 | VERMOX 100 MG tablett 100mg N6 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1063561 | medroksüprogesteroon | G03DA02 | DEPO-PROVERA süstesuspensioon 150mgml viaal 1ml N1 | Pfizer Enterprises Sarl | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | ||||
| 1063550 | medroksüprogesteroon | G03DA02 | DEPO-PROVERA süstesuspensioon 150mgml viaal 3.3ml N1 | Pfizer Enterprises Sarl | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | ||||
| 1063594 | medroksüprogesteroon | G03DA02 | PROVERA tablett 10mg N100 | Pfizer Enterprises Sarl | 50% | |||||||
| 1009044 | medroksüprogesteroon | G03DA02 | PROVERA tablett 10mg N40 | Pfizer Enterprises Sarl | 50% | |||||||
| 1009022 | medroksüprogesteroon | G03DA02 | PROVERA tablett 5mg N24 | Pfizer Enterprises Sarl | 50% | |||||||
| 1009213 | medroksüprogesteroon | L02AB02 | DEPO-PROVERA süstesuspensioon 150mg/ml täidetud süstal 1ml N1 | Pfizer Enterprises Sarl | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | ||||
| 1013195 | medroksüprogesteroon | L02AB02 | FARLUTAL tablett 500mg N30 | Pfizer Enterprises Sarl | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | ||||
| 1071100 | megestrool | L02AB01 | MEGACE suspensioon 40mg/ml 240ml N1 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1004410 | melfalaan | L01AA03 | ALKERAN TABLETS tablett 2mg N25 | Glaxo Wellcome Operations | 50% | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | ||||
| 1035021 | meloksikaam | M01AC06 | MOVALIS tablett 15mg N20 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1072853 | meloksikaam | M01AC06 | MOVALIS tablett 15mg N50 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1035009 | meloksikaam | M01AC06 | MOVALIS tablett 7,5mg N20 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1146350 | meloksikaam | M01AC06 | MOVALIS tablett 7,5mg N50 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1175925 | meloksikaam | M01AC06 | RECOXA 15 tablett 15 mg N10 | Zentiva a.s. | 50% | |||||||
| 1175936 | meloksikaam | M01AC06 | RECOXA 15 tablett 15 mg N20 | Zentiva a.s. | 50% | |||||||
| 1175903 | meloksikaam | M01AC06 | RECOXA 7,5 tablett 7,5 mg N10 | Zentiva a.s. | 50% | |||||||
| 1175914 | meloksikaam | M01AC06 | RECOXA 7,5 tablett 7,5 mg N20 | Zentiva a.s. | 50% | |||||||
| 1188761 [RTL 2006, 26, 482 – jõust. 1.04.2006] | meloksikaam | M01AC06 | MELOBAX tablett 7,5 mg N30 | Ranbaxy (UK) Limited | 50% | |||||||
| 1188895 [RTL 2006, 26, 482 – jõust. 1.04.2006] | meloksikaam | M01AC06 | MELOBAX tablett 15 mg N20 | Ranbaxy (UK) Limited | 50% | |||||||
| 1192227 [RTL 2006, 26, 482 – jõust. 1.04.2006] | meloksikaam | M01AC06 | MELOXICAM HEXAL 7,5 MG tablett 7,5 mg N50 | HEXAL AG | 50% | |||||||
| 1192261 [RTL 2006, 26, 482 – jõust. 1.04.2006] | meloksikaam | M01AC06 | MELOXICAM HEXAL 15 MG tablett 15 mg N20 | HEXAL AG | 50% | |||||||
| 1006007 | melperoon | N05AD03 | BURONIL kaetud tablett 25mg N100 | Ovation Healthcare International Ltd. | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1006030 | melperoon | N05AD03 | BURONIL kaetud tablett 50mg N100 | Ovation Healthcare International Ltd. | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1123524 | memantiin | N06DX01 | AXURA kaetud tablett 10 mg N28 | Merz Pharmaceuticals GmbH | 50% | |||||||
| 1123535 | memantiin | N06DX01 | AXURA kaetud tablett 10 mg N56 | Merz Pharmaceuticals GmbH | 50% | |||||||
| 1123546 | memantiin | N06DX01 | AXURA kaetud tablett 10 mg N112 | Merz Pharmaceuticals GmbH | 50% | |||||||
| 1004971 | merkaptopuriin | L01BB02 | PURI-NETHOL TABLETS tablett 50mg N25 | Glaxo Wellcome Operations | 50% | 100% | (C00-D48)* | *rv onkoloogil, hematoloogil ja pediaatril | ||||
| 1023826 | mesalasiin | A07EC02 | PENTASA prolong tablett 500mg N100 | Ferring A/S | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1083114 | mesalasiin | A07EC02 | SALOFALK 250 TABLETS Gastroresistentne tablett 250mg N100 | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1044852 | mesalasiin | A07EC02 | SALOFALK 250 TABLETS Gastroresistentne tablett 250mg N50 | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1083125 | mesalasiin | A07EC02 | SALOFALK 500 TABLETS Gastroresistentne tablett 500mg N100 | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1044841 | mesalasiin | A07EC02 | SALOFALK 500 TABLETS Gastroresistentne tablett 500mg N50 | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1023815 | mesalasiin | A07EC02 | PENTASA suposiit 1g N28 | Ferring A/S | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1044830 | mesalasiin | A07EC02 | SALOFALK 250 SUPPOSITORIES suposiit | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 250mg N10 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1083136 | mesalasiin | A07EC02 | SALOFALK 250 SUPPOSITORIES suposiit 250mg N30 | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1044829 | mesalasiin | A07EC02 | SALOFALK 500 SUPPOSITORIES suposiit 500mg N10 | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1083147 | mesalasiin | A07EC02 | SALOFALK 500 SUPPOSITORIES suposiit 500mg N30 | DR.FALK PHARMA GmbH | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1146541 | mesalasiin | A07EC02 | ASACOL suposiidid 500 mg N20 | Nycomed Sefa AS | 50% | 75% | K50; K51 | *rv gastroenteroloogil ja pediaatril | ||||
| 1155743 | mesalasiin | A07EC02 | ASACOL 400 MG modifitseeritud tablett 400mg N20 | Nycomed Sefa AS | 50% | 75% | (K50-51)* | *rv gastroenteroloogil ja pediaatril | ||||
| 1146574 | mesalasiin | A07EC02 | ASACOL 400 MG modifitseeritud tablett 400mg N100 | Nycomed Sefa AS | 50% | 75% | (K50-51)* | *rv gastroenteroloogil ja pediaatril | ||||
| 1184970 [RTL 2006, 26, 482 – jõust. 1.04.2006] | mesalasiin | A07EC02 | ASACOL 800 MG modifitseeritud tablett 800mg N50 | Nycomed Sefa AS | 50% | 75% | (K50-51)* | *rv gastroenteroloogil ja pediaatril | ||||
| 1034109 | metadoon | N02AC02 | METADON DAK 1 MG/ML suukaudne lahus 1mg/ml 1000ml N1 | Nycomed Sefa AS | 50% | 100% | C00-D48 | |||||
| 1034110 | metadoon | N02AC02 | METADON DAK tablett 20mg N25 | Nycomed Sefa AS | 50% | 100% | C00-D48 | |||||
| 1043558 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1086140 | metformiin | A10BA02 | GLUFORMIN tablett 850 N30 | AWD.Pharma Ltd. | 50% | |||||||
| 1013218 | metformiin | A10BA02 | GLUFORMIN tablett 850 N60 | AWD.Pharma Ltd. | 50% | |||||||
| 1064719 | metformiin | A10BA02 | METFORAL 500 tablett 500mg N120 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | E11; E14 | |||||
| 1011317 | metformiin | A10BA02 | METFORAL 500 tablett 500mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1064708 | metformiin | A10BA02 | METFORAL 500 tablett 500mg N60 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1064731 | metformiin | A10BA02 | METFORAL 850 tablett 850mg N120 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | E11; E14 | |||||
| 1011328 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metformiin | A10BA02 | METFORAL 850 tablett 850mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1064720 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metformiin | A10BA02 | METFORAL 850 tablett 850mg N60 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1090112 | metformiin | A10BA02 | METFORMIN ALPHARMA TABLETS 500 MG tablett 500mg N30 | ALPHARMA Limited | 50% | |||||||
| 1041635 | metformiin | A10BA02 | METFORMIN ALPHARMA TABLETS 850 MG tablett 850mg N50 | ALPHARMA Limited | 50% | |||||||
| 1007402 | metformiin | A10BA02 | METFORMIN-HEXAL 500 tablett 500mg N100 | Hexal AG | 50% | 75% | E11; E14 | |||||
| 1083169 | metformiin | A10BA02 | METFORMIN-RATIOPHARM 500 MG tablett 500mg N120 | ratiopharm GmbH | 50% | 75% | E11; E14 | |||||
| 1045370 | metformiin | A10BA02 | METFORMIN-RATIOPHARM 500 MG tablett 500mg N30 | ratiopharm GmbH | 50% | |||||||
| 1083158 | metformiin | A10BA02 | METFORMIN-RATIOPHARM 850 MG tablett 850mg N120 | ratiopharm GmbH | 50% | 75% | E11; E14 | |||||
| 1045325 | metformiin | A10BA02 | METFORMIN-RATIOPHARM 850 MG tablett 850mg N30 | ratiopharm GmbH | 50% | |||||||
| 1164798 | metformiin | A10BA02 | METFORAL 1000 tabletid 1000 mg N120 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | E11; E14 | |||||
| 1156609 | metformiin | A10BA02 | METFORMIN-HEXAL 850 tablett 850 mg N120 | Hexal AG | 50% | 75% | E11; E14 | |||||
| 1156586 | metformiin | A10BA02 | METFORMIN-HEXAL 850 tablett 850 mg N30 | Hexal AG | 50% | |||||||
| 1115569 | metformiin | A10BA02 | METFORMIN-HEXAL 500 tablett 500mg N30 | Hexal AG | 50% | |||||||
| 1133480 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metformiin | A10BA02 | GLUCOPHAGE 1000 MG tablett 1000 mg N60 | MERCK SANTE s.a.s. | 50% | |||||||
| 1133468 [RTL 2006, | ||||||||||||
| 26, 482 – jõust. 1.04.2006] | metformiin | A10BA02 | GLUCOPHAGE 500 MG tablett 500 mg N100 | MERCK SANTE s.a.s. | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1149151 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metformiin+ glibenklamiid | A10BD80 | GLUCOVANCE 500 mg/2,5 mg kaetud tablett N60 | MERCK SANTE s.a.s | 50% | |||||||
| 1133525 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metformiin+ glibenklamiid | A10BD80 | GLUCOVANCE 500 mg/5 mg kaetud tablett N60 | MERCK SANTE s.a.s | 50% | |||||||
| 1000674 | metoklopramiid | A03FA01 | CERUCAL tablett 10mg N50 | ARZNEIMITTELWERK DRESDEN GmbH | 50% | 100% | C00-D48 | |||||
| 1033917 | metoklopramiid | A03FA01 | METOCLOPRAMIDE ALPHARMA TABLETS 10 MG tablett 10mg N20 | ALPHARMA Limited | 50% | 100% | C00-D48 | |||||
| 1022421 | metoklopramiid | A03FA01 | MCP-RATIOPHARM 10 suposiit 10mg N5 | ratiopharm GmbH | 50% | 100% | C00-D48 | |||||
| 1000742 | metoklopramiid | A03FA01 | CERUCAL süstelahus 5mg/ml 2ml N10 | ARZNEIMITTELWERK DRESDEN GmbH | 50% | 100% | C00-D48 | |||||
| 1083406 | metoprolool | C07AB02 | BETALOC ZOK 25 MG retardtablett 25mg N28 | AstraZeneca AB | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1019720 | metoprolool | C07AB02 | BETALOC ZOK retardtablett 100mg N30 | AstraZeneca AB | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1019719 | metoprolool | C07AB02 | BETALOC ZOK retardtablett 50mg N30 | AstraZeneca AB | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1078129 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1010811 | metoprolool | C07AB02 | EMZOK tablett 100mg N30 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1078130 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1010822 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1078118 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1010800 | metoprolool | C07AB02 | EMZOK tablett 50mg N30 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1072246 | metoprolool | C07AB02 | METOPROLOL 100 STADA tablett 100mg N100 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1017458 | metoprolool | C07AB02 | METOPROLOL 100 STADA tablett 100mg N20 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1072235 | metoprolool | C07AB02 | METOPROLOL 100 STADA tablett 100mg N50 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1072268 | metoprolool | C07AB02 | METOPROLOL 200 STADA RETARD retardtablett 200mg N100 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil | ||||
| 1017414 | metoprolool | C07AB02 | METOPROLOL 200 STADA RETARD retardtablett 200mg N50 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil | ||||
| 1072190 | metoprolool | C07AB02 | METOPROLOL 50 STADA tablett 50mg N100 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1017447 | metoprolool | C07AB02 | METOPROLOL 50 STADA tablett 50mg N20 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1072167 | metoprolool | C07AB02 | METOPROLOL 50 STADA tablett 50mg N50 | Stada Arzneimittel | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1009055 | metoprolool | C07AB02 | METOPROLOL-RATIOPHARM 50 tablett 50mg N30 | ratiopharm GmbH | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1129744 | metoprolool | C07AB02 | METOHEXAL 50 tablett 50 mg N30 | Hexal AG | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1129711 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metoprolool | C07AB02 | METOHEXAL 100 tablett 100 mg N30 | Hexal AG | 50% | 75% | I10-I13; I15; I50*; I20 | *rev kardioloogil ja pediaatril | ||||
| 1001136 | metotreksaat | L01BA01 | TREXAN tablett 2,5mg N100 | ORION CORPORATION ORION PHARMA | 50% | 75% | L40; M07; M05; M06; M08; (M30- M33); M35; M45; M46* | rv dermatoveneroloogil ja reumatoloogil; *rv reumatoloogil | 100% | (C00-D48)* | *rv onkoloogil ja hematoloogil | |
| 1046179 | metronidasool | D06BX01 | ROZEX geel 0,75%/ 15g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1046180 | metronidasool | D06BX01 | ROZEX geel 0,75%/ 30g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1046191 | metronidasool | D06BX01 | ROZEX geel 0,75%/ 50g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1012644 | metronidasool | D06BX01 | ROZEX geel 0,75%/ 5g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1046203 | metronidasool | D06BX01 | ROZEX kreem 0,75%/ 15g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1046214 | metronidasool | D06BX01 | ROZEX kreem 0,75%/ 30g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1012655 | metronidasool | D06BX01 | ROZEX kreem 0,75%/ 5g N1 | GALDERMA INTERNATIONAL | 50% | |||||||
| 1107694 | metronidasool | J01XD01 | APO-METRONIDAZOLE tablett 250mg N20 | Apotex International Inc | 50% | |||||||
| 1107706 | metronidasool | J01XD01 | APO-METRONIDAZOLE tablett 250mg N40 | Apotex International Inc | 50% | |||||||
| 1033636 | metronidasool | J01XD01 | ARILIN KOMBIPACKUNG tabl/vagin supp N12 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1008706 | metronidasool | J01XD01 | METRONIDAZOL NYCOMED tablett 500mg N10 | Nycomed Sefa AS | 50% | |||||||
| 1071324 | metronidasool | J01XD01 | METRONIDAZOL NYCOMED tablett 500mg N100 | Nycomed Sefa AS | 50% | |||||||
| 1008706 | metronidasool | P01AB01 | METRONIDAZOL NYCOMED tablett 500mg N10 | Nycomed Sefa AS | 50% | |||||||
| 1071324 | metronidasool | P01AB01 | METRONIDAZOL NYCOMED tablett 500mg N100 | Nycomed Sefa AS | 50% | |||||||
| 1009190 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloon | H02AB04 | DEPO-MEDROL süstesuspensioon 40mg/ml viaal 1ml N1 | Pfizer Enterprises Sarl | 50% | 75% | M05; M06; M08; (M30- M33); M35; M45; M46; (N00- N08)* | rev reumatoloogil ja pediaatril; *rv nefroloogil ja pediaatril | 100% | G35*; T86 | *rev neuroloogil ja pediaatril | |
| 1065495 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloon | H02AB04 | DEPO-MEDROL süstesuspensioon 40mg/ml viaal 2ml N1 | Pfizer Enterprises Sarl | 50% | 75% | M05; M06; M08; (M30- M33); M35; M45; M46; (N00- N08)* | rev reumatoloogil ja pediaatril; *rv nefroloogil ja pediaatril | 100% | G35*; T86 | *rev neuroloogil ja pediaatril | |
| 1009099 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloon | H02AB04 | MEDROL tablett 16mg N50 | Pfizer Enterprises Sarl | 50% | 75% | K50; K51; K73;K74; M05; M06; M08; (M30- M33); M35; M45; M46; (N00- N08)* | rv gastroenteroloogil ja pediaatril; rev reumatoloogil ja pediaatril; **rv nefroloogil ja pediaatril | 100% | G35*; T86 | *rev neuroloogil ja pediaatril | |
| 1065754 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloon | H02AB04 | MEDROL tablett 4mg N100 | Pfizer Enterprises Sarl | 50% | 75% | K50; K51; K73;K74; M05; M06; M08; (M30- M33); M35; M45; M46; (N00- N08)* | rv gastroenteroloogil ja pediaatril; rev reumatoloogil ja pediaatril; **rv nefroloogil ja pediaatril | 100% | G35*; T86 | *rev neuroloogil ja pediaatril | |
| 1009077 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloon | H02AB04 | MEDROL tablett 4mg N30 | Pfizer Enterprises Sarl | 50% | 75% | K50; K51; K73;K74; M05; M06; M08; (M30- M33); M35; M45; M46; (N00- N08)* | rv gastroenteroloogil ja pediaatril; rev reumatoloogil ja pediaatril; **rv nefroloogil ja pediaatril | 100% | G35*; T86 | *rev neuroloogil ja pediaatril | |
| 1028102 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloonatseponaat | D07AC14 | ADVANTAN kreem 0,1%/ 15g | Intendis GmbH | 50% | 75% | L20; L23; L40** | rv dermatoveneroloogil ja pediaatril; *rv dermatoveneroloogil; | ||||
| 1062009 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloonatseponaat | D07AC14 | ADVANTAN salv 0,1% 15g | Intendis GmbH | 50% | 75% | L20; L23; L40** | rv dermatoveneroloogil ja pediaatril; *rv dermatoveneroloogil; | ||||
| 1133356 [RTL 2006, 26, 482 – jõust. 1.04.2006] | metüülprednisoloonatseponaat | D07AC14 | ADVANTAN MILK nahaemulsioon 0,1 % 20 g | Intendis GmbH | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1024579 | mikonasool | A01AB09 | DAKTARIN suugeel 20mg/ml 40g | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1018167 | mikonasool | D01AC02 | DAKTARIN kreem 2%/g 15g | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1060906 | mikonasool | D01AC02 | DAKTARIN kreem 2%/g 30g | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1013049 | milnatsipraan | N06AX17 | IXEL kapsel 50mg N56 | Pierre Fabre Medicament | 50% | |||||||
| 1038484 | mirtasapiin | N06AX11 | REMERON tablett 45mg N30 | N.V. ORGANON | 50% | |||||||
| 1116841 | mirtasapiin | N06AX11 | REMERON SOLTAB suus dispergeeruv tablett 15 mg N 30 | N.V. ORGANON | 50% | |||||||
| 1116896 | mirtasapiin | N06AX11 | REMERON SOLTAB suus dispergeeruv tablett 30 mg N 30 | N.V. ORGANON | 50% | |||||||
| 1158252 | mirtasapiin | N06AX11 | MIRZATEN tablett 15 mg N30 | KRKA, d.d. | 50% | |||||||
| 1158421 | mirtasapiin | N06AX11 | MIRZATEN tablett 30 mg N30 | KRKA, d.d. | 50% | |||||||
| 1158588 | mirtasapiin | N06AX11 | MIRZATEN tablett 45 mg N30 | KRKA, d.d. | 50% | |||||||
| 1170201 | mirtasapiin | N06AX11 | ESPRITAL 15 tablett 15 mg N30 | Zentiva a.s. | 50% | |||||||
| 1170166 | mirtasapiin | N06AX11 | ESPRITAL 30 tablett 30 mg N30 | Zentiva a.s. | 50% | |||||||
| 1170199 | mirtasapiin | N06AX11 | ESPRITAL 45 tablett 45 mg N30 | Zentiva a.s. | 50% | |||||||
| 1013779 | moksonidiin | C02AC05 | PHYSIOTENS 0,2 tablett 0,2 mg N28 | Solvay Pharmaceuticals GmbH | 50% | |||||||
| 1013780 | moksonidiin | C02AC05 | PHYSIOTENS 0,3 mg N28 | Solvay Pharmaceuticals GmbH | 50% | |||||||
| 1013791 | moksonidiin | C02AC05 | PHYSIOTENS 0,4 mg N28 | Solvay Pharmaceuticals GmbH | 50% | |||||||
| 1145999 | moksonidiin | C02AC05 | MOXONIDIN HEXAL 0,2 kaetud tablett 0,2 mg N30 | Hexal AG | 50% | |||||||
| 1146079 | moksonidiin | C02AC05 | MOXONIDIN HEXAL 0,3 kaetud tablett 0,3 mg N30 | Hexal AG | 50% | |||||||
| 1146170 | moksonidiin | C02AC05 | MOXONIDIN HEXAL 0,4 kaetud tablett 0,4 mg N30 | Hexal AG | 50% | |||||||
| 1157778 | moksonidiin | C02AC05 | MOXOGAMMA 0,2 MG kaetud tablett 0,2 mg N30 | Wörwag Pharma GmbH | 50% | |||||||
| 1157857 | moksonidiin | C02AC05 | MOXOGAMMA 0,3 MG kaetud tablett 0,3 mg N30 | Wörwag Pharma GmbH | 50% | |||||||
| 1157947 | moksonidiin | C02AC05 | MOXOGAMMA 0,4 MG kaetud tablett 0,4 mg N30 | Wörwag Pharma GmbH | 50% | |||||||
| 1155091 [RTL 2006, 26, 482 – jõust. 1.04.2006] | moksonidiin | C02AC05 | STADAPRESS kaetud tablett 0,2 mg N30 | STADA ARZNEIMITTEL AG | 50% | |||||||
| 1155259 [RTL 2006, 26, 482 – jõust. 1.04.2006] | moksonidiin | C02AC05 | STADAPRESS kaetud tablett 0,4 mg N30 | STADA ARZNEIMITTEL AG | 50% | |||||||
| 1028955 | mometasoon | D07AC13 | ELOCON kreem 0,1% 20g | Schering Plough Europe | 50% | 75% | L20; L23; L40**; *** | rv dermatoveneroloogil ja pediaatril; rv dermatoveneroloogil; **soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1061985 | mometasoon | D07AC13 | ELOCON kreem 0,1% 50g | Schering Plough Europe | 50% | |||||||
| 1028933 | mometasoon | D07AC13 | ELOCON nahalahus 0,1% 20ml N1 | Schering Plough Europe | 50% | 75% | L20; L23; L40**; *** | rv dermatoveneroloogil ja pediaatril; rv dermatoveneroloogil; **soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1061952 | mometasoon | D07AC13 | ELOCON nahalahus 0,1% 50ml N1 | Schering Plough Europe | 50% | |||||||
| 1028944 | mometasoon | D07AC13 | ELOCON salv 0,1% 20g N1 | Schering Plough Europe | 50% | 75% | L20; L23; L40**; *** | rv dermatoveneroloogil ja pediaatril; rv dermatoveneroloogil; **soodustus ei kehti | ||||
| enne hinnakokkuleppe jõustumist | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1061963 | mometasoon | D07AC13 | ELOCON salv 0,1% 50g N1 | Schering Plough Europe | 50% | |||||||
| 1028966 | mometasoon | R01AD09 | NASONEX ninasprei 0,5mg/ml 18g (140 annust) | Schering Plough Europe | 50% | |||||||
| 1135178 | mometasoon | R03BA07 | ASMANEX TWISTHALER inhal pulb 200 mcg/annuses 30 annust | Schering Plough Europe | 50% | |||||||
| 1135167 | mometasoon | R03BA07 | ASMANEX TWISTHALER inhal pulb 200 mcg/annuses 60 annust | Schering Plough Europe | 50% | |||||||
| 1135189 | mometasoon | R03BA07 | ASMANEX TWISTHALER inhal pulb 400 mcg/annuses 30 annust | Schering Plough Europe | 50% | |||||||
| 1135190 | mometasoon | R03BA07 | ASMANEX TWISTHALER inhal pulb 400 mcg/annuses 60 annust | Schering Plough Europe | 50% | |||||||
| 1193509 [RTL 2006, 26, 482 – jõust. 1.04.2006] | mometasoon+ salitsüülhape | D07XC03 | ELOSALIC salv 0,1 %+5 % 45 g | Schering Plough Europe | 50% | |||||||
| 1011283 [RTL 2006, 26, 482 – jõust. 1.04.2006] | montelukast | R03DC03 | SINGULAIR 4 MG närimistablett 4mg N14 | Merck Sharp & Dohme OÜ | 50% | 75% | J45* | *rv alla 11-aastastele lastele, rev pulmonoloogil ja pediaatril. | ||||
| 1077364 [RTL 2006, 26, 482 – jõust. 1.04.2006] | montelukast | R03DC03 | SINGULAIR 4 MG närimistablett 4mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | J45* | *rv alla 11-aastastele lastele, rev pulmonoloogil ja pediaatril. | ||||
| 1077320 [RTL 2006, 26, 482 – jõust. 1.04.2006] | montelukast | R03DC03 | SINGULAIR närimistablett 5mg N14 | Merck Sharp & Dohme OÜ | 50% | 75% | J45* | *rv alla 11-aastastele lastele, rev pulmonoloogil ja pediaatril. | ||||
| 1077331 [RTL 2006, 26, 482 – jõust. 1.04.2006] | montelukast | R03DC03 | SINGULAIR närimistablett 5mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | J45* | *rv alla 11-aastastele lastele, rev pulmonoloogil ja pediaatril. | ||||
| 1084520 | montelukast | R03DC03 | SINGULAIR tablett 10mg N14 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1084531 | montelukast | R03DC03 | SINGULAIR tablett 10mg N28 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1111082 [RTL 2006, 26, 482 – jõust. 1.04.2006] | montelukast | R03DC03 | SINGULAIR MINI 4 MG graanulid 4 mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | J45* | *rv alla 11-aastastele lastele, rev pulmonoloogil ja pediaatril. | ||||
| 1014051 | morfiin | N02AA01 | DOLTARD retardtablett 30mg N20 | Nycomed Sefa AS | 50% | 100% | C00-D48 | |||||
| 1014062 | morfiin | N02AA01 | DOLTARD retardtablett 60mg N20 | Nycomed Sefa AS | 50% | 100% | C00-D48 | |||||
| 1043222 | morfiin | N02AA01 | MORFIN DAK 20 MG/ML süstelahus 20mg/ml amp 1ml N10 | Nycomed Sefa AS | 50% | 100% | C00-D48 | |||||
| 1014006 | morfiin | N02AA01 | MORFIN NYCOMED 30 MG tablett 30mg N25 | Nycomed Sefa AS | 50% | 100% | C00-D48 | |||||
| 1041590 | morfiin | N02AA01 | MSI 10 MUNDIPHARMA süstelahus 10mg/ml 1ml N10 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1041567 | morfiin | N02AA01 | MSI 20 MG MUNDIPHARMA süstelahus 20mg/ml 1ml N10 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1033254 | morfiin | N02AA01 | MST CONTINUS 100 MG suspensioonigraanulid 100mg N30 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080289 | morfiin | N02AA01 | MST CONTINUS 30 MG suspensioonigraanulid 30mg N30 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080313 | morfiin | N02AA01 | MST CONTINUS 60 MG suspensioonigraanulid 60mg N30 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1111835 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1111778 | morfiin | N02AA01 | MST CONTINUS retardtablett 10mg N60 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1111857 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1026740 | morfiin | N02AA01 | MST CONTINUS retardtablett 30mg N60 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1026751 | morfiin | N02AA01 | MST CONTINUS retardtablett 60mg N60 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1078826 | morfiin | N02AA01 | MST CONTINUS suspensioonigraanulid 20mg N30 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080346 | morfiin | N02AA01 | MXL 120 MG kapsel 120mg N28 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080368 | morfiin | N02AA01 | MXL 150 MG kapsel 150mg N28 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080380 | morfiin | N02AA01 | MXL 200 MG kapsel 200mg N28 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080403 | morfiin | N02AA01 | MXL 30 MG kapsel 30mg N28 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080425 | morfiin | N02AA01 | MXL 60 MG kapsel 60mg N28 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080469 | morfiin | N02AA01 | MXL 90 MG kapsel 90mg N28 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080470 | morfiin | N02AA01 | SEVREDOL tablett 10mg N56 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1080492 | morfiin | N02AA01 | SEVREDOL tablett 20mg N56 | Mundipharma Ges.m.b.H. | 50% | 100% | C00-D48 | |||||
| 1035717 | morfiin | N02AA01 | VENDAL RETARD 10 MG prolong tablett 10mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 100% | C00-D48 | |||||
| 1035740 | morfiin | N02AA01 | VENDAL RETARD 100 MG prolong tablett 100mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 100% | C00-D48 | |||||
| 1035751 | morfiin | N02AA01 | VENDAL RETARD 200 MG prolong tablett 200mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 100% | C00-D48 | |||||
| 1035728 | morfiin | N02AA01 | VENDAL RETARD 30 MG prolong tablett 30mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 100% | C00-D48 | |||||
| 1035739 | morfiin | N02AA01 | VENDAL RETARD 60 MG prolong tablett 60mg N30 | LANNACHER HEILMITTEL GmbH | 50% | 100% | C00-D48 | |||||
| 1063774 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | KREON 10 000 kapsel 10 000+8000+600 TÜ N100 | Solvay Pharmaceuticals GmbH | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1044469 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | KREON 10 000 kapsel 10 000+8000+600 TÜ N20 | Solvay Pharmaceuticals GmbH | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063763 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | KREON 10 000 kapsel 10 000+8000+600 TÜ N50 | Solvay Pharmaceuticals GmbH | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063729 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | KREON 25 000 kapsel 25000+18000+1000 TÜ N100 | Solvay Pharmaceuticals GmbH | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1044470 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | KREON 25 000 kapsel 25000+18000+1000 TÜ N20 | Solvay Pharmaceuticals GmbH | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063707 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | KREON 25 000 kapsel 25000+18000+1000 TÜ N50 | Solvay Pharmaceuticals GmbH | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1060434 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | MEZYM FORTE 20 000 gastroresistentne tablett 20000+12000+900 TÜ N100 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1060445 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | MEZYM FORTE 20 000 gastroresistentne tablett 20000+12000+900 TÜ N200 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1020216 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | MEZYM FORTE 20 000 gastroresistentne tablett 20000+12000+900 TÜ N50 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063741 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 10000 kapsel 10000+9000+500 TÜ N100 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1020205 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 10000 kapsel 10000+9000+500 TÜ N20 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063752 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 10000 kapsel 10000+9000+500 TÜ N200 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063730 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 10000 kapsel 10000+9000+500 TÜ N50 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063842 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 25000 kapsel 25000+22500+1250 TÜ N100 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1020182 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 25000 kapsel 25000+22500+1250 TÜ N20 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063853 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 25000 kapsel 25000+22500+1250 TÜ N200 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1063820 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANGROL 25000 kapsel 25000+22500+1250 TÜ N50 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1109618 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1021622 | Multiensüümid (lipaas, proteaas jt) | A09AA02 | PANZYTRAT 10000 kapsel 10000+9500+500 TÜ N20 | Abbott GmbH & Co. KG | 50% | 100% | E84* | *rev pulmonoloogil ja pediaatril | ||||
| 1023556 [RTL 2006, | Hoffmann-La Roche | |||||||||||
| 26, 482 – jõust. 1.04.2006] | mükofenoolhape | L04AA06 | CELLCEPT kapsel 250mg N100 | Ltd. Eesti filiaal | 50% | 100% | T86 | |||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1085958 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1085936 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1023567 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1088344 [RTL 2006, 26, 482 – jõust. 1.04.2006] | mükofenoolhape | L04AA06 | CELLCEPT tablett 500mg N50 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | T86 | |||||
| 1037090 | naatriumsulfaat+kaaliumkloriid+naatriumkloriid +naatriumvesinikkarbonaat+macrogol | A06AD81 | COLOLYT gran N3 | Spirig Baltikum Lithuanian-Swiss Ltd. | 50% | |||||||
| 1035346 | naatriumsulfaat+kaaliumkloriid+naatriumkloriid +naatriumvesinikkarbonaat+macrogol | A06AD81 | FORTRANS pulber 5,7g+0,75g+1,46g+1,68g+64g N4 | Beaufour Ipsen International Ipsen Int | 50% | |||||||
| 1073898 | nabumetoon | M01AX01 | RELIFEX kihisev tablett 1g N100 | Meda AB | 50% | |||||||
| 1023949 | nabumetoon | M01AX01 | RELIFEX kihisev tablett 1g N20 | Meda AB | 50% | |||||||
| 1073887 | nabumetoon | M01AX01 | RELIFEX tablett 500mg N100 | Meda AB | 50% | |||||||
| 1023848 | nabumetoon | M01AX01 | RELIFEX tablett 500mg N20 | Meda AB | 50% | |||||||
| 1087242 | nadropariin | B01AB06 | FRAXIPARINE FORTE süstelahus 11400 TÜ anti Xa 0.6ml täidetud süstal 0.6ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1045314 | nadropariin | B01AB06 | FRAXIPARINE FORTE süstelahus 11400TÜ anti Xa 0.6ml täidetud süstal 0.6ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1087264 | nadropariin | B01AB06 | FRAXIPARINE FORTE süstelahus 15200TÜ anti Xa 0.8ml täidetud süstal 0.8ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1045369 | nadropariin | B01AB06 | FRAXIPARINE FORTE süstelahus 15200TÜ anti Xa 0.8ml täidetud süstal 0.8ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1087253 | nadropariin | B01AB06 | FRAXIPARINE FORTE süstelahus 19000TÜ anti Xa/ml täidetud süstal 1ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1045303 | nadropariin | B01AB06 | FRAXIPARINE FORTE süstelahus 19000TÜ anti Xa/ml täidetud süstal 1ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065664 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 3800TÜ anti Xa 0.4ml 0.4ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1035223 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 3800TÜ anti Xa 0.4ml 0.4ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1124109 [RTL 2006, 26, 482 – jõust. 1.04.2006] | nadropariin | B01AB06 | FRAXIPARINE süstelahus 5700TÜ anti Xa 0.6ml 0.6ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1124110 [RTL 2006, 26, 482 – jõust. 1.04.2006] | nadropariin | B01AB06 | FRAXIPARINE süstelahus 5700TÜ anti Xa 0.6ml 0.6ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1129496 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 7600TÜ anti Xa 0.8ml 0.8ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1035245 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 7600TÜ anti Xa 0.8ml 0.8ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1129519 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 2850IU/0,3ml 0.3ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1129508 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 2850IU/0,3ml 0.3ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1065686 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 9500TÜ anti Xa/ml 1ml N10 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1035234 | nadropariin | B01AB06 | FRAXIPARINE süstelahus 9500TÜ anti Xa/ml 1ml N2 | SANOFI- SYNTHELABO FRANCE | 50% | 75% | O99.8* | *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1147890 | naftidrofurüül | C04AX21 | ENELBIN 100 RETARD prolongeeritud tablett 100 mg N20 | Zentiva a.s. | 50% | |||||||
| ENELBIN 100 RETARD | ||||||||||||
| 1147902 | naftidrofurüül | C04AX21 | prolongeeritud tablett 100 mg N50 | Zentiva a.s. | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | |||||
| 1147913 | naftidrofurüül | C04AX21 | ENELBIN 100 RETARD prolongeeritud tablett 100 mg N100 | Zentiva a.s. | 50% | |||||||
| 1061075 | naftifiin | D01AE22 | EXODERIL CREAM kreem 1% 15g | Biochemie GmbH | 50% | |||||||
| 1061097 | naftifiin | D01AE22 | EXODERIL CREAM kreem 1% 200g | Biochemie GmbH | 50% | |||||||
| 1061086 | naftifiin | D01AE22 | EXODERIL CREAM kreem 1% 30g | Biochemie GmbH | 50% | |||||||
| 1020294 | naftifiin | D01AE22 | EXODERIL CREAM kreem 1% 5g | Biochemie GmbH | 50% | |||||||
| 1020306 | naftifiin | D01AE22 | EXODERIL SOLUTION lahus 1% 10ml | Biochemie GmbH | 50% | |||||||
| 1061110 | naftifiin | D01AE22 | EXODERIL SOLUTION lahus 1% 20ml | Biochemie GmbH | 50% | |||||||
| 1014703 | nandroloon | A14AB01 | RETABOLIL süstelahus 50mg/ml 1ml N1 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1065428 | nandroloon | A14AB01 | RETABOLIL süstelahus 50mg/ml 1ml N25 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1010585 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1023107 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1023095 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1009527 | naprokseen | M01AE02 | NAPROXEN ALPHARMA TABLETS 250 MG tablett 250mg N20 | ALPHARMA Limited | 50% | 75% | M05; M06; M08; M45; M46 | |||||
| 1036459 | naratriptaan | N02CC02 | NARAMIG tablett 2,5mg N2 | Glaxo Wellcome Operations | 50% | |||||||
| 1076790 | naratriptaan | N02CC02 | NARAMIG tablett 2,5mg N4 | Glaxo Wellcome Operations | 50% | |||||||
| 1076802 | naratriptaan | N02CC02 | NARAMIG tablett 2,5mg N6 | Glaxo Wellcome Operations | 50% | |||||||
| 1013904 | nategliniid | A10BX03 | STARLIX 120 tablett 120mg N12 | Novartis Pharma AG | 50% | |||||||
| 1092732 | nategliniid | A10BX03 | STARLIX 120 tablett 120mg N120 | Novartis Pharma AG | 50% | |||||||
| 1092697 | nategliniid | A10BX03 | STARLIX 120 tablett 120mg N24 | Novartis Pharma AG | 50% | |||||||
| 1092709 | nategliniid | A10BX03 | STARLIX 120 tablett 120mg N30 | Novartis Pharma AG | 50% | |||||||
| 1092743 | nategliniid | A10BX03 | STARLIX 120 tablett 120mg N360 | Novartis Pharma AG | 50% | |||||||
| 1092710 | nategliniid | A10BX03 | STARLIX 120 tablett 120mg N60 | Novartis Pharma AG | 50% | |||||||
| 1092721 | nategliniid | A10BX03 | STARLIX 120 tablett 120mg N84 | Novartis Pharma AG | 50% | |||||||
| 1013915 | nategliniid | A10BX03 | STARLIX 180 tablett 180mg N12 | Novartis Pharma AG | 50% | |||||||
| 1092798 | nategliniid | A10BX03 | STARLIX 180 tablett 180mg N120 | Novartis Pharma AG | 50% | |||||||
| 1092754 | nategliniid | A10BX03 | STARLIX 180 tablett 180mg N24 | Novartis Pharma AG | 50% | |||||||
| 1092765 | nategliniid | A10BX03 | STARLIX 180 tablett 180mg N30 | Novartis Pharma AG | 50% | |||||||
| 1092800 | nategliniid | A10BX03 | STARLIX 180 tablett 180mg N360 | Novartis Pharma AG | 50% | |||||||
| 1092776 | nategliniid | A10BX03 | STARLIX 180 tablett 180mg N60 | Novartis Pharma AG | 50% | |||||||
| 1092787 | nategliniid | A10BX03 | STARLIX 180 tablett 180mg N84 | Novartis Pharma AG | 50% | |||||||
| 1013892 | nategliniid | A10BX03 | STARLIX 60 tablett 60mg N12 | Novartis Pharma AG | 50% | |||||||
| 1080931 | nategliniid | A10BX03 | STARLIX 60 tablett 60mg N120 | Novartis Pharma AG | 50% | |||||||
| 1080896 | nategliniid | A10BX03 | STARLIX 60 tablett 60mg N24 | Novartis Pharma AG | 50% | |||||||
| 1080908 | nategliniid | A10BX03 | STARLIX 60 tablett 60mg N30 | Novartis Pharma AG | 50% | |||||||
| 1080942 | nategliniid | A10BX03 | STARLIX 60 tablett 60mg N360 | Novartis Pharma AG | 50% | |||||||
| 1080919 | nategliniid | A10BX03 | STARLIX 60 tablett 60mg N60 | Novartis Pharma AG | 50% | |||||||
| 1080920 | nategliniid | A10BX03 | STARLIX 60 tablett 60mg N84 | Novartis Pharma AG | 50% | |||||||
| 1072426 | nebivolool | C07AB12 | NEBILET tablett 5mg N14 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1072437 | nebivolool | C07AB12 | NEBILET tablett 5mg N28 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1032297 | nebivolool | C07AB12 | NEBILET tablett 5mg N7 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1085150 | nelfinaviir | J05AE04 | VIRACEPT kaetud tablett 250mg N270 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1042377 | nelfinaviir | J05AE04 | VIRACEPT tablett 250mg N270 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1082618 | nevirapiin | J05AX03 | VIRAMUNE suspensioon 50mg/5ml 240ml N1 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1073450 | nevirapiin | J05AX03 | VIRAMUNE tablett 200mg N100 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1037113 | nevirapiin | J05AX03 | VIRAMUNE tablett 200mg N60 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1141805 | nifedipiin | C08CA05 | ADALAT 10 RETARD prolong tablett 10mg N100 | Bayer AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1006311 | nifedipiin | C08CA05 | ADALAT OROS 30 MG DEPOT TABLETS retardtablett 30mg N28 | Bayer AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1072617 | nifedipiin | C08CA05 | ADALAT OROS 30 MG DEPOT TABLETS retardtablett 30mg N98 | Bayer AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1042456 | nifedipiin | C08CA05 | ADALAT OROS retardtablett 20mg N28 | Bayer AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1072606 | nifedipiin | C08CA05 | ADALAT OROS retardtablett 20mg N98 | Bayer AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1042467 | nifedipiin | C08CA05 | ADALAT OROS retardtablett 60mg N28 | Bayer AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1072640 | nifedipiin | C08CA05 | ADALAT OROS retardtablett 60mg N98 | Bayer AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1005703 | nifedipiin | C08CA05 | CORDIPIN RETARD retardtablett 20mg N30 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1023422 | nifedipiin | C08CA05 | CORDIPIN XL tablett 40mg N20 | KRKA, d.d. | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1072550 | nifedipiin | C08CA05 | CORINFAR RETARD retardtablett 20mg N100 | AWD. Pharma GmbH & Co | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1034301 | nifedipiin | C08CA05 | CORINFAR RETARD retardtablett 20mg N30 | AWD. Pharma GmbH & Co | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1072549 | nifedipiin | C08CA05 | CORINFAR RETARD retardtablett 20mg N50 | AWD. Pharma GmbH & Co | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1072572 | nifedipiin | C08CA05 | CORINFAR tablett 10mg N100 | AWD. Pharma GmbH & Co | 50% | |||||||
| 1034299 | nifedipiin | C08CA05 | CORINFAR tablett 10mg N30 | AWD. Pharma GmbH & Co | 50% | |||||||
| 1072561 | nifedipiin | C08CA05 | CORINFAR tablett 10mg N50 | AWD. Pharma GmbH & Co | 50% | |||||||
| 1035706 | nifedipiin | C08CA05 | NIFEDIPIN-RATIOPHARM 20 retardtablett 20mg N30 | ratiopharm GmbH | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1036190 | nifedipiin | C08CA05 | NIFEHEXAL 20 RETARD retardtablett 20mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1027886 | nifedipiin | C08CA05 | NYCOPIN modif tablett 40mg N30 | Nycomed Sefa AS | 50% | 75% | (I10-I13); I15; I20; M34*; O10- O16 | *rev reumatoloogil ja pediaatril | ||||
| 1006254 | nimodipiin | C08CA06 | NIMOTOP 30 MG TABLETS tablett 30mg N100 | Bayer AG | 50% | |||||||
| INSTITUTO | (I10-I13); | |||||||||||
| 1014545 | nitrendipiin | C08CA08 | LUSOPRESS tablett 20mg N28 | LUSOFARMACO d ´Italia S.p.A | 50% | 75% | I15 | |||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1003857 | nitrofurantoiin | G04AC01 | NITROFURANTOIN NYCOMED tablett 50mg N20 | Nycomed Sefa AS | 50% | |||||||
| 1131589 | norelgestromiin+etinüülöstradiool | G03AA82 | EVRA TTS 6 mg+0,6 mg N3 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1131590 | norelgestromiin+etinüülöstradiool | G03AA82 | EVRA TTS 6 mg+0,6 mg N9 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1014770 | noretisteroon | G03DC02 | NORCOLUT tablett 5mg N20 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1175464 [RTL 2006, 26, 482 – jõust. 1.04.2006] | noretisteroon+östradiool | G03FA01 | ACTIVELLE tablett 0,5mg+1mg N28 | Novo Nordisk A/S | 50% | |||||||
| 1083901 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1045471 | noretisteroon+östradiool | G03FA01 | KLIANE tablett 1mg+2mg N28 | Schering AG | 50% | |||||||
| 1063718 | noretisteroon+östradiool | G03FA01 | KLIANE tablett 1mg+2mg N28x3 | Schering AG | 50% | |||||||
| 1030464 | noretisteroon+östradiool | G03FA01 | KLIOGEST tablett 1mg+2mg N28 | Novo Nordisk A/S | 50% | |||||||
| 1005455 | norfloksatsiin | J01MA06 | NOLICIN tablett 400mg N20 | KRKA, d.d. | 50% | |||||||
| 1020430 | norgestimaat+etünüülöstradiool | G03AA11 | CILEST tablett 0,25mg+0,03mg N21 | JANSSEN-CILAG INTERNATIONAL NV | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1062997 | norgestimaat+etünüülöstradiool | G03AA11 | CILEST tablett 0,25mg+0,03mg N21x3 | JANSSEN-CILAG INTERNATIONAL NV | 50% | 75% | Z30* | *rv ühe aasta jooksul pärast sünnitust ja 3 kuu jooksul pärast aborti ning sünnitamisele meditsiinilise vastunäidustuse korral | ||||
| 1006186 | norgestreel+östrageen | G03FA10 | CYCLO-PROGYNOVA drazhee 0,5mg+2mg N10/2mg N11 | Schering AG | 50% | |||||||
| 1005927 | nortriptüliin | N06AA10 | NORITREN tablett 25mg N100 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1070693 | ofloksatsiin | J01MA01 | TARIVID tablett 200mg N10 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1070705 | ofloksatsiin | J01MA01 | TARIVID tablett 200mg N100 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1007637 | ofloksatsiin | J01MA01 | TARIVID tablett 200mg N3 | Aventis-Pharma Deutchland GmbH | 50% | |||||||
| 1089424 | ofloksatsiin | J01MA01 | OFLOXIN 200 tablett 200 mg N20 | Leciva a.s. | 50% | |||||||
| 1089402 | ofloksatsiin | J01MA01 | OFLOXIN 200 tablett 200mg N10 | Leciva a.s. | 50% | |||||||
| 1012374 | ofloksatsiin | J01MA01 | MEDOFLOXINE 200 MG tablett 200 mg N10 | Medochemie Ltd | 50% | |||||||
| 1077285 | okskarbasepiin | N03AF02 | APYDAN 300 MG tablett 300mg N100 | Desitin Arzneimittel GmbH | 50% | |||||||
| 1036044 | okskarbasepiin | N03AF02 | APYDAN 300 MG tablett 300mg N50 | Desitin Arzneimittel GmbH | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele epilepsia (G40) korral ning rev neuroloogil täiskasvanule II valiku ravimina epilepsia (G40) näidustusel kõrvaltoimete tekkimisel karbamasepiinile. | ||||
| 1077241 | okskarbasepiin | N03AF02 | APYDAN 600 MG tablett 600mg N100 | Desitin Arzneimittel GmbH | 50% | |||||||
| 1036033 | okskarbasepiin | N03AF02 | APYDAN 600 MG tablett 600mg N50 | Desitin Arzneimittel GmbH | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele epilepsia (G40) korral ning rev neuroloogil täiskasvanule II valiku ravimina epilepsia (G40) näidustusel kõrvaltoimete tekkimisel karbamasepiinile. | ||||
| 1009662 | okskarbasepiin | N03AF02 | TRILEPTAL 150 kaetud tablett 150mg N50 | Novartis Finland OY | 50% | |||||||
| *rv neuroloogil alla 18-aastasele | ||||||||||||
| 1009673 | okskarbasepiin | N03AF02 | TRILEPTAL 300 kaetud tablett 300mg N50 | Novartis Finland OY | 50% | 100% | G40* | lapsele epilepsia (G40) korral ning rev neuroloogil täiskasvanule II valiku ravimina epilepsia (G40) näidustusel kõrvaltoimete tekkimisel karbamasepiinile. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1009684 | okskarbasepiin | N03AF02 | TRILEPTAL 600 kaetud tablett 600mg N50 | Novartis Finland OY | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele epilepsia (G40) korral ning rev neuroloogil täiskasvanule II valiku ravimina epilepsia (G40) näidustusel kõrvaltoimete tekkimisel karbamasepiinile. | ||||
| 1028483 | oksübutüniin | G04BD04 | DRIPTANE tablett 5mg N60 | LABORATOIRES FOURNIER S.A | 50% | 75% | N31* | *rv neuroloogil ja urolooogil | ||||
| 1043165 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 10 MG tablett 10mg N25 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1080605 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 10 MG tablett 10mg N100 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1080582 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 10 MG tablett 10mg N28 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1043176 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 20 MG tablett 20mg N25 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1080638 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 20 MG tablett 20mg N100 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1080616 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 20 MG tablett 20mg N28 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1043187 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 40 MG tablett 40mg N25 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1080661 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 40 MG tablett 40mg N100 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1080649 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 40 MG tablett 40mg N28 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1075553 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 80 MG tablett 80mg N100 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1043198 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 80 MG tablett 80mg N25 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1075531 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 80 MG tablett 80mg N28 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1080593 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 10 MG tablett 10mg N56 | Mundipharma Ges.m.b.H. | 50% | 100% | (C00-D48)* | *rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kellel suukaudne morfiin tekitab kõrvaltoimeid | ||||
| 1080627 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 20 MG tablett 20mg N56 | Mundipharma Ges.m.b.H. | 50% | 100% | (C00-D48)* | *rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kellel suukaudne morfiin tekitab kõrvaltoimeid | ||||
| 1080650 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 40 MG tablett 40mg N56 | Mundipharma Ges.m.b.H. | 50% | 100% | (C00-D48)* | *rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kellel suukaudne morfiin tekitab kõrvaltoimeid | ||||
| 1075542 | oksükodoon | N02AA05 | OXYCONTIN TABLETS 80 MG tablett 80mg N56 | Mundipharma Ges.m.b.H. | 50% | 100% | (C00-D48)* | *rev onkoloogil, hematoloogil, anestesioloogil ja Eesti Vähiliidu koduse toetusravi arstil patsientidele, kellel suukaudne morfiin tekitab kõrvaltoimeid | ||||
| 1041309 | oktreotiid | H01CB02 | SANDOSTATIN LAR injektsioonisubstants 10mg viaal+2 ml lahustit N1 | Novartis Finland OY | 50% | |||||||
| 1041310 | oktreotiid | H01CB02 | SANDOSTATIN LAR injektsioonisubstants 20mg viaal+2ml lahustit N1 | Novartis Finland OY | 50% | |||||||
| 1041321 | oktreotiid | H01CB02 | SANDOSTATIN LAR injektsioonisubstants 30mg viaal+2 ml lahustit N1 | Novartis Finland OY | 50% | |||||||
| 1004959 | oktreotiid | H01CB02 | SANDOSTATIN süstelahus 0,05mg/ml amp 1ml N5 | Novartis Finland OY | 50% | |||||||
| 1004926 | oktreotiid | H01CB02 | SANDOSTATIN süstelahus 0,1mg/ml amp 1ml N5 | Novartis Finland OY | 50% | |||||||
| 1195950 | olansapiin | N05AH03 | ZYPREXA VELOTAB suus dispergeeruv tablett 10 mg N28 | Eli Lilly Nederland B.V. | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhistele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| *rv psühhiaatril vastavalt Eesti ravijuhistele ning juhul, kui | ||||||||||||
| 1067284 | olansapiin | N05AH03 | ZYPREXA tablett 10mg N28 | Eli Lilly Export S.A. | 50% | 100% | F20-F29* | risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1026234 | olansapiin | N05AH03 | ZYPREXA tablett 5mg N28 | Eli Lilly Export S.A. | 50% | |||||||
| 1139060 | olmesartaan | C09CA08 | MESAR 10 MG FILM COATED TABLETS kaetud tablett 10 mg N28 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1139105 | olmesartaan | C09CA08 | MESAR 20 MG FILM COATED TABLETS kaetud tablett 20 mg N28 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1139150 | olmesartaan | C09CA08 | MESAR 40 MG FILM COATED TABLETS kaetud tablett 40 mg N28 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1140220 | olopatadiin | S01GX09 | OPATANOL silmatilgad, lahus 1 mg/ml 5 ml | Alcon Laboratoires (UK) Ltd. | 50% | |||||||
| 1140231 | olopatadiin | S01GX09 | OPATANOL silmatilgad, lahus 1 mg/ml 3x5 ml | Alcon Laboratoires (UK) Ltd. | 50% | |||||||
| 1062199 | omeprasool | A02BC01 | GASEC-20 enterokapsel 20mg N14 | Mepha LDA | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1062201 | omeprasool | A02BC01 | GASEC-20 enterokapsel 20mg N28 | Mepha LDA | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1039586 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1062234 | omeprasool | A02BC01 | LOSEC MUPS enterotablett 20mg N100 | AstraZeneca AB | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1062212 | omeprasool | A02BC01 | LOSEC MUPS enterotablett 20mg N14 | AstraZeneca AB | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1062223 | omeprasool | A02BC01 | LOSEC MUPS enterotablett 20mg N28 | AstraZeneca AB | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1062245 | omeprasool | A02BC01 | OMEP 20 kapsel 20mg N15 | Hexal AG | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1041613 | omeprasool | A02BC01 | OMEPRAZOL-RATIOPHARM NT kapsel 20mg N15 | ratiopharm GmbH | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1062166 | omeprasool | A02BC01 | OMEPRAZOL-RATIOPHARM NT kapsel 20mg N30 | ratiopharm GmbH | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1062335 | omeprasool | A02BC01 | ULCEX EC caps 20mg N14 | Grindeks | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1112814 | omeprasool | A02BC01 | GASEC-40 GASTOCAPS kapsel 40mg N14 | Mepha LDA | 50% | 75% | (K25-27)* | *(3) | ||||
| 1114603 | omeprasool | A02BC01 | OMEP 20 TAB tablett 20 mg N7 | Hexal AG | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1101542 | omeprasool | A02BC01 | LOSEPRAZOL kapsel 20 mg N14 | LICONSA, S.A. | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1101564 | omeprasool | A02BC01 | LOSEPRAZOL kapsel 20 mg N28 | LICONSA, S.A. | 50% | 75% | (K25-K27)* | *(3) | ||||
| 1041983 | omoconasool | G01AF16 | MIKOGAL vaginaalsuposiit 150mg N6 | Biogal Pharmaceutical Works Ltd. | 50% | |||||||
| 1041994 | omoconasool | G01AF16 | MIKOGAL vaginaalsuposiit 300mg N3 | Biogal Pharmaceutical Works Ltd. | 50% | |||||||
| 1042007 | omoconasool | G01AF16 | MIKOGAL vaginaalsuposiit 900mg N1 | Biogal Pharmaceutical Works Ltd. | 50% | |||||||
| 1036224 | ondansetroon | A04AA01 | EMETRON tablett 8mg N10 | GEDEON RICHTER Ltd. | 50% | 100% | C00-D48* | *rv onkoloogil ja hematoloogil vähktõve ja muude pahaloomuliste kasvajate, s.h. hematoloogiliste kasvajate näidustusel kõrge emetogeensusega tsütostaatiliste preparaatide poolt põhjustatud iivelduse ja oksendamise profülaktikaks ja raviks, kui antiemeetiline ravi metoklopramiidi ja deksametasooniga pole tõhus või on vastunäidustatud | ||||
| 1005163 | ondansetroon | A04AA01 | ZOFRAN tablett 8mg N10 | Glaxo Wellcome Operations | 50% | 100% | C00-D48* | *rv onkoloogil ja hematoloogil vähktõve ja muude pahaloomuliste kasvajate, s.h. hematoloogiliste kasvajate näidustusel kõrge emetogeensusega tsütostaatiliste preparaatide poolt põhjustatud iivelduse ja oksendamise profülaktikaks ja raviks, kui antiemeetiline ravi metoklopramiidi ja deksametasooniga pole tõhus või on vastunäidustatud | ||||
| 1005107 | ondansetroon | A04AA01 | ZOFRAN süstelahus 2mg/ml 2ml N5 | Glaxo Wellcome Operations | 50% | |||||||
| 1063077 | ondansetroon | A04AA01 | ZOFRAN süstelahus 2mg/ml 4ml N5 | Glaxo Wellcome Operations | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1036246 | ondansetroon | A04AA01 | EMETRON süstelahus 2mg/ml 2ml N5 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1063066 | ondansetroon | A04AA01 | EMETRON süstelahus 2mg/ml 4ml N5 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1137372 | oomega-3-rasvhappe etüülestrid | C10AX80 | OMACOR caps 1000 mg N28 | Pronova Biocare a.s. | 50% | |||||||
| 1137383 | oomega-3-rasvhappe etüülestrid | C10AX80 | OMACOR caps 1000 mg N100 | Pronova Biocare a.s. | 50% | |||||||
| 1000810 | ornidasool | P01AB03 | TIBERAL tablett 500mg N10 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1110643 | oseltamiviir | J05AH02 | TAMIFLU kapsel 75mg N10 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1110654 | oseltamiviir | J05AH02 | TAMIFLU pulber suspensiooniks 12 mg/ml 30g | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1062368 | pantoprasool | A02BC02 | CONTROLOC 20 MG enterotablett 20mg N100 | Altana Pharma AG | 50% | |||||||
| 1043020 | pantoprasool | A02BC02 | CONTROLOC 20 MG enterotablett 20mg N14 | Altana Pharma AG | 50% | |||||||
| 1062346 | pantoprasool | A02BC02 | CONTROLOC 20 MG enterotablett 20mg N28 | Altana Pharma AG | 50% | |||||||
| 1062357 | pantoprasool | A02BC02 | CONTROLOC 20 MG enterotablett 20mg N56 | Altana Pharma AG | 50% | |||||||
| 1043031 | pantoprasool | A02BC02 | CONTROLOC 40 MG enterotablett 40mg N14 | Altana Pharma AG | 50% | |||||||
| 1062379 | pantoprasool | A02BC02 | CONTROLOC 40 MG enterotablett 40mg N28 | Altana Pharma AG | 50% | |||||||
| 1060243 | paroksetiin | N06AB05 | SEROXAT tablett 20mg N100 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1027044 | paroksetiin | N06AB05 | SEROXAT tablett 20mg N14 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1060221 | paroksetiin | N06AB05 | SEROXAT tablett 20mg N20 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1060232 | paroksetiin | N06AB05 | SEROXAT tablett 20mg N30 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1110799 | paroksetiin | N06AB05 | PAROXETINHEXAL 20 tablett 20 mg N30 | Hexal AG | 50% | |||||||
| 1110834 | paroksetiin | N06AB05 | PAROXETINHEXAL 40 tablett 40 mg N30 | Hexal AG | 50% | |||||||
| 1115514 | paroksetiin | N06AB05 | SEROXAT tablett 30mg N30 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1096837 | paroksetiin | N06AB05 | REXETIN tablett 20 mg N30 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1121229 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1139868 | paroksetiin | N06AB05 | PAROXAT kaetud tablett 20 mg N30 | Glaxo Group Ltd. | 50% | |||||||
| 1176049 | paroksetiin | N06AB05 | PAROXETIN NYCOMED tablett 20 mg N30 | NYCOMED DANMARK ApS | 50% | |||||||
| 1110407 | peginterferoon alfa-2a | L03AB11 | PEGASYS 180 inj 180mcg/0.5ml süstel N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | B18.2* | *rv gastroenteroloogil ja infektsionistil vastavalt Eesti ravijuhisele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1011856 | peginterferoon alfa-2b | L03AB10 | PEGINTRON injektsioonisubstants 100mcg N1+lahusti N1 | Schering Plough Europe | 50% | |||||||
| 1011867 | peginterferoon alfa-2b | L03AB10 | PEGINTRON injektsioonisubstants 120mcg N1+lahusti N1 | Schering Plough Europe | 50% | |||||||
| 1011834 | peginterferoon alfa-2b | L03AB10 | PEGINTRON injektsioonisubstants 50mcg N1+lahusti N1 | Schering Plough Europe | 50% | |||||||
| 1011845 | peginterferoon alfa-2b | L03AB10 | PEGINTRON injektsioonisubstants 80mcg N1+lahusti N1 | Schering Plough Europe | 50% | |||||||
| 1015018 | pentoksüfülliin | C04AD03 | PENTILIN tablett 400 mg N20 | KRKA, d.d. | 50% | |||||||
| 1037630 | pentoksüfülliin | C04AD03 | PENTILIN FORTE retardtablett 600 mg N20 | KRKA, d.d. | 50% | |||||||
| 1009404 | pentoksüfülliin | C04AD03 | TRENTAL tablett 400 mg N100 | Aventis-Pharma Deutschland GmbH | 50% | |||||||
| 1028854 | pentoksüfülliin | C04AD03 | VASONIT RETARD prolong tablett 600 mg N20 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1022937 | pentoksüveriin | R05DB05 | TOCLASE siirup 1,5mg/ml 200ml | UCB Pharma Oy Finland | 50% | |||||||
| 1064528 | pergoliid | N04BC02 | PERMAX tablett 0,05mg N100 | Eli Lilly Holding Limited | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1031533 | pergoliid | N04BC02 | PERMAX tablett 0,25mg N30 | Eli Lilly Holding Limited | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1031544 | pergoliid | N04BC02 | PERMAX tablett 1mg N30 | Eli Lilly Holding Limited | 50% | 100% | G20* | *rev neuroloogil | ||||
| 1031252 | perindopriil | C09AA04 | COVEREX tablett 4mg N30 | Egis Pharmaceuticals Limited | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |||
| 1019393 | perindopriil | C09AA04 | PRESTARIUM tablett 4mg N30 | Les Laboratories Servier | 50% | |||||||
| 1132782 | perindopriil | C09AA04 | PRESTARIUM tablett 8 mg N30 | Les Laboratories Servier | 50% | |||||||
| 1042412 | perindopriil+indapamiid | C09BA80 | NOLIPREL FORTE tablett 4mg+1,25mg N30 | Les Laboratories Servier | 50% | |||||||
| 1042401 | perindopriil+indapamiid | C09BA80 | NOLIPREL tablett 2mg+0,625mg N30 | Les Laboratories Servier | 50% | |||||||
| 1038888 | piimhape+naatriumlaktaat | G01AD80 | VAGISAN vaginaalsuposiit 167mg+100mg N7 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1123759 | pilokarpiin | S01EB01 | ISOPTO CARPINE silmatilgad 2% 15 ml N1 | s.a. ALCON- COUVREUR n.v. | 50% | 100% | (H40-H42)* | *rv oftalmoloogil | ||||
| 1002025 | pilokarpiin+timolool | S01EB80 | FOTIL FORTE silmatilgad 4%+0,5% 5 ml | Santen OY | 50% | 100% | (H40-H42)* | *rv oftalmoloogil | ||||
| 1001855 | pilokarpiin+timolool | S01EB80 | FOTIL silmatilgad 2%+0,5% 5 ml | Santen OY | 50% | 100% | (H40-H42)* | *rv oftalmoloogil | ||||
| 1104680 [RTL 2006, 26, 482 – jõust. 1.04.2006] | pimekrolimus | D11AX15 | ELIDEL kreem 1% 15,0 | Novartis Finland OY | 50% | |||||||
| 1013566 | pioglitasoon | A10BG03 | ACTOS tablett 15mg N28 | Eli Lilly Export S.A. | 50% | |||||||
| 1013577 | pioglitasoon | A10BG03 | ACTOS tablett 30mg N28 | Eli Lilly Export S.A. | 50% | |||||||
| 1013588 | pioglitasoon | A10BG03 | ACTOS tablett 45mg N28 | Eli Lilly Export S.A. | 50% | |||||||
| 1023365 | piratsetaam | N06BX03 | NOOTROPIL suukaudne lahus 330mg/ml 125ml | UCB Pharma Oy Finland | 50% | |||||||
| 1074417 | piratsetaam | N06BX03 | NOOTROPIL tablett 1200mg N100 | UCB Pharma Oy Finland | 50% | |||||||
| 1023332 | piratsetaam | N06BX03 | NOOTROPIL tablett 1200mg N20 | UCB Pharma Oy Finland | 50% | |||||||
| 1074406 | piratsetaam | N06BX03 | NOOTROPIL tablett 1200mg N60 | UCB Pharma Oy Finland | 50% | |||||||
| 1023343 | piratsetaam | N06BX03 | NOOTROPIL tablett 800mg N30 | UCB Pharma Oy Finland | 50% | |||||||
| 1074439 | piratsetaam | N06BX03 | NOOTROPIL tablett 800mg N60 | UCB Pharma Oy Finland | 50% | |||||||
| 1074440 | piratsetaam | N06BX03 | NOOTROPIL tablett 800mg N90 | UCB Pharma Oy Finland | 50% | |||||||
| 1027943 | piratsetaam | N06BX03 | PIRACETAM TFT kapsel 400mg N30 | Tallinna Farmaatsiatehase AS | 50% | |||||||
| 1082438 | piratsetaam | N06BX03 | PIRACETAM TFT kapsel 400mg N60 | Tallinna Farmaatsiatehase AS | 50% | |||||||
| 1039890 | piroksikaam | M01AC01 | BREXIN pulber suukaudse lahuse valmistamiseks 20mg N20 | Chiesi Farmaceutici S.p.A. | 50% | |||||||
| 1039889 | piroksikaam | M01AC01 | BREXIN tablett 20mg N20 | Chiesi Farmaceutici S.p.A. | 50% | |||||||
| 1021172 | piroksikaam | M01AC01 | PIROXICAM TFT tablett 20mg N20 | Tallinna Farmaatsiatehase AS | 50% | |||||||
| 1087781 | piroksikaam | M01AC01 | PIROXICAM TFT tablett 20mg N25 | Tallinna Farmaatsiatehase AS | 50% | |||||||
| 1009493 | Plastic IUD+progestogeenid | G02BA03 | MIRENA emakasisene süsteem 20mcg 24h N1 | Schering AG | 50% | |||||||
| 1094026 | podofüllotoksiin | D06BB04 | WARTEC kreem 0,15% 5 g | Stiefel Laboratoires UK Ltd | 50% | |||||||
| 1033681 | podofüllotoksiin | D06BB04 | WARTEC lahus 5mgml 3ml | Stiefel Laboratoires UK Ltd | 50% | |||||||
| 1039542 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1078455 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1084294 | polüvidoonjodiid+allantoiin | R02AA89 | JOX lahus 8,5%+0,1%/ 50ml N1 | IVAX Pharmaceuticals s.r.o. | 50% | |||||||
| 1041242 | pramipeksool | N04BC05 | MIRAPEXIN tablett 0,125mg N30 | Pfizer Enterprises Sarl | 50% | 100% | G20* | *rev neuroloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1041253 | pramipeksool | N04BC05 | MIRAPEXIN tablett 0,25mg N30 | Pfizer Enterprises Sarl | 50% | 100% | G20* | *rev neuroloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1041264 | pramipeksool | N04BC05 | MIRAPEXIN tablett 1mg N30 | Pfizer Enterprises Sarl | 50% | 100% | G20* | *rev neuroloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| E78; I21; | ||||||||||||
| 1026201 | pravastatiin | C10AA03 | LIPOSTAT tablett 20mg N30 | Bristol-Myers Squibb Eesti AS | 50% | 75% | I22; I25.2; Z45; Z95 | *(4) | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1044874 | pravastatiin | C10AA03 | LIPOSTAT 40 MG tablett 40 mg N30 | Bristol-Myers Squibb Eesti AS | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1118023 | pravastatiin | C10AA03 | PRAVAHEXAL 10 tablett 10 mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1118034 | pravastatiin | C10AA03 | PRAVAHEXAL 20 tablett 20 mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1118045 | pravastatiin | C10AA03 | PRAVAHEXAL 30 tablett 30 mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1118056 | pravastatiin | C10AA03 | PRAVAHEXAL 40 tablett 40 mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1162235 | pravastatiin | C10AA03 | PRAVASTATIN NYCOMED 20 MG tablett 20 mg N30 | Nycomed Sefa AS | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1162336 | pravastatiin | C10AA03 | PRAVASTATIN NYCOMED 40 MG tablett 40 mg N30 | Nycomed Sefa AS | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1061727 | prednisoloon | D07AA03 | LINOLA-H N kreem 0,4% 250g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1031724 | prednisoloon | D07AA03 | LINOLA-H N kreem 0,4% 25g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1061738 | prednisoloon | D07AA03 | LINOLA-H-FETT N kreem 0,4% 100g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1061749 | prednisoloon | D07AA03 | LINOLA-H-FETT N kreem 0,4% 250g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1031779 | prednisoloon | D07AA03 | LINOLA-H-FETT N kreem 0,4% 25g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1065776 | prednisoloon | H02AB06 | PREDNISOLON tablett 5mg N100 | GEDEON RICHTER Ltd. | 50% | 75% | K50; K51; K73; K74; L10; L12; L13.0; L20; L23; L40; M07; M05; M06; M08; (M30- M33); M35; M45; M46; (N00- N08); J45*** | rv gastroenteroloogil ja pediaatril; rv dermatoveneroloogil ja pediaatril; rv dermatoveneroloogil, reumatoloogil ja pediaatril; rev reumatoloogil ja pediaatril; rv nefroloogil ja pediaatril; ***rev pediaatril ja pulmonoloogil | 100% | (C00- D48); D59; (D60- D64); D69; E23; E25; E27; E89.3; E89.6; G70** | rv hematoloogil, onkoloogil, uroloogil ja pediaatril; rv hematoloogil ja pediaatril; rev endokrinoloogil ja pediaatril; **rev neuroloogil ja pediaatril | |
| 1031702 | prednisoloon+salitsüülhape | D07XA81 | ALPICORT paikne lahus 0,2%+0,4% 100ml | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1077027 | primidoon | N03AA03 | LISKANTIN tablett 250mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | G40* | *rev neuroloogil | ||||
| 1123849 | proksümetakaiin | S01HA04 | ALCAINE silmatilgad, lahus 0,5% 15ml | s.a. ALCON- COUVREUR n.v. | 50% | |||||||
| 1044526 | propafenoon | C01BC03 | PROPANORM 150 MG tablett 150mg N50 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1020126 | propafenoon | C01BC03 | RYTMONORM tablett 150mg N50 | Abbott GmbH & Co. KG | 50% | |||||||
| 1020137 | propafenoon | C01BC03 | RYTMONORM tablett 300mg N50 | Abbott GmbH & Co. KG | 50% | |||||||
| 1033906 | propranolool | C07AA05 | PROPRANOLOL ALPHARMA TABLETS 40 MG tablett 40mg N50 | ALPHARMA Limited | 50% | |||||||
| 1071829 | propranolool | C07AA05 | PROPRA-RATIOPHARM 40 tablett 40mg N100 | ratiopharm GmbH | 50% | |||||||
| 1053223 | propranolool | C07AA05 | PROPRA-RATIOPHARM 40 tablett 40mg N50 | ratiopharm GmbH | 50% | |||||||
| 1028696 | propüültiouratsiil | H03BA02 | TIOTIL tablett 50mg N100 | ABIGO MEDICAL AB | 50% | |||||||
| 1078310 | pseudoefedriin+loratadiin | R01BA89 | CLARINASE prolong tablett 240mg+10mg N7 | Schering Plough Europe | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1074451 | püridostigmiin | N07AA02 | KALYMIN 60 N tablett 60mg N100 | Arzneimittelwerk Dresden GmbH | 50% | 100% | G70* | *rev neuroloogil | ||||
| 1038394 | raloxifeen | G03XC01 | EVISTA kaetud tablett 60mg N14 | Eli Lilly Export S.A. | 50% | |||||||
| 1064135 | raloxifeen | G03XC01 | EVISTA kaetud tablett 60mg N28 | Eli Lilly Export S.A. | 50% | |||||||
| 1005826 | ramipriil | C09AA05 | CARDACE 2,5 MG tablett 2,5mg N28 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074743 | ramipriil | C09AA05 | CARDACE 2,5 MG tablett 2,5mg N98 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1005859 | ramipriil | C09AA05 | CARDACE 5 MG tablett 5mg N28 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1074754 | ramipriil | C09AA05 | CARDACE 5 MG tablett 5mg N98 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1059218 | ramipriil | C09AA05 | CARDACE tablett 10mg N28 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1140590 | ramipriil | C09AA05 | RAMIRACE 5 MG tablett 5 mg N30 | Nycomed Sefa AS | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1140613 | ramipriil | C09AA05 | RAMIRACE 5 MG tablett 5 mg N98 | Nycomed Sefa AS | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1140567 | ramipriil | C09AA05 | RAMIRACE 2,5 MG tablett 2,5 mg N30 | Nycomed Sefa AS | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1140589 | ramipriil | C09AA05 | RAMIRACE 2,5 MG tablett 2,5 mg N98 | Nycomed Sefa AS | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1113714 | ramipriil | C09AA05 | RAMICOR 2,5 tablett 2,5 mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1113725 | ramipriil | C09AA05 | RAMICOR 2,5 tablett 2,5 mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1143942 | ramipriil | C09AA05 | RAMICOR 5 tablett 5 mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1143953 | ramipriil | C09AA05 | RAMICOR 5 tablett 5 mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1154764 | ramipriil | C09AA05 | CORPRIL kapsel 2,5 mg N30 | Ranbaxy UK Ltd | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1154753 | ramipriil | C09AA05 | CORPRIL kapsel 5 mg N30 | Ranbaxy UK Ltd | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1156654 | ramipriil | C09AA05 | RAMICOR 10 MG TABLETID tablett 10 mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1156676 | ramipriil | C09AA05 | RAMICOR 10 MG TABLETID tablett 10 mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153516 | ramipriil | C09AA05 | PIRAMIL 10 tabletid 10 mg N28 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153527 | ramipriil | C09AA05 | PIRAMIL 10 tabletid 10 mg N30 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153370 | ramipriil | C09AA05 | PIRAMIL 2,5 tabletid 2,5 mg N28 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153381 | ramipriil | C09AA05 | PIRAMIL 2,5 tabletid 2,5 mg N30 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153404 | ramipriil | C09AA05 | PIRAMIL 2,5 tabletid 2,5 mg N100 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153448 | ramipriil | C09AA05 | PIRAMIL 5 tabletid 5 mg N28 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153459 | ramipriil | C09AA05 | PIRAMIL 5 tabletid 5 mg N30 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1153471 | ramipriil | C09AA05 | PIRAMIL 5 tabletid 5 mg N100 | Sandoz GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1021936 | ramipriil+hüdroklorotiasiid | C09BA05 | CARDACE COMP tablett 2,5mg+12,5mg N28 | Aventis-Pharma Deutchland GmbH | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1113680 | ramipriil+hüdroklorotiasiid | C09BA05 | CO-RAMICOR 5+25 tablett 5 mg+25 mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1113703 | ramipriil+hüdroklorotiasiid | C09BA05 | CO-RAMICOR 5+25 tablett 5 mg+25 mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1113657 | ramipriil+hüdroklorotiasiid | C09BA05 | CO-RAMICOR 2,5+12,5 tablett 2,5 mg+12,5 mg N30 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1113679 | ramipriil+hüdroklorotiasiid | C09BA05 | CO-RAMICOR 2,5+12,5 tablett 2,5 mg+12,5 mg N100 | Hexal AG | 50% | 75% | (I10-I13); I15; I50 | |||||
| 1061806 | ranitidiin | A02BA02 | RANIBERL 150 tablett 150mg N50 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | (K25-K27)* | *soodustus ei kehti enne hinnakokkuleppe sõlmimist | ||||
| 1026885 | ranitidiin | A02BA02 | RANIBERL 300 tablett 300mg N20 | Berlin-Chemie AG (Menarini Group) | 50% | 75% | (K25-K27)* | *soodustus ei kehti enne hinnakokkuleppe sõlmimist | ||||
| 1019922 | ranitidiin | A02BA02 | RANISAN 150 MG tablett 150mg N20 | PRO. MED. CS. PRAHA a.s. | 50% | 75% | K25-27 | |||||
| 1084227 | ranitidiin | A02BA02 | RANITIDINE ALPHARMA TABLETS 150 MG tablett 150mg N30 | ALPHARMA Limited | 50% | |||||||
| 1004601 | ranitidiin | A02BA02 | ZANTAC EFFERVESCENT TABLETS 150 MG lahustuv tablett 150mg N10 | Glaxo Wellcome Operations | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1005477 | ranitidiin | A02BA02 | ZANTAC kaetud tablett 150mg N20 | Glaxo Wellcome Operations | 50% | |||||||
| 1061525 | ranitidiin | A02BA02 | ZANTAC kaetud tablett 150mg N60 | Glaxo Wellcome Operations | 50% | |||||||
| 1134986 | ranitidiin | A02BA02 | RANISAN 150 MG tablett 150mg N60 | PRO. MED. CS. PRAHA a.s. | 50% | 75% | K25-27 | |||||
| 1203422 | rasagiliin | N04BD02 | AZILECT tablett 1 mg N28 | Teva Pharma GmbH | 50% | |||||||
| 1028551 | raudaspartaat | B03AA09 | SPARTOCINE tablett 250 mg N40 | UCB Pharma Oy Finland | 50% | diagnoosi D50 korral alla 3- aastastele lastele | 75% | D50* | *rv rasedatele | |||
| 1066227 | raudaspartaat | B03AA09 | SPARTOCINE tablett 250 mg N100 | UCB Pharma Oy Finland | 50% | diagnoosi D50 korral alla 3- aastastele lastele | 75% | D50* | *rv rasedatele | |||
| 1125245 | raudaspartaat | B03AA09 | SPARTOCINE peroraalse lahuse graanulid 105 mg N30 | UCB Pharma Oy Finland | 50% | diagnoosi D50 korral alla 3- aastastele lastele | 75% | D50* | *rv rasedatele | |||
| 1011036 | raudpolümaltoos | B03AB02 | FERRUM LEK närimistablett 100mg N30 | Lek Pharmaceuticals d.d. | 50% | diagnoosi D50 korral alla 3- aastastele lastele | 75% | D50* | *rv rasedatele | |||
| 1011025 | raudpolümaltoos | B03AB02 | FERRUM LEK siirup 10mg/ml 100ml N1 | Lek Pharmaceuticals d.d. | 50% | diagnoosi D50 korral alla 3- aastastele lastele | 75% | D50* | *rv rasedatele | |||
| 1018202 | raudsulfaat | B03AA07 | RETAFER prolong tablett 100 mg N30 | ORION CORPORATION ORION PHARMA | 50% | diagnoosi D50 korral alla 3- aastastele lastele | 75% | D50* | *rv rasedatele | |||
| 1043323 | reboksetiin | N06AX18 | EDRONAX tablett 4mg N20 | Pfizer Enterprises Sarl | 50% | |||||||
| 1070930 | reboksetiin | N06AX18 | EDRONAX tablett 4mg N60 | Pfizer Enterprises Sarl | 50% | |||||||
| 1039171 | repagliniid | A10BX02 | NOVONORM tablett 0,5mg N30 | Novo Nordisk A/S | 50% | |||||||
| 1065260 | repagliniid | A10BX02 | NOVONORM tablett 0,5mg N90 | Novo Nordisk A/S | 50% | |||||||
| 1039182 | repagliniid | A10BX02 | NOVONORM tablett 1mg N30 | Novo Nordisk A/S | 50% | |||||||
| 1065259 | repagliniid | A10BX02 | NOVONORM tablett 1mg N90 | Novo Nordisk A/S | 50% | |||||||
| 1044638 | repagliniid | A10BX02 | NOVONORM tablett 2mg N30 | Novo Nordisk A/S | 50% | |||||||
| 1065204 | repagliniid | A10BX02 | NOVONORM tablett 2mg N90 | Novo Nordisk A/S | 50% | |||||||
| 1044380 | retinool+dekspantenool | S01XA80 | OFTAN A-PANT silmasalv 20TÜ +20mg/g 3.5g | Santen OY | 50% | |||||||
| 1073034 | ribaviriin | J05AB04 | REBETOL kapsel 200mg N140 | Schering Plough Europe | 50% | 100% | B18.2* | *rv gastroenteroloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1073056 | ribaviriin | J05AB04 | REBETOL kapsel 200mg N168 | Schering Plough Europe | 50% | 100% | B18.2* | *rv gastroenteroloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1009583 | ribaviriin | J05AB04 | REBETOL kapsel 200mg N84 | Schering Plough Europe | 50% | 100% | B18.2* | *rv gastroenteroloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1161447 | ribaviriin | J05AB04 | COPEGUS kaetud tablett 200 mg N168 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | B18.2* | *rv gastroenteroloogil, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1035289 | rilusool | N07XX02 | RILUTEK tablett 50mg N56 | Aventis Pharma SA | 50% | |||||||
| 1032804 | risatriptaan | N02CX80 | MAXALT 10 mg peroraalne lüofilisaat 10mg N2 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1076981 | risatriptaan | N02CX80 | MAXALT 5 mg peroraalne lüofilisaat 5mg N2 | Merck Sharp & Dohme OÜ | 50% | |||||||
| 1083822 | risedroonhape | M05BA07 | ACTONEL 30 MG tablett 30mg N28 | Aventis Pharma AB | 50% | 75% | M80* | *rev ortopeedil alla 16- aastastele lastele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1083798 | risedroonhape | M05BA07 | ACTONEL 5 MG tablett 5mg N14 | Aventis Pharma AB | 50% | 75% | M80* | *rev ortopeedil alla 16- aastastele lastele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| *rev ortopeedil alla 16- | ||||||||||||
| 1083800 | risedroonhape | M05BA07 | ACTONEL 5 MG tablett 5mg N28 | Aventis Pharma AB | 50% | 75% | M80* | aastastele lastele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1083811 | risedroonhape | M05BA07 | ACTONEL 5 MG tablett 5mg N84 | Aventis Pharma AB | 50% | 75% | M80* | *rev ortopeedil alla 16- aastastele lastele, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1107571 | risedroonhape | M05BA07 | ACTONEL 35 MG OAW kaetud tablett 35 mg N1 | Aventis Pharma AB | 50% | |||||||
| 1107582 | risedroonhape | M05BA07 | ACTONEL 35 MG OAW kaetud tablett 35 mg N2 | Aventis Pharma AB | 50% | |||||||
| 1107593 | risedroonhape | M05BA07 | ACTONEL 35 MG OAW kaetud tablett 35 mg N4 | Aventis Pharma AB | 50% | |||||||
| 1107605 | risedroonhape | M05BA07 | ACTONEL 35 MG OAW kaetud tablett 35 mg N10 | Aventis Pharma AB | 50% | |||||||
| 1107616 | risedroonhape | M05BA07 | ACTONEL 35 MG OAW kaetud tablett 35 mg N12 | Aventis Pharma AB | 50% | |||||||
| 1107627 | risedroonhape | M05BA07 | ACTONEL 35 MG OAW kaetud tablett 35 mg N16 | Aventis Pharma AB | 50% | |||||||
| 1041028 | risperidoon | N05AX08 | RISPOLEPT suukaudne lahus 1mg/ml 100ml N1 | Janssen Pharmaceutica N.V. | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile;*soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1060456 | risperidoon | N05AX08 | RISPOLEPT kaetud tablett 1mg N60 | Janssen Pharmaceutica N.V. | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1067509 | risperidoon | N05AX08 | RISPOLEPT kaetud tablett 2mg N60 | Janssen Pharmaceutica N.V. | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1067521 | risperidoon | N05AX08 | RISPOLEPT kaetud tablett 3mg N60 | Janssen Pharmaceutica N.V. | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1067532 | risperidoon | N05AX08 | RISPOLEPT kaetud tablett 4mg N60 | Janssen Pharmaceutica N.V. | 50% | 100% | F20-F29* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1122129 | risperidoon | N05AX08 | RISPOLEPT CONSTA 25 MG pulber ja lahusti süstesuspensiooni valm 25 mg + eeltäidetud süstal lahustiga N1 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1122130 | risperidoon | N05AX08 | RISPOLEPT CONSTA 37,5 MG pulber ja lahusti süstesuspensiooni valm 37,5 mg + eeltäidetud süstal lahustiga N1 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1122141 | risperidoon | N05AX08 | RISPOLEPT CONSTA 50 pulber ja lahusti süstesuspensiooni valm 50 mg + eeltäidetud süstal lahustiga N1 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1119855 | risperidoon | N05AX08 | RISPEN 1 kaetud tablett 1 mg N20 | Leciva a.s. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1119877 | risperidoon | N05AX08 | RISPEN 1 kaetud tablett 1 mg N50 | Leciva a.s. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti | ||||||||||||
| 1119888 | risperidoon | N05AX08 | RISPEN 2 kaetud tablett 2 mg N20 | Leciva a.s. | 50% | 100% | (F20-F29)* | Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1119901 | risperidoon | N05AX08 | RISPEN 2 kaetud tablett 2 mg N50 | Leciva a.s. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1119912 | risperidoon | N05AX08 | RISPEN 3 kaetud tablett 3 mg N20 | Leciva a.s. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1119934 | risperidoon | N05AX08 | RISPEN 3 kaetud tablett 3 mg N50 | Leciva a.s. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1119967 | risperidoon | N05AX08 | RISPEN 4 kaetud tablett 4 mg N20 | Leciva a.s. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1119989 | risperidoon | N05AX08 | RISPEN 4 kaetud tablett 4 mg N50 | Leciva a.s. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114502 | risperidoon | N05AX08 | RISSET 1 MG tablett 1 mg N20 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114513 | risperidoon | N05AX08 | RISSET 1 MG tablett 1 mg N60 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114524 | risperidoon | N05AX08 | RISSET 2 MG tablett 2 mg N20 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114535 | risperidoon | N05AX08 | RISSET 2 MG tablett 2 mg N60 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114546 | risperidoon | N05AX08 | RISSET 3 MG tablett 3 mg N20 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114557 | risperidoon | N05AX08 | RISSET 3 MG tablett 3 mg N60 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114568 | risperidoon | N05AX08 | RISSET 4 MG tablett 4 mg N20 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1114579 | risperidoon | N05AX08 | RISSET 4 MG tablett 4 mg N60 | AWD Pharma Ltd. | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1161144 | risperidoon | N05AX08 | RISPERIDON SANDOZ õhukese polümeerikilega kaetud tablett 2 mg N60 | Sandoz GmbH | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1161223 | risperidoon | N05AX08 | RISPERIDON SANDOZ õhukese polümeerikilega kaetud tablett 3 mg N60 | Sandoz GmbH | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1161302 | risperidoon | N05AX08 | RISPERIDON SANDOZ õhukese polümeerikilega kaetud tablett 4 mg N60 | Sandoz GmbH | 50% | 100% | (F20-F29)* | *rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile | ||||
| 1074608 | rivastigmiin | N07AA80 | EXELON kapsel 1,5mg N112 | Novartis Pharma AG | 50% | |||||||
| 1031465 | rivastigmiin | N07AA80 | EXELON kapsel 1,5mg N14 | Novartis Pharma AG | 50% | |||||||
| 1074585 | rivastigmiin | N07AA80 | EXELON kapsel 1,5mg N28 | Novartis Pharma AG | 50% | |||||||
| 1074596 | rivastigmiin | N07AA80 | EXELON kapsel 1,5mg N56 | Novartis Pharma AG | 50% | |||||||
| 1074631 | rivastigmiin | N07AA80 | EXELON kapsel 3mg N112 | Novartis Pharma AG | 50% | |||||||
| 1031476 | rivastigmiin | N07AA80 | EXELON kapsel 3mg N14 | Novartis Pharma AG | 50% | |||||||
| 1074619 | rivastigmiin | N07AA80 | EXELON kapsel 3mg N28 | Novartis Pharma AG | 50% | |||||||
| 1074620 | rivastigmiin | N07AA80 | EXELON kapsel 3mg N56 | Novartis Pharma AG | 50% | |||||||
| 1074484 | rivastigmiin | N07AA80 | EXELON kapsel 4,5mg N112 | Novartis Pharma AG | 50% | |||||||
| 1031421 | rivastigmiin | N07AA80 | EXELON kapsel 4,5mg N14 | Novartis Pharma AG | 50% | |||||||
| 1074462 | rivastigmiin | N07AA80 | EXELON kapsel 4,5mg N28 | Novartis Pharma AG | 50% | |||||||
| 1074473 | rivastigmiin | N07AA80 | EXELON kapsel 4,5mg N56 | Novartis Pharma AG | 50% | |||||||
| 1074518 | rivastigmiin | N07AA80 | EXELON kapsel 6mg N112 | Novartis Pharma AG | 50% | |||||||
| 1031432 | rivastigmiin | N07AA80 | EXELON kapsel 6mg N14 | Novartis Pharma AG | 50% | |||||||
| 1074495 | rivastigmiin | N07AA80 | EXELON kapsel 6mg N28 | Novartis Pharma AG | 50% | |||||||
| 1074507 | rivastigmiin | N07AA80 | EXELON kapsel 6mg N56 | Novartis Pharma AG | 50% | |||||||
| 1043345 | rivastigmiin | N07AA80 | EXELON suukaudne lahus 2mg/ml 120ml N1 | Novartis Pharma AG | 50% | |||||||
| 1158836 | ropinirool | N04BC04 | REQUIP tablett 0,25mg N84 | SmithKline Beecham Plc | 50% | 100% | G20,* | rev neuroloogil *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1158825 | ropinirool | N04BC04 | REQUIP tablett 1mg N84 | SmithKline Beecham Plc | 50% | 100% | G20,* | rev neuroloogil *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1158814 | ropinirool | N04BC04 | REQUIP tablett 2mg N84 | SmithKline Beecham Plc | 50% | 100% | G20,* | rev neuroloogil *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1158803 | ropinirool | N04BC04 | REQUIP tablett 5mg N84 | SmithKline Beecham Plc | 50% | 100% | G20,* | rev neuroloogil *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1078501 | rosiglitasoon | A10BG02 | AVANDIA tablett 4mg N28 | SMITHKLINE BEECHAM PLC. | 50% | |||||||
| 1207000 [RTL 2006, 26, 482 – jõust. 1.04.2006] | rosiglitasoon+metformiin | A10BD03 | AVANDAMET tablett 2/1000 mg N56 | GlaxoSmithKline | 50% | |||||||
| 1207033 [RTL 2006, 26, 482 – jõust. 1.04.2006] | rosiglitasoon+metformiin | A10BD03 | AVANDAMET tablett 4/1000 mg N56 | GlaxoSmithKline | 50% | |||||||
| 1142345 | rosiglitasoon+metformiin | A10BD03 | AVANDAMET tablett 2/500 mg N28 | GlaxoSmithKline | 50% | |||||||
| 1206997 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1207022 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1106053 | rosuvastatiin | C10AA07 | CRESTOR tablett 10 mg N28 | AstraZeneca UK Ltd. | 50% | |||||||
| 1106132 | rosuvastatiin | C10AA07 | CRESTOR tablett 20 mg N28 | AstraZeneca UK Ltd. | 50% | |||||||
| 1106233 | rosuvastatiin | C10AA07 | CRESTOR tablett 40 mg N28 | AstraZeneca UK Ltd. | 50% | |||||||
| 1034479 | sakvinaviir | J05AE01 | FORTOVASE kapsel 200mg N180 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | |||||||
| 1010697 | salbutamool | R03AC02 | ECOSAL EASI-BREATHE aerosool 0,1mg/annuses 200annust N1 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1094789 | salbutamool | R03AC02 | ECOSAL EASI-BREATHE aerosool 0,1mg/annuses 200annust N3 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1045572 | salbutamool | R03AC02 | ECOSAL inhal aeros 0,1mg/annuses 200annust N1 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| VENTOLIN DISKUS | *rev pediaatril ja | |||||||||||
| 1031308 | salbutamool | R03AC02 | inhalatsioonipulber 200mcg/annuses N60 | Glaxo Wellcome Operations | 50% | 75% | J45; J43; J44* | pulmonoloogil; **rev pulmonoloogil | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1005512 | salbutamool | R03AC02 | VENTOLIN inhal aeros 0,1mg/annuses 200annust N1 | Glaxo Group Ltd. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1004948 | salbutamool | R03AC02 | VENTOLIN RESPIRATOR SOLUTION inhalatsioonilahus 5mg/ml 20ml N1 | Glaxo Wellcome Operations | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1004319 | salbutamool | R03CC02 | VENTOLIN SYRUP siirup 0,4mg/ml 150ml N1 | Glaxo Wellcome Operations | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1000472 | salbutamool | R03CC02 | VOLMAX prolong tablett 4mg 1TABL N14 | Glaxo Group Ltd. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1029473 | salbutamool+ipratroopiumbromiid | R03AK81 | COMBIVENT inhal aeros 0,12mg+0,02mg/annuses 200annust 10 ml | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1007907 | salmeterool | R03AC12 | SEREVENT DISKUS 50 MCG inhalatsioonipulber 50mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1000405 | salmeterool | R03AC12 | SEREVENT inhal aeros 0,025mg/annuses 120annust N1 | Glaxo Smithkline Export Ltd. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1037607 | salmeterool+flutikasoonpropionaat | R03AK82 | SERETIDE DISKUS 100 inhalatsioonipulber 50mcg+100mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45* | * rev pulmonoloogil ja pediaatril vastavalt Eesti ravijuhisele | ||||
| 1037595 | salmeterool+flutikasoonpropionaat | R03AK82 | SERETIDE DISKUS 250 inhalatsioonipulber 50mcg+250mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45* | * rev pulmonoloogil ja pediaatril vastavalt Eesti ravijuhisele | ||||
| 1153167 | salmeterool+flutikasoonpropionaat | R03AK82 | SERETIDE DISKUS 500 inhalatsioonipulber 50mcg+500mcg/annuses 60annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45*; ** | * rev pulmonoloogil ja pediaatril vastavalt Eesti ravijuhisele; **soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1107335 [RTL 2006, 26, 482 – jõust. 1.04.2006] | salmeterool+flutikasoonpropionaat | R03AK82 | SERETIDE INHALER 50 inhal aeros, susp 25mcg+50 mcg/annus 120 annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45,* | rev pulmonoloogil ja pediaatril vastavalt Eesti ravijuhisele,*soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1107346 [RTL 2006, 26, 482 – jõust. 1.04.2006] | salmeterool+flutikasoonpropionaat | R03AK82 | SERETIDE INHALER 125 inhal aeros, susp 25mcg+125 mcg/annus 120 annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45,* | rev pulmonoloogil ja pediaatril vastavalt Eesti ravijuhisele,*soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1107357 [RTL 2006, 26, 482 – jõust. 1.04.2006] | salmeterool+flutikasoonpropionaat | R03AK82 | SERETIDE INHALER 250 inhal aeros, susp 25mcg+250 mcg/annus 120 annust N1 | Glaxo Wellcome Operations | 50% | 75% | J45,* | rev pulmonoloogil ja pediaatril vastavalt Eesti ravijuhisele,*soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1040083 | sanamiviir | J05AH01 | RELENZA inhalatsioonipulber 5mg N5 | Glaxo Wellcome Operations | 50% | |||||||
| 1000157 | sennosiid | A06AB06 | X-PREP suukaudne lahus 2mg/ml 75ml N1 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1064832 | sertindool | N05AE03 | SERDOLECT tablett 12mg N100 | H. Lundbeck AS | 50% | |||||||
| 1027066 | sertindool | N05AE03 | SERDOLECT tablett 12mg N28 | H. Lundbeck AS | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1064887 | sertindool | N05AE03 | SERDOLECT tablett 16mg N100 | H. Lundbeck AS | 50% | |||||||
| 1027077 | sertindool | N05AE03 | SERDOLECT tablett 16mg N28 | H. Lundbeck AS | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1064900 | sertindool | N05AE03 | SERDOLECT tablett 20mg N100 | H. Lundbeck AS | 50% | |||||||
| 1027088 | sertindool | N05AE03 | SERDOLECT tablett 20mg N28 | H. Lundbeck AS | 50% | 100% | F20- | *rv psühhiaatril vastavalt Eesti ravijuhisele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab | ||||
| F29;* | olulisi kõrvaltoimeid; **soodustus ei kehti enne hinnakokkuleppe jõustumist | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1064821 | sertindool | N05AE03 | SERDOLECT tablett 4mg N100 | H. Lundbeck AS | 50% | |||||||
| 1027055 | sertindool | N05AE03 | SERDOLECT tablett 4mg N30 | H. Lundbeck AS | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning juhul, kui risperidoon on vastunäidustatud, ebaefektiivne või põhjustab olulisi kõrvaltoimeid; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1008638 | sertraliin | N06AB06 | ZOLOFT tablett 50mg N28 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1110856 | sertraliin | N06AB06 | SERTRAL 50 tablett 50 mg N28 | Hexal AG | 50% | |||||||
| 1110867 | sertraliin | N06AB06 | SERTRAL 100 tablett 100 mg N28 | Hexal AG | 50% | |||||||
| 1189346 | sertraliin | N06AB06 | SERTRALIN NYCOMED 50 MG tablett 50 mg N30 | NYCOMED DANMARK ApS | 50% | |||||||
| 1188020 | sertraliin | N06AB06 | SERTRALIN NYCOMED 100 MG tablett 100 mg N30 | NYCOMED DANMARK ApS | 50% | |||||||
| 1010765 | simvastatiin | C10AA01 | SIMGAL tablett 10mg N28 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1010776 | simvastatiin | C10AA01 | SIMGAL tablett 20mg N28 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1010787 | simvastatiin | C10AA01 | SIMGAL tablett 40mg N28 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1113534 | simvastatiin | C10AA01 | SIMVOR tablett 10mg N30 | Ranbaxy UK Ltd | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1113523 | simvastatiin | C10AA01 | SIMVOR tablett 20mg N30 | Ranbaxy UK Ltd | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1042681 | simvastatiin | C10AA01 | SIMVOR tablett 40mg N10 | Ranbaxy UK Ltd | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1060793 | simvastatiin | C10AA01 | SIMVOR tablett 40mg N50 | Ranbaxy UK Ltd | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1163023 | simvastatiin | C10AA01 | ZOCOR 10 MG tablett N28 | Merck Sharp & Dohme OÜ | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1080740 | simvastatiin | C10AA01 | ZOCOR 20 MG tablett 20mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1060715 | simvastatiin | C10AA01 | ZOCOR FORTE 40 tablett 40mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1084542 | simvastatiin | C10AA01 | ZOCOR FORTE XL 80 MG tablett 80 mg N28 | Merck Sharp & Dohme OÜ | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1010271 | simvastatiin | C10AA01 | VASILIP tablett 10mg N28 | KRKA, d.d. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1010260 | simvastatiin | C10AA01 | VASILIP tablett 20mg N28 | KRKA, d.d. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1086218 | simvastatiin | C10AA01 | VASILIP tablett 40mg N28 | KRKA, d.d. | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1154797 | simvastatiin | C10AA01 | SIMVOR tablett 40mg N30 | Ranbaxy UK Ltd | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1080166 | simvastatiin | C10AA01 | SIMVACOR 10 tablett 10mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1080177 | simvastatiin | C10AA01 | SIMVACOR 20 tablett 20mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1121016 | simvastatiin | C10AA01 | SIMVASTATIN NYCOMED 10 MG tablett 10 mg N30 | Nycomed Sefa AS | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1121038 | simvastatiin | C10AA01 | SIMVASTATIN NYCOMED 20 MG tablett 20 mg N30 | Nycomed Sefa AS | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1121049 | simvastatiin | C10AA01 | SIMVASTATIN NYCOMED 40 MG tablett 40 mg N30 | Nycomed Sefa AS | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1129698 | simvastatiin | C10AA01 | SIMVACOR 30 kaetud tablett 30 mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1129700 | simvastatiin | C10AA01 | SIMVACOR 40 kaetud tablett 40 mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1083934 | simvastatiin | C10AA01 | SIMVASTATIN-RATIOPHARM kaetud tablett 10 mg N30 | ratiopharm GmbH | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1083956 | simvastatiin | C10AA01 | SIMVASTATIN-RATIOPHARM kaetud tablett 20 mg N30 | ratiopharm GmbH | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1083978 | simvastatiin | C10AA01 | SIMVASTATIN-RATIOPHARM kaetud tablett 40 mg N30 | ratiopharm GmbH | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1083989 | simvastatiin | C10AA01 | SIMVASTATIN-RATIOPHARM kaetud tablett 40 mg N50 | ratiopharm GmbH | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1128507 | simvastatiin | C10AA01 | SIMVACOR 80 kaetud tablett 80 mg N30 | Hexal AG | 50% | 75% | E78; I21; I22; I25.2; Z45; Z95 | *(4) | ||||
| 1082955 | siroliimus | L04AA10 | RAPAMUNE ORAL SOLUTION suukaudne lahus 1mg/ml 150ml N1 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1082966 | siroliimus | L04AA10 | RAPAMUNE ORAL SOLUTION suukaudne lahus 1mg/ml 1ml N30 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1082977 | siroliimus | L04AA10 | RAPAMUNE ORAL SOLUTION suukaudne lahus 1mg/ml 2ml N30 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1082988 | siroliimus | L04AA10 | RAPAMUNE ORAL SOLUTION suukaudne lahus 1mg/ml 5ml N30 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1012857 | siroliimus | L04AA10 | RAPAMUNE ORAL SOLUTION suukaudne lahus 1mg/ml 60ml N1 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1022072 | somatropiin | H01AC01 | GENOTROPIN injektsioonisubstants 16TÜ amp N1 | Pfizer Enterprises Sarl | 50% | 100% | E23; E89.3; N18; Q96 | *rv endokrinoloogil kuni kasvutsoonide sulgumiseni | ||||
| 1041185 | somatropiin | H01AC01 | GENOTROPIN injektsioonisubstants 36TÜ kaheosaline kolbampull N1 | Pfizer Enterprises Sarl | 50% | 100% | E23; E89.3; N18; Q96 | *rv endokrinoloogil kuni kasvutsoonide sulgumiseni | ||||
| 1064281 | somatropiin | H01AC01 | GENOTROPIN injektsioonisubstants 36TÜ kaheosaline kolbampull N5 | Pfizer Enterprises Sarl | 50% | 100% | E23; E89.3; N18; Q96 | *rv endokrinoloogil kuni kasvutsoonide sulgumiseni | ||||
| 1013432 | somatropiin | H01AC01 | HUMATROPE injektsioonisubstants 18 TÜ viaal+eeltäidetud süstal N1 | Eli Lilly Holding Limited | 50% | 100% | E23; E89.3; N18; Q96 | *rv endokrinoloogil kuni kasvutsoonide sulgumiseni | ||||
| 1013836 | somatropiin | H01AC01 | HUMATROPE injektsioonisubstants 36 TÜ viaal+eeltäidetud süstal N1 | Eli Lilly Holding Limited | 50% | 100% | E23; E89.3; N18; Q96 | *rv endokrinoloogil kuni kasvutsoonide sulgumiseni | ||||
| 1043705 | somatropiin | H01AC01 | SAIZEN 8 MG CLICK.EASY injektsioonisubstants 24TÜ viaal+1 ml lahustiga täidetud | Sereno Austria GmbH | 50% | 100% | E23; E89.3; N18; Q96 | *rv endokrinoloogil kuni kasvutsoonide sulgumiseni | ||||
| viaalid N1 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1064269 | somatropiin | H01AC01 | SAIZEN 8 MG CLICK.EASY injektsioonisubstants 24TÜ viaal+1 ml lahustiga täidetud viaalid N5 | Sereno Austria GmbH | 50% | 100% | E23; E89.3; N18; Q96 | *rv endokrinoloogil kuni kasvutsoonide sulgumiseni | ||||
| 1034491 | sotalool | C07AA07 | SOTAHEXAL 160 tablett 160mg N20 | Hexal AG | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | ||||
| 1034480 | sotalool | C07AA07 | SOTAHEXAL 80 tablett 80mg N20 | Hexal AG | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | ||||
| 1071863 | sotalool | C07AA07 | SOTAHEXAL 80 tablett 80mg N50 | Hexal AG | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | ||||
| 1036707 | sotalool | C07AA07 | SOTALEX MITE tablett 80mg N30 | Bristol-Myers Squibb Eesti AS | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | ||||
| 1028786 | spiramütsiin | J01FA02 | ROVAMYCINE tablett 1500000TÜ N16 | LABORATOIRE AVENTIS | 50% | |||||||
| 1023310 | spiramütsiin | J01FA02 | ROVAMYCINE tablett 3000000TÜ N10 | LABORATOIRE AVENTIS | 50% | |||||||
| 1036538 | spirapriil | C09AA11 | QUADROPRIL tablett 6mg N30 | Arzneimittelwerk Dresden GmbH | 50% | |||||||
| 1001091 | spironolaktoon | C03DA01 | SPIRIX 100 MG tablett 100mg N20 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1000944 | spironolaktoon | C03DA01 | SPIRIX 25 MG tablett 25mg N20 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1071650 | spironolaktoon | C03DA01 | SPIRIX 50 MG tablett 50mg N100 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1001013 | spironolaktoon | C03DA01 | SPIRIX 50 MG tablett 50mg N20 | Nycomed Sefa AS | 50% | 75% | I50 | |||||
| 1004993 | spironolaktoon | C03DA01 | SPIRONOLACTON- RATIOPHARM 50 tablett 50mg N20 | ratiopharm GmbH | 50% | 75% | I50 | |||||
| 1042018 | spironolaktoon | C03DA01 | VEROSPIRON CAPSULES 50 MG kapsel 50mg N30 | GEDEON RICHTER Ltd. | 50% | 75% | I50 | |||||
| 1014848 | spironolaktoon | C03DA01 | VEROSPIRON tablett 25mg N20 | GEDEON RICHTER Ltd. | 50% | 75% | I50 | |||||
| 1120712 | spironolaktoon | C03DA01 | SPIROGAMMA 50 tabletid 50 mg N20 | Wörwag Pharma GmbH | 50% | 75% | I50 | |||||
| 1120723 | spironolaktoon | C03DA01 | SPIROGAMMA 50 tabletid 50 mg N50 | Wörwag Pharma GmbH | 50% | 75% | I50 | |||||
| 1120734 | spironolaktoon | C03DA01 | SPIROGAMMA 50 tabletid 50 mg N100 | Wörwag Pharma GmbH | 50% | 75% | I50 | |||||
| 1120790 | spironolaktoon | C03DA01 | SPIROGAMMA 100 tabletid 100 mg N20 | Wörwag Pharma GmbH | 50% | 75% | I50 | |||||
| 1120824 | spironolaktoon | C03DA01 | SPIROGAMMA 100 tabletid 100 mg N50 | Wörwag Pharma GmbH | 50% | 75% | I50 | |||||
| 1120813 | spironolaktoon | C03DA01 | SPIROGAMMA 100 tabletid 100 mg N100 | Wörwag Pharma GmbH | 50% | 75% | I50 | |||||
| 1032411 | stavudiin | J05AX04 | ZERIT kapsel 15mg N56 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1073472 | stavudiin | J05AX04 | ZERIT kapsel 15mg N60 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1032422 | stavudiin | J05AX04 | ZERIT kapsel 20mg N56 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1073528 | stavudiin | J05AX04 | ZERIT kapsel 20mg N60 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1032433 | stavudiin | J05AX04 | ZERIT kapsel 30mg N56 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1073539 | stavudiin | J05AX04 | ZERIT kapsel 30mg N60 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1032444 | stavudiin | J05AX04 | ZERIT kapsel 40mg N56 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1073540 | stavudiin | J05AX04 | ZERIT kapsel 40mg N60 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1032400 | stavudiin | J05AX04 | ZERIT pulber lahuse valmistamiseks 1mgml 200ml N1 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1186949 | strontsiumranelaat | M05BX03 | PROTELOS graanulid peroraalse suspensiooni valmistamiseks 2 g N28 | Les Laboratories Servier | 50% | |||||||
| 1054055 | sulfadiasiinhõbe | D06BA01 | SULFARGIN salv 1%/g 50g N1 | Tallinna Farmaatsiatehase AS | 50% | |||||||
| 1107717 | sulfametoksasool+trimetoprim | J01EE01 | APO-SULFATRIM tablett 400mg+80mg N20 | Apotex International Inc | 50% | 100% | (B20- B24); Z20.6; Z21* | *rv patsienti jälgival ja ravival infektsionistil | ||||
| 1107728 | sulfametoksasool+trimetoprim | J01EE01 | APO-SULFATRIM tablett 400mg+80mg N40 | Apotex International Inc | 50% | 100% | (B20- B24); Z20.6; Z21* | *rv patsienti jälgival ja ravival infektsionistil | ||||
| 1008830 | sulfametoksasool+trimetoprim | J01EE01 | BACTRIM FORTE tablett 800mg+160mg N10 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | (B20- B24); Z20.6; Z21* | *rv patsienti jälgival ja ravival infektsionistil | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1008818 | sulfametoksasool+trimetoprim | J01EE01 | BACTRIM SYRUP siirup 40mg+8mgml 100ml N1 | Hoffmann-La Roche Ltd. Eesti filiaal | 50% | 100% | (B20- B24); Z20.6; Z21* | *rv patsienti jälgival ja ravival infektsionistil | ||||
| 1016086 | sulfametoksasool+trimetoprim | J01EE01 | BERLOCID 960 tablett 800mg+160mg N20 | Berlin-Chemie AG (Menarini Group) | 50% | 100% | (B20- B24); Z20.6; Z21* | *rv patsienti jälgival ja ravival infektsionistil | ||||
| 1014938 | sulfametoksasool+trimetoprim | J01EE01 | CO-TRIMOXAZOLS tablett 400mg+80mg N20 | Grindeks | 50% | 100% | (B20- B24); Z20.6; Z21* | *rv patsienti jälgival ja ravival infektsionistil | ||||
| 1009460 | sulfametrool+trimetoprim | J01EE03 | LIDAPRIM FORTE tablett 800mg+160mg N10 | Nycomed Sefa AS | 50% | |||||||
| 1009482 | sulfametrool+trimetoprim | J01EE03 | LIDAPRIM SUSPENSIOON suspensioon 40mg+8mgml 100ml N1 | Nycomed Sefa AS | 50% | |||||||
| 1009448 | sulfametrool+trimetoprim | J01EE03 | LIDAPRIM tablett 400mg+80mg N20 | Nycomed Sefa AS | 50% | |||||||
| 1023455 | sulfasalasiin | A07EC01 | SALAZOPYRIN EN gastroresistentne tablett 500mg N100 | Pfizer Enterprises Sarl | 50% | 75% | K50; K51;M05; M06; M08; M45; M46** | rv gastroenteroloogil ja pediaatril; *rv reumatoloogil ja pediaatril | ||||
| 1040612 | sulpiriid | N05AL01 | BETAMAKS tablett 100mg N30 | Grindeks | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1040601 | sulpiriid | N05AL01 | BETAMAKS tablett 200mg N30 | Grindeks | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1040623 | sulpiriid | N05AL01 | BETAMAKS tablett 50mg N30 | Grindeks | 50% | 100% | F20- F29;* | rv psühhiaatril vastavalt Eesti ravijuhisele ning arvestades Eesti Psühhiaatrite Seltsi poolt väljatöötatud kriteeriume üleminekuks konventsionaalselt atüüpilisele antipsühhootikumile; *soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1018493 | sultamitsilliin | J01CR04 | UNASYN pulber p.o. suspensiooni valmistamiseks 50mgml 30ml N1 | Pfizer H.C.P. Corporation | 50% | (5) | ||||||
| 1018482 | sultamitsilliin | J01CR04 | UNASYN tablett 375mg N12 | Pfizer H.C.P. Corporation | 50% | (5) | ||||||
| 1024771 | sumatriptaan | N02CC01 | IMIGRAN ninasprei 20mg/annuses N1 | Glaxo Wellcome Operations | 50% | |||||||
| 1005321 | sumatriptaan | N02CC01 | IMIGRAN tablett 100mg N2 | Glaxo Wellcome Operations | 50% | |||||||
| 1008515 | sumatriptaan | N02CC01 | IMIGRAN tablett 50mg N2 | Glaxo Wellcome Operations | 50% | |||||||
| 1139880 | sumatriptaan | N02CC01 | IMIGRAN FDT kaetud tablett 50mg N2 | Glaxo Wellcome Operations | 50% | |||||||
| 1139914 | sumatriptaan | N02CC01 | IMIGRAN FDT kaetud tablett 100mg N2 | Glaxo Wellcome Operations | 50% | |||||||
| 1192092 [RTL 2006, 26, 482 – jõust. 1.04.2006] | sumatriptaan | N02CC01 | SUMATRIPTAN SANDOZ 100 MG tablett 100 mg N2 | Sandoz GmbH | 50% | |||||||
| 1191978 [RTL 2006, 26, 482 – jõust. 1.04.2006] | sumatriptaan | N02CC01 | SUMATRIPTAN SANDOZ 50 MG tablett 50 mg N2 | Sandoz GmbH | 50% | |||||||
| 1008492 | zidovudiin | J05AB05 | RETROVIR CAPSULES 100 MG kapsel 100mg N100 | Glaxo Wellcome Operations | 50% | 100% | (B20- B24); Z20.6; | *rv patsienti jälgival ja ravival infektsionistil | ||||
| Z21* | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1113422 | zidovudiin | J05AB05 | RETROVIR siirup 10 mg/ml 200 ml | Glaxo Group Ltd. | 50% | 100% | (B20- B24); Z20.6; Z21* | *rv patsienti jälgival ja ravival infektsionistil HIV-positiivse ema vastsündinule HIV-infektsiooni primaarseks profülaktikaks 6 nädala jooksul peale sündi ning HIV-positiivse lapse kombinatsioonravi osana kuni eani, mil on võimalik ravimi manustamine kapslitena, soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1119169 | ziprasidoon | N05AE04 | ZELDOX kapslid 20 mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1119204 | ziprasidoon | N05AE04 | ZELDOX kapslid 40 mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1119260 | ziprasidoon | N05AE04 | ZELDOX kapslid 60 mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1119305 | ziprasidoon | N05AE04 | ZELDOX kapslid 80 mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1108954 | zofenopriil | C09AA15 | ZOFISTAR 30 MG kaetud tablett 30 mg N28 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1110722 | zolmitriptaan | N02CC03 | ZOMIG RAPIMELT suus dispergeeruv tablett 2,5 mg N2 | AstraZeneca UK Ltd. | 50% | |||||||
| 1006232 | zuklopentiksool | N05AF05 | CISORDINOL DEPOT inj 200mg/ml amp 1ml N1 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1065226 | zuklopentiksool | N05AF05 | CISORDINOL DEPOT süstelahus 200mg/ml amp 1ml N10 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1005815 | zuklopentiksool | N05AF05 | CISORDINOL tablett 10mg N50 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1005781 | zuklopentiksool | N05AF05 | CISORDINOL tablett 25mg N50 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1005758 | zuklopentiksool | N05AF05 | CISORDINOL tablett 2mg N50 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1006322 | zuklopentiksool | N05AF05 | CISORDINOL-ACUTARD süstelahus 50mg/ml 1ml N10 | H. Lundbeck AS | 50% | 100% | (F00-F09); (F10-F19.4- 7) (F20-F29) (F30-F31) (F32/33.2- 3) F60.3 (F70-F79)* | *rev psühhiaatril | ||||
| 1002665 | tamoksifeen | L02BA01 | NOLVADEX D tablett 20mg N30 | AstraZeneca UK Ltd. | 50% | 100% | (C00-D48)* | *rv hematoloogil, onkoloogil ja uroloogil | ||||
| 1015692 | tamoksifeen | L02BA01 | TAMOXIFEN-EBEWE tablett 10mg N30 | EBEWE Pharma Ges.m.b.H.Nfg.KG | 50% | 100% | (C00-D48)* | *rv hematoloogil, onkoloogil ja uroloogil | ||||
| 1015704 | tamoksifeen | L02BA01 | TAMOXIFEN-EBEWE tablett 20mg N30 | EBEWE Pharma Ges.m.b.H.Nfg.KG | 50% | 100% | (C00-D48)* | *rv hematoloogil, onkoloogil ja uroloogil | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1038282 | tamsulosiin | G04CA02 | OMNIC prolong kapsel 0,4mg N30 | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1064258 | tamsulosiin | G04CA02 | OMNIC prolong kapsel 0,4mg N90 | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1013443 | telmisartaan | C09CA07 | MICARDIS 20 MG tablett 20mg N14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046225 | telmisartaan | C09CA07 | MICARDIS 20 MG tablett 20mg N28 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046236 | telmisartaan | C09CA07 | MICARDIS 20 MG tablett 20mg N56 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046247 | telmisartaan | C09CA07 | MICARDIS 20 MG tablett 20mg N98 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046281 | telmisartaan | C09CA07 | MICARDIS 40 MG tablett 40mg N14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046292 | telmisartaan | C09CA07 | MICARDIS 40 MG tablett 40mg N28 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046304 | telmisartaan | C09CA07 | MICARDIS 40 MG tablett 40mg N56 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046315 | telmisartaan | C09CA07 | MICARDIS 40 MG tablett 40mg N98 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1039485 | telmisartaan | C09CA07 | MICARDIS 80 MG tablett 80mg N14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046258 | telmisartaan | C09CA07 | MICARDIS 80 MG tablett 80mg N28 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046269 | telmisartaan | C09CA07 | MICARDIS 80 MG tablett 80mg N56 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1046270 | telmisartaan | C09CA07 | MICARDIS 80 MG tablett 80mg N98 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1011485 | telmisartaan | C09CA07 | PRITOR tablett 20mg N14 | Glaxo Wellcome Operations | 50% | |||||||
| 1060614 | telmisartaan | C09CA07 | PRITOR tablett 20mg N28 | Glaxo Wellcome Operations | 50% | |||||||
| 1060625 | telmisartaan | C09CA07 | PRITOR tablett 20mg N56 | Glaxo Wellcome Operations | 50% | |||||||
| 1060636 | telmisartaan | C09CA07 | PRITOR tablett 20mg N98 | Glaxo Wellcome Operations | 50% | |||||||
| 1060524 | telmisartaan | C09CA07 | PRITOR tablett 40mg N28 | Glaxo Wellcome Operations | 50% | |||||||
| 1060535 | telmisartaan | C09CA07 | PRITOR tablett 40mg N56 | Glaxo Wellcome Operations | 50% | |||||||
| 1183519 [RTL 2006, 26, 482 – jõust. 1.04.2006] | telmisartaan | C09CA07 | PRITOR tablett 80mg N28 | Glaxo Wellcome Operations | 50% | |||||||
| 1060579 | telmisartaan | C09CA07 | PRITOR tablett 80mg N56 | Glaxo Wellcome Operations | 50% | |||||||
| 1121454 | telmisartaan+hüdroklorotiasiid | C09DA80 | PRITORPLUS tablett 80/12,5 mg N 14 | Glaxo Group Ltd. | 50% | |||||||
| 1121465 | telmisartaan+hüdroklorotiasiid | C09DA80 | PRITORPLUS tablett 80/12,5 mg N 28 | Glaxo Group Ltd. | 50% | |||||||
| 1121476 | telmisartaan+hüdroklorotiasiid | C09DA80 | PRITORPLUS tablett 80/12,5 mg N 56 | Glaxo Group Ltd. | 50% | |||||||
| 1121487 | telmisartaan+hüdroklorotiasiid | C09DA80 | PRITORPLUS tablett 80/12,5 | Glaxo Group Ltd. | 50% | |||||||
| mg N 98 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1114793 | telmisartaan+hüdroklorotiasiid | C09DA80 | MICARDISPLUS tablett 80/12,5 mg N28 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | 50% | |||||||
| 1114951 | temosolomiid | L01AX03 | TEMODAL kapsel 5 mg N 5 | Schering Plough Europe | 50% | |||||||
| 1114962 | temosolomiid | L01AX03 | TEMODAL kapsel 5 mg N 20 | Schering Plough Europe | 50% | |||||||
| 1114973 | temosolomiid | L01AX03 | TEMODAL kapsel 20 mg N 5 | Schering Plough Europe | 50% | |||||||
| 1114984 | temosolomiid | L01AX03 | TEMODAL kapsel 20 mg N 20 | Schering Plough Europe | 50% | |||||||
| 1114995 | temosolomiid | L01AX03 | TEMODAL kapsel 100 mg N 5 | Schering Plough Europe | 50% | |||||||
| 1115008 | temosolomiid | L01AX03 | TEMODAL kapsel 100 mg N 20 | Schering Plough Europe | 50% | |||||||
| 1115019 | temosolomiid | L01AX03 | TEMODAL kapsel 250 mg N 5 | Schering Plough Europe | 50% | |||||||
| 1115020 | temosolomiid | L01AX03 | TEMODAL kapsel 250 mg N 20 | Schering Plough Europe | 50% | |||||||
| 1124031 | teofülliin | R03DA04 | RETAFYLLIN retardtablett 200mg 1TABL N100 | ORION CORPORATION ORION PHARMA | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1124042 | teofülliin | R03DA04 | RETAFYLLIN retardtablett 300mg 1TABL N100 | ORION CORPORATION ORION PHARMA | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1033861 | teofülliin | R03DA04 | TEOTARD retardkapsel 200mg N40 | KRKA, d.d. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1033850 | teofülliin | R03DA04 | TEOTARD retardkapsel 350mg N40 | KRKA, d.d. | 50% | 75% | J45; J43; J44* | rev pediaatril ja pulmonoloogil; *rev pulmonoloogil | ||||
| 1061031 | terbinafiin | D01AE15 | LAMISIL DERMGEL geel 1% 30g N1 | Novartis Finland OY | 50% | |||||||
| 1034356 | terbinafiin | D01AE15 | LAMISIL lahus paikseks kasut. 1% 30ml N1 | Novartis Finland OY | 50% | |||||||
| 1034345 | terbinafiin | D01AE15 | LAMISIL nahasprei 1% 30ml N1 | Novartis Finland OY | 50% | |||||||
| 1012969 | terbinafiin | D01BA02 | TERBISIL tablett 250 mg N14 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1085880 | terbinafiin | D01BA02 | TERBISIL tablett 250 mg N28 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1012970 | terbinafiin | D01BA02 | TERBISIL tablett 125 mg N14 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1002766 | terbinafiin | D01BA02 | LAMISIL tablett 250mg N14 | Novartis Finland OY | 50% | |||||||
| 1158858 | terbinafiin | D01BA02 | TERBINAFIN HEXAL 125 MG TABLETID tabletid 125 mg N14 | Hexal AG | 50% | |||||||
| 1158724 | terbinafiin | D01BA02 | TERBINAFIN HEXAL 250 MG TABLETID tabletid 250 mg N14 | Hexal AG | 50% | |||||||
| 1146552 | terbinafiin | D01BA02 | TERBINAFIN NYCOMED 250 MG tablett 250 mg N14 | Nycomed Sefa AS | 50% | |||||||
| 1176308 [RTL 2006, 26, 482 – jõust. 1.04.2006] | terbinafiin | D01BA02 | TERBINAFIN ACTAVIS tablett 250 mg N14 | Actavis Nordic A/ | 50% | |||||||
| 1022588 | testosteroon | G03BA03 | ANDRIOL TESTOCAPS kapsel 40 mg N60 | N.V. ORGANON | 50% | 100% | (C00- D48); E23; E29.1; E89.5; Q98* | rv hematoloogil, onkoloogil ja uroloogil; *rv endokrinoloogil ja günekoloogil | ||||
| 1022623 | testosteroon | G03BA03 | SUSTANON "250" süstelahus 250mgml AMP 1ml N1 | N.V. ORGANON | 50% | 100% | (C00- D48); E23; E29.1; E89.5; Q98* | rv hematoloogil, onkoloogil ja uroloogil; *rv endokrinoloogil ja günekoloogil | ||||
| 1169445 | testosteroon | G03BA03 | NEBIDO süstelahus 250 mg/ml 4 ml N1 | Schering AG | 50% | |||||||
| 1017403 | tetratsükliin | D06AA04 | IMEX salv 3% 20g N1 | Merz Pharmaceuticals GmbH | 50% | |||||||
| 1014163 | tetratsükliin | J01AA07 | TETRACYCLIN NYCOMED tablett 250mg N24 | Nycomed Sefa AS | 50% | 100% | (A50-A53)* | *rv dermatoveneroloogil | ||||
| 1019360 | tianeptiin | N06AA80 | COAXIL tablett 12,5mg N30 | Les Laboratories Servier | 50% | |||||||
| 1034165 | tiboloon | G03DC05 | LIVIAL tablett 2,5mg N28 | N.V. ORGANON | 50% | |||||||
| 1063673 | tiboloon | G03DC05 | LIVIAL tablett 2,5mg N84 | N.V. ORGANON | 50% | |||||||
| 1085295 | tiklopidiin | B01AC05 | APO-TICLOPIDINE tablett 250 mg N30 | Apotex International Inc | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||
| 1085284 | tiklopidiin | B01AC05 | APO-TICLOPIDINE tablett 250 mg N60 | Apotex International Inc | 50% | |||||||
| 1023433 | tiklopidiin | B01AC05 | TAGREN tablett 250mg N30 | KRKA, d.d. | 50% | |||||||
| 1018684 | timolool | S01ED01 | ARUTIMOL silmatilgad 0,25% 5 ml N1 | Chauvin ankerpharm GmbH | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1018695 | timolool | S01ED01 | ARUTIMOL silmatilgad 0,5% 5ml N1 | Chauvin ankerpharm GmbH | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1078062 | timolool | S01ED01 | NYOLOL silmatilgad 0,5% 5ml N1 | Novartis Pharma SAS | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1112634 | timolool | S01ED01 | OFTAN TIMOLOL silmatilgad 0,25% 5 ml N1 | Santen OY | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1112645 | timolool | S01ED01 | OFTAN TIMOLOL silmatilgad 0,5% 5 ml N1 | Santen OY | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1008762 | timolool | S01ED01 | TIMOPTIC XE silmageel 0,25% 2.5ml N1 | Merck Sharp & Dohme OÜ | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1008784 | timolool | S01ED01 | TIMOPTIC XE silmatilgad 0,5% 2.5ml N1 | Merck Sharp & Dohme OÜ | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1038956 | timolool | S01ED01 | TIMOSAN silmageel 0,1% 5g N1 | Santen OY | 50% | 100% | (H40-H42)* | *rev oftalmoloogil | ||||
| 1039799 | timolool+dorsolamiid | S01ED80 | COSOPT silmatilgad 2%+0,5% 5ml N1 | Merck Sharp & Dohme OÜ | 50% | 100% | (H40-H42)* | *rv oftalmoloogil, kombinatsioonpreparaate kasutatakse juhul, kui monoteraapia beeta- adrenoblokaatori, lokaalse karboanhüdraasi inhibiitori ja prostaglandiini analoogiga ei ole langetanud piisavalt siserõhku | ||||
| 1004375 | tioguaniin | L01BB03 | LANVIS tablett 40mg N25 | Glaxo Wellcome Operations | 50% | |||||||
| 1173822 | tisanidiin | M03BX02 | SIRDALUD tablett 2mg N30 | Novartis Finland OY | 50% | 75% | G81; G82 | |||||
| 1211599 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tisanidiin | M03BX02 | SIRDALUD tablett 4mg N30 | Novartis Finland OY | 50% | 75% | G81; G82 | |||||
| 1012543 | tobramütsiin | S01AA12 | TOBREX silmasalv 0,3% 3.5g N1 | s.a. ALCON- COUVREUR n.v. | 50% | |||||||
| 1150120 | tobramütsiin | S01AA12 | TOBREX 2X silmatilgad, lahus 0,3 % 5 ml N1 | Alcon Cusi S.A. | 50% | |||||||
| 1124255 | tobramütsiin | S01AA12 | TOBREX silmatilgad, lahus 0,3% 5 ml N1 | s.a. ALCON- COUVREUR n.v. | 50% | |||||||
| 7000120 [RTL 2006, 26, 482 – jõust. 1.04.2006] | toitained ilma fenüülalaniinita | V06CA80 | XP ANALOG pulber 400g N4 | SHS International | 50% | 100% | E70.0; E70.1 | |||||
| 7000131 [RTL 2006, 26, 482 – jõust. 1.04.2006] | toitained ilma fenüülalaniinita | V06CA80 | XP MAXAMAID (ORANGE FLAVOURED) pulber 500g N4 | SHS International | 50% | 100% | E70.0; E70.1 | |||||
| 7000142 [RTL 2006, 26, 482 – jõust. 1.04.2006] | toitained ilma fenüülalaniinita | V06CA80 | XP MAXAMAID (UNFLAVOURED) pulber 500g N4 | SHS International | 50% | 100% | E70.0; E70.1 | |||||
| 7000153 [RTL 2006, 26, 482 – jõust. 1.04.2006] | toitained ilma fenüülalaniinita | V06CA80 | XP MAXAMUM (ORANGE FLAVOURED) pulber 500g N4 | SHS International | 50% | 100% | E70.0; E70.1 | |||||
| 7000164 [RTL 2006, 26, 482 – jõust. 1.04.2006] | toitained ilma fenüülalaniinita | V06CA80 | XP MAXAMUM (UNFLAVOURED) pulber 500g N4 | SHS International | 50% | 100% | E70.0; E70.1 | |||||
| 7000119 | toitained ilma fenüülalaniinita | V06CA80 | PHLEXY-10 DRINK MIX 30 x 20 g | SHS International | 50% | 100% | E70.0; E70.1 | |||||
| 7000186 | toitained ilma fenüülalaniinita | V06CA80 | DUOCAL Supersoluble 400 g | SHS International | 50% | 100% | E70.0; E70.1 | |||||
| 1196940 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tolkapoon | N04BX01 | TASMAR õhukese polümeerikattega tablett 100 mg N100 | Valeant Pharmaceuticals Ltd. | 50% | |||||||
| 1043301 | tolterodiin | G04BD07 | DETRUSITOL 1 MG tablett 1mg N28 | Pfizer Enterprises Sarl | 50% | |||||||
| 1064146 | tolterodiin | G04BD07 | DETRUSITOL 1 MG tablett 1mg | Pfizer Enterprises | 50% | |||||||
| N56 | Sarl | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1043312 | tolterodiin | G04BD07 | DETRUSITOL 2 MG tablett 2mg N28 | Pfizer Enterprises Sarl | 50% | |||||||
| 1064157 | tolterodiin | G04BD07 | DETRUSITOL 2 MG tablett 2mg N56 | Pfizer Enterprises Sarl | 50% | |||||||
| 1076846 | topiramaat | N03AX11 | TOPAMAX TABLETS 200 MG tablett 200mg N60 | JANSSEN-CILAG INTERNATIONAL NV | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustustel | ||||
| 1076734 | topiramaat | N03AX11 | TOPAMAX TABLETS 50 MG tablett 50mg N60 | JANSSEN-CILAG INTERNATIONAL NV | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustustel | ||||
| 1076778 | topiramaat | N03AX11 | TOPAMAX TABLETS 100 MG tablett 100mg N60 | JANSSEN-CILAG INTERNATIONAL NV | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustustel | ||||
| 1076688 | topiramaat | N03AX11 | TOPAMAX TABLETS 25 MG tablett 25mg N60 | JANSSEN-CILAG INTERNATIONAL NV | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustustel | ||||
| 1010158 | topiramaat | N03AX11 | TOPAMAX SPRINKLE CAPSULES 15 MG kapsel 15mg N60 | JANSSEN-CILAG INTERNATIONAL NV | 50% | 100% | G40* | *rv neuroloogil alla 18-aastasele lapsele ning täiskasvanule rev neuroloogil konventsionaalsetele antiepileptilistele ravimitele resistentse epilepsia näidustustel | ||||
| 1071582 | torasemiid | C03CA04 | TRIFAS 10 tablett 10mg N100 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1032332 | torasemiid | C03CA04 | TRIFAS 10 tablett 10mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1071571 | torasemiid | C03CA04 | TRIFAS 10 tablett 10mg N50 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1071605 | torasemiid | C03CA04 | TRIFAS 200 tablett 200mg N100 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1032321 | torasemiid | C03CA04 | TRIFAS 200 tablett 200mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1071593 | torasemiid | C03CA04 | TRIFAS 200 tablett 200mg N50 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1071560 | torasemiid | C03CA04 | TRIFAS COR tablett 5mg N100 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1032310 | torasemiid | C03CA04 | TRIFAS COR tablett 5mg N30 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1071559 | torasemiid | C03CA04 | TRIFAS COR tablett 5mg N50 | Berlin-Chemie AG (Menarini Group) | 50% | |||||||
| 1158005 | torasemiid | C03CA04 | TORASEMID HEXAL 50 MG TABLETID tabletid 50 mg N30 | Hexal AG | 50% | |||||||
| 1158050 | torasemiid | C03CA04 | TORASEMID HEXAL 100 MG TABLETID tabletid 100 mg N30 | Hexal AG | 50% | |||||||
| 1158106 | torasemiid | C03CA04 | TORASEMID HEXAL 200 MG TABLETID tabletid 200 mg N30 | Hexal AG | 50% | |||||||
| 1043457 | tramadool | N02AX02 | ADAMON SR 100 MG retardkapsel 100mg N20 | Asta Medica AG | 50% | |||||||
| 1043446 | tramadool | N02AX02 | ADAMON SR 150 MG retardkapsel 150mg N20 | Asta Medica AG | 50% | |||||||
| 1043435 | tramadool | N02AX02 | ADAMON SR 200 MG retardkapsel 200mg N20 | Asta Medica AG | 50% | |||||||
| 1043468 | tramadool | N02AX02 | ADAMON SR 50 MG retardkapsel 50mg N20 | Asta Medica AG | 50% | |||||||
| 1023242 | tramadool | N02AX02 | DOLOL kapsel 50mg N20 | Nycomed Sefa AS | 50% | |||||||
| 1086623 | tramadool | N02AX02 | DOLOL kapsel 50mg N30 | Nycomed Sefa AS | 50% | |||||||
| 1075799 | tramadool | N02AX02 | DOLOL kapsel 50mg N60 | Nycomed Sefa AS | 50% | |||||||
| 1085846 | tramadool | N02AX02 | TRAMADOL LANNACHER RETARD 150 MG retardtablett 150 mg N10 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1085857 | tramadool | N02AX02 | TRAMADOL LANNACHER RETARD 150 MG retardtablett 150 mg N30 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1085868 | tramadool | N02AX02 | TRAMADOL LANNACHER RETARD 200 MG retardtablett 200 mg N10 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1085879 | tramadool | N02AX02 | TRAMADOL LANNACHER RETARD 200 MG retardtablett 200 mg N30 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1043648 | tramadool | N02AX02 | MABRON kapsel 50mg N10 | Medochemie Ltd. | 50% | |||||||
| 1075700 | tramadool | N02AX02 | MABRON kapsel 50mg N20 | Medochemie Ltd. | 50% | |||||||
| 1038338 | tramadool | N02AX02 | PROTRADON kapsel 50mg N10 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| --- | --- | --- | --- | --- | --- | |||||||
| 1075979 | tramadool | N02AX02 | PROTRADON kapsel 50mg N20 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1016367 | tramadool | N02AX02 | TRAMADOL 50 STADA kapsel 50mg N10 | Stada Arzneimittel AG | 50% | |||||||
| 1075823 | tramadool | N02AX02 | TRAMADOL 50 STADA kapsel 50mg N30 | Stada Arzneimittel AG | 50% | |||||||
| 1075834 | tramadool | N02AX02 | TRAMADOL 50 STADA kapsel 50mg N50 | Stada Arzneimittel AG | 50% | |||||||
| 1015580 | tramadool | N02AX02 | TRAMADOL kapsel 50mg N20 | KRKA, d.d. | 50% | |||||||
| 1084249 | tramadool | N02AX02 | TRAMADOL ALPHARMA CAPSULES 50 MG kapslid 50 mg N30 | ALPHARMA Limited | 50% | |||||||
| 1011508 | tramadool | N02AX02 | TRAMADOL LANNACHER retardtablett 100mg N10 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1075665 | tramadool | N02AX02 | TRAMADOL LANNACHER retardtablett 100mg N30 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1032680 | tramadool | N02AX02 | TRAMADOL LANNACHER SOL. tilgad 100mg/ml 10ml N1 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1032691 | tramadool | N02AX02 | TRAMADOL LANNACHER SUPP. suposiit 100mg N5 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1075766 | tramadool | N02AX02 | TRAMADOL LANNACHER tablett 50mg N1000 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1032679 | tramadool | N02AX02 | TRAMADOL LANNACHER tablett 50mg N20 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1043525 | tramadool | N02AX02 | TRAMADOL RETARD retardtablett 100mg N30 | KRKA, d.d. | 50% | |||||||
| 1033175 | tramadool | N02AX02 | TRAMADOL- SLOVAKOFARMA suukaudne lahus 100mg/ml 10ml N1 | Slovakofarma | 50% | |||||||
| 1015591 | tramadool | N02AX02 | TRAMADOL suposiit 100mg N5 | KRKA, d.d. | 50% | |||||||
| 1015614 | tramadool | N02AX02 | TRAMADOL tilgad 100mg/ml 10ml N1 | KRKA, d.d. | 50% | |||||||
| 1094307 | tramadool | N02AX02 | TRAMADOL tilgad 100mg/ml 96ml N1 | KRKA, d.d. | 50% | |||||||
| 1015377 | tramadool | N02AX02 | TRAMAL kapsel 50mg N20 | Grünenthal GmbH | 50% | |||||||
| 1041297 | tramadool | N02AX02 | TRAMAL dispergeeritav tablett 50mg N10 | Grünenthal GmbH | 50% | |||||||
| 1085745 | tramadool | N02AX02 | TRAMAL dispergeeritav tablett 50mg N20 | Grünenthal GmbH | 50% | |||||||
| 1085756 | tramadool | N02AX02 | TRAMAL dispergeeritav tablett 50mg N30 | Grünenthal GmbH | 50% | |||||||
| 1085767 | tramadool | N02AX02 | TRAMAL dispergeeritav tablett 50mg N50 | Grünenthal GmbH | 50% | |||||||
| 1041534 | tramadool | N02AX02 | TRAMAL RETARD 100 MG retardtablett 100mg N10 | Grünenthal GmbH | 50% | |||||||
| 1075890 | tramadool | N02AX02 | TRAMAL RETARD 100 MG retardtablett 100mg N30 | Grünenthal GmbH | 50% | |||||||
| 1075902 | tramadool | N02AX02 | TRAMAL RETARD 100 MG retardtablett 100mg N50 | Grünenthal GmbH | 50% | |||||||
| 1041545 | tramadool | N02AX02 | TRAMAL RETARD 150 MG retardtablett 150mg N10 | Grünenthal GmbH | 50% | |||||||
| 1075913 | tramadool | N02AX02 | TRAMAL RETARD 150 MG retardtablett 150mg N30 | Grünenthal GmbH | 50% | |||||||
| 1075924 | tramadool | N02AX02 | TRAMAL RETARD 150 MG retardtablett 150mg N50 | Grünenthal GmbH | 50% | |||||||
| 1041556 | tramadool | N02AX02 | TRAMAL RETARD 200 MG retardtablett 200mg N10 | Grünenthal GmbH | 50% | |||||||
| 1075935 | tramadool | N02AX02 | TRAMAL RETARD 200 MG retardtablett 200mg N30 | Grünenthal GmbH | 50% | |||||||
| 1075946 | tramadool | N02AX02 | TRAMAL RETARD 200 MG retardtablett 200mg N50 | Grünenthal GmbH | 50% | |||||||
| 1015399 | tramadool | N02AX02 | TRAMAL suposiit 100mg N5 | Grünenthal GmbH | 50% | |||||||
| 1015401 | tramadool | N02AX02 | TRAMAL tilgad 100mg/ml 10ml N1 | Grünenthal GmbH | 50% | |||||||
| 1028584 | tramadool | N02AX02 | TRAMUNDIN RETARD prolong tablett 100mg N10 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1075621 | tramadool | N02AX02 | TRAMUNDIN RETARD prolong tablett 100mg N20 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1075632 | tramadool | N02AX02 | TRAMUNDIN RETARD prolong tablett 100mg N30 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1075643 | tramadool | N02AX02 | TRAMUNDIN RETARD prolong tablett 100mg N50 | Mundipharma Ges.m.b.H. | 50% | |||||||
| 1085138 | tramadool | N02AX02 | TRAMADOLOR 100 ID modif tablett 100 mg N30 | Hexal AG | 50% | |||||||
| 1085149 | tramadool | N02AX02 | TRAMADOLOR 100 ID modif tablett 100 mg N50 | Hexal AG | 50% | |||||||
| 1096196 | tramadool | N02AX02 | TRAMADOLOR 150 ID modif tablett 150 mg N10 | Hexal AG | 50% | |||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1096219 | tramadool | N02AX02 | TRAMADOLOR 150 ID modif tablett 150 mg N50 | Hexal AG | 50% | |||||||
| 1096231 | tramadool | N02AX02 | TRAMADOLOR 200 ID modif tablett 200 mg N10 | Hexal AG | 50% | |||||||
| 1096253 | tramadool | N02AX02 | TRAMADOLOR 200 ID modif tablett 200 mg N50 | Hexal AG | 50% | |||||||
| 1074855 | trandolapriil | C09AA10 | GOPTEN kapsel 0,5mg N100 | Abbott GmbH & Co. KG | 50% | |||||||
| 1008054 | trandolapriil | C09AA10 | GOPTEN kapsel 0,5mg N20 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074811 | trandolapriil | C09AA10 | GOPTEN kapsel 0,5mg N28 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074822 | trandolapriil | C09AA10 | GOPTEN kapsel 0,5mg N50 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074833 | trandolapriil | C09AA10 | GOPTEN kapsel 0,5mg N60 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074844 | trandolapriil | C09AA10 | GOPTEN kapsel 0,5mg N98 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074800 | trandolapriil | C09AA10 | GOPTEN kapsel 2mg N100 | Abbott GmbH & Co. KG | 50% | |||||||
| 1008076 | trandolapriil | C09AA10 | GOPTEN kapsel 2mg N20 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074765 | trandolapriil | C09AA10 | GOPTEN kapsel 2mg N28 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074776 | trandolapriil | C09AA10 | GOPTEN kapsel 2mg N50 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074787 | trandolapriil | C09AA10 | GOPTEN kapsel 2mg N60 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074798 | trandolapriil | C09AA10 | GOPTEN kapsel 2mg N98 | Abbott GmbH & Co. KG | 50% | |||||||
| 1051816 | traneksaamhape | B02AA02 | CYKLOKAPRON süstelahus 100mg/ml amp 5ml N10 | Pfizer Enterprises Sarl | 50% | |||||||
| 1065967 [RTL 2006, 26, 482 – jõust. 1.04.2006] | traneksaamhape | B02AA02 | CYKLOKAPRON tablett 500mg N100 | Meda AB | 50% | |||||||
| 1083316 [RTL 2006, 26, 482 – jõust. 1.04.2006] | traneksaamhape | B02AA02 | CYKLOKAPRON tablett 500mg N20 | Meda AB | 50% | |||||||
| 1051827 [RTL 2006, 26, 482 – jõust. 1.04.2006] | traneksaamhape | B02AA02 | CYKLOKAPRON tablett 500mg N50 | Meda AB | 50% | |||||||
| 1097041 | travoprost | S01EX80 | TRAVATAN silmatilgad, lahus 40mcg/ml 2.5ml N3 | Alcon Laboratoires (UK) Ltd. | 50% | 100% | (H40-H42)* | *rv oftalmoloogil, kui monoteraapia beeta- adrenoblokaatori ja karboanhüdraasi inhibiitoriga ei ole langetanud piisavalt silma siserõhku või mõlema rühma ravimid on vastunäidustatud, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1130454 | travoprost | S01EX80 | TRAVATAN silmatilgad, lahus 40mcg/ml 2.5ml N1 | Alcon Laboratoires (UK) Ltd. | 50% | 100% | (H40-H42)* | *rv oftalmoloogil, kui monoteraapia beeta- adrenoblokaatori ja karboanhüdraasi inhibiitoriga ei ole langetanud piisavalt silma siserõhku või mõlema rühma ravimid on vastunäidustatud, soodustus ei kehti enne hinnakokkuleppe jõustumist | ||||
| 1007200 | triamtsinoloon | D07AB09 | FTOROCORT 0,1% OINTMENT salv 0,1% 15g | GEDEON RICHTER Ltd. | 50% | |||||||
| 1008425 | triamtsinoloon | H02AB08 | KENALOG 40 süstesuspensioon 40mg/ml amp 1ml N5 | KRKA, d.d. | 50% | |||||||
| 1014422 | triheksüfenidüül | N04AA01 | CYCLODOL tablett 2mg N50 | Grindeks | 50% | |||||||
| 1078141 | triheksüfenidüül | N04AA01 | PARKOPAN 2 tablett 2mg N100 | Hexal AG | 50% | |||||||
| 1010596 | triheksüfenidüül | N04AA01 | PARKOPAN 2 tablett 2mg N50 | Hexal AG | 50% | |||||||
| 1078152 | triheksüfenidüül | N04AA01 | PARKOPAN 5 tablett 5mg N100 | Hexal AG | 50% | |||||||
| 1010608 | triheksüfenidüül | N04AA01 | PARKOPAN 5 tablett 5mg N50 | Hexal AG | 50% | |||||||
| 1019405 [RTL 2006, 26, 482 – jõust. | trimetasidiin | C01EB15 | PREDUCTAL tablett 20mg N60 | Les Laboratories Servier | 50% | |||||||
| 1.04.2006] | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1109641 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trimetasidiin | C01EB15 | PREDUCTAL MR modifitseeritud tablett 35 mg N60 | Les Laboratories Servier | 50% | |||||||
| 1068465 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1016312 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trimetoprim | J01EA01 | TRIMETOP 100 MG tablett 100mg N30 | Vitabalans OY | 50% | |||||||
| 1029721 | triptoreliin | L02AE04 | DECAPEPTYL DEPOT mikrokapslid süstimiseks 3,75mg+lahusti N1 | Ferring GmbH | 50% | |||||||
| 1071144 | triptoreliin | L02AE04 | DECAPEPTYL DEPOT mikrokapslid süstimiseks 3,75mg+lahusti N3 | Ferring GmbH | 50% | |||||||
| 1012868 | triptoreliin | L02AE04 | DIPHERELINE 0,1 MG injektsioonisubstants 0,1mg N7+lahusti 1 ml N7 | Beaufour Ipsen International | 50% | |||||||
| 1040397 | triptoreliin | L02AE04 | DIPHERELINE 3,75 MG injektsioonisubstants 3,75mg N1+lahusti N1 | Beaufour Ipsen International | 50% | 75% | N80; E22.8* | rv günekoloogil III-IV astme endometrioosi põdevatele patsientidele, soodustus ei kehti enne hinnakokkuleppe jõustumist; *rv endokrinoloogil ja pediaatril, soodustus ei kehti enne hinnakokkuleppe jõustumist. | ||||
| 1007963 | tromantadiin | D06BB02 | VIRU-MERZ SEROL, GEL geel 1% 2g N1 | Merz Pharmaceuticals GmbH | 50% | |||||||
| 1061671 | tromantadiin | D06BB02 | VIRU-MERZ SEROL, GEL geel 1% 5g N1 | Merz Pharmaceuticals GmbH | 50% | |||||||
| 1123850 | tropikamiid | S01FA06 | MYDRIACYL silmatilgad, lahus 0,5% 15ml N1 | s.a. ALCON- COUVREUR n.v. | 50% | |||||||
| 1042399 | tropisetroon | A04AA03 | NAVOBAN 2 MG/2 ML süstelahus 2mg 2ml 2ml N1 | Novartis Finland OY | 50% | |||||||
| 1002643 | tropisetroon | A04AA03 | NAVOBAN 5 MG/5 ML süstelahus 1mg/ml 5ml N1 | Novartis Finland OY | 50% | |||||||
| 1063099 | tropisetroon | A04AA03 | NAVOBAN 5 MG/5 ML süstelahus 1mg/ml 5ml N10 | Novartis Finland OY | 50% | |||||||
| 1002698 | tropisetroon | A04AA03 | NAVOBAN kapsel 5mg N5 | Novartis Finland OY | 50% | |||||||
| 1090123 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trospium | G04BD80 | SPASMED (SPASMEX) 5 tablett 5 mg N30 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1090134 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trospium | G04BD80 | SPASMED 5 tablett 5 mg N50 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1090145 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trospium | G04BD80 | SPASMED 5 tablett 5 mg N100 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1090189 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trospium | G04BD80 | SPASMED 15 kaetud tablett 15 mg N30 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1090190 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trospium | G04BD80 | SPASMED 15 tablett 15 mg N50 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1090202 [RTL 2006, 26, 482 – jõust. 1.04.2006] | trospium | G04BD80 | SPASMED 15 tablett 15 mg N100 | PRO. MED. CS. PRAHA a.s. | 50% | |||||||
| 1067330 [RTL 2006, 26, 482 – | tsefadroksiil | J01DB05 | DURACEF kapsel 250mg N100 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| jõust. 1.04.2006] | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | ||||||
| 1027123 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF kapsel 250mg N12 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1067329 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF kapsel 250mg N50 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1067352 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF kapsel 500mg N100 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1027134 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF kapsel 500mg N12 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1067341 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF kapsel 500mg N50 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1025064 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF lahustuv tablett 1g N10 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1067318 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF suspensioonigraanulid 50mgml 100ml N1 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1027101 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefadroksiil | J01DB05 | DURACEF suspensioonigraanulid 50mgml 60ml N1 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1012992 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefaleksiin | J01DB01 | CEFALEKSINS kapsel 500mg N20 | Grindeks | 50% | |||||||
| 1043086 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1043097 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1019203 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1066991 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefaleksiin | J01DB01 | OSPEXIN 500 MG CAPSULES kapsel 500mg N12 | Biochemie GmbH | 50% | |||||||
| 1068319 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefprosiil | J01DC10 | CEFZIL suspensioonigraanulid 50mgml 100ml N1 | Bristol-Myers Squibb Eesti AS | 50% | (5) | ||||||
| 1028506 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefprosiil | J01DC10 | CEFZIL suspensioonigraanulid 50mgml 60ml N1 | Bristol-Myers Squibb Eesti AS | 50% | (5) | ||||||
| 1068320 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefprosiil | J01DC10 | CEFZIL tablett 250mg N10 | Bristol-Myers Squibb Eesti AS | 50% | (5) | ||||||
| 1068375 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefprosiil | J01DC10 | CEFZIL tablett 500mg N10 | Bristol-Myers Squibb Eesti AS | 50% | (5) | ||||||
| 1137350 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefuroksiim | J01DC02 | ZINNAT suspensioonigraanulid 25mgml 100ml N1 | Glaxo Group Ltd. | 50% | (5) | ||||||
| 1007198 | ||||||||||||
| [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefuroksiim | J01DC02 | ZINNAT suspensioonigraanulid 25mgml 50ml N1 | Glaxo Group Ltd. | 50% | (5) | ||||||
| --- | --- | --- | --- | --- | --- | --- | ||||||
| 1007110 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefuroksiim | J01DC02 | ZINNAT tablett 250mg N10 | Glaxo Group Ltd. | 50% | (5) | ||||||
| 1007143 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsefuroksiim | J01DC02 | ZINNAT tablett 500mg N10 | Glaxo Group Ltd. | 50% | (5) | ||||||
| 1073630 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N10 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073696 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N100 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1009909 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N2 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073641 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N20 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073652 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073663 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N40 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073674 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N50 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073629 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N6 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073685 | tselekoksiib | M01AH01 | CELEBREX kapsel 100mg N60 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073731 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N10 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073797 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N100 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1009910 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N2 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073742 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N20 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073753 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N30 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073764 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N40 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073775 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N50 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073720 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N6 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1073786 | tselekoksiib | M01AH01 | CELEBREX kapsel 200mg N60 | Pfizer H.C.P. Corporation | 50% | |||||||
| 1098918 | tsetirisiin | R06AE07 | CETIRIZINE ALPHARMA TABLETS 10 MG tabletid 10 mg N30 | ALPHARMA Limited | 50% | |||||||
| 1092068 | tsetirisiin | R06AE07 | LETIZEN tablett 10mg N20 | KRKA, d.d. | 50% | |||||||
| 1092079 | tsetirisiin | R06AE07 | LETIZEN tablett 10mg N30 | KRKA, d.d. | 50% | |||||||
| 1083068 | tsetirisiin | R06AE07 | ZODAC tablett 10mg N30 | LÉCIVA a.s. | 50% | |||||||
| 1077847 | tsetirisiin | R06AE07 | ZYRTEC tablett 10mg N100 | UCB Pharma Oy Finland | 50% | |||||||
| 1077836 | tsetirisiin | R06AE07 | ZYRTEC tablett 10mg N30 | UCB Pharma Oy Finland | 50% | |||||||
| 1022869 | tsetirisiin | R06AE07 | ZYRTEC tilgad 10mg/ml 20ml N1 | UCB Pharma Oy Finland | 50% | |||||||
| 1121870 | tsetirisiin | R06AE07 | ACETERIN kaetud tablett 10 mg N30 | Hexal AG | 50% | |||||||
| 1141311 | tsetirisiin+pseudoefedriin | R06AE81 | CIRRUS prolong tablett 5mg+120mg N14 | UCB Pharma Oy Finland | 50% | |||||||
| 1043356 | tsetroreliks | H01CC02 | CETROTIDE 0,25 MG injektsioonisubstants 0,25mg viaal N1+1 ml lahustiga täidetud süstal N1 | Serono Europe Ltd | 50% | |||||||
| 1064696 | tsetroreliks | H01CC02 | CETROTIDE 0,25 MG injektsioonisubstants 0,25mg viaal N7+1 ml lahustiga täidetud süstal N7 | Serono Europe Ltd | 50% | |||||||
| 1043367 | tsetroreliks | H01CC02 | CETROTIDE 3 MG injektsioonisubstants 3mg viaal N1+3 ml lahustiga täidetud süstal N1 | Serono Europe Ltd | 50% | |||||||
| 1092833 | tsimetidiin | A02BA01 | CIMETIDINS 200 MG tablett | Grindeks | 50% | |||||||
| 200mg N60 | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |||
| 1013768 | tsimetidiin | A02BA01 | CIMETIDINS 400 MG tablett 400mg N30 | Grindeks | 50% | |||||||
| 1001080 | tsimetidiin | A02BA01 | ULCOMET 200 tablett 200mg N100 | Medochemie Ltd. | 50% | |||||||
| 1008975 | tsinnarisiin | N07CA02 | STUGERON FORTE kapsel 75mg N20 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1008953 | tsinnarisiin | N07CA02 | STUGERON tablett 25mg N50 | Janssen Pharmaceutica N.V. | 50% | |||||||
| 1019944 | tsiprofibraat | C10AB08 | LIPANOR kapsel 100mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | |||||||
| 1041455 | tsiprofloksatsiin | J01MA02 | BACTIFLOX-250 tablett 250mg N10 | Mepha LDA | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1041466 | tsiprofloksatsiin | J01MA02 | BACTIFLOX-500 tablett 500mg N10 | Mepha LDA | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1038372 | tsiprofloksatsiin | J01MA02 | CIFLOXINAL tablett 250mg N10 | PRO. MED. CS. PRAHA a.s. | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1070895 | tsiprofloksatsiin | J01MA02 | CIFLOXINAL tablett 250mg N20 | PRO. MED. CS. PRAHA a.s. | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1005488 | tsiprofloksatsiin | J01MA02 | CIPRINOL 250 tablett 250mg N10 | KRKA, d.d. | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1005545 | tsiprofloksatsiin | J01MA02 | CIPRINOL 500 tablett 500mg N10 | KRKA, d.d. | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1070738 | tsiprofloksatsiin | J01MA02 | CIPROXIN tablett 250mg N20 | Bayer AG | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1001934 | tsiprofloksatsiin | J01MA02 | CIPROXIN tablett 500mg N10 | Bayer AG | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1042827 | tsiprofloksatsiin | S01AX13 | CILOXAN silmatilgad 0,3% 5 ml N1 | Alcon | 50% | |||||||
| 1038248 | tsiprofloksatsiin | J01MA02 | CIFRAN kaetud tablett 500 mg N10 | Ranbaxy UK Ltd | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1038237 | tsiprofloksatsiin | J01MA02 | CIFRAN kaetud tablett 250 mg N10 | Ranbaxy UK Ltd | 50% | 100% | (D60- D64); E84* | rv hematoloogil ja pediaatril; *rv pulmonoloogil ja pediaatril | ||||
| 1023534 | tsitalopraam | N06AB04 | CIPRAMIL 10 MG tablett 10mg N14 | H. Lundbeck AS | 50% | |||||||
| 1070503 | tsitalopraam | N06AB04 | CIPRAMIL 10 MG tablett 10mg N28 | H. Lundbeck AS | 50% | |||||||
| 1006265 | tsitalopraam | N06AB04 | CIPRAMIL 20 MG tablett 20 mg N14 | H. Lundbeck AS | 50% | |||||||
| 1070525 | tsitalopraam | N06AB04 | CIPRAMIL 20 MG tablett 20 mg N28 | H. Lundbeck AS | 50% | |||||||
| 1070547 | tsitalopraam | N06AB04 | CIPRAMIL 20 MG tablett 20 mg N100 | H. Lundbeck AS | 50% | |||||||
| 1083552 | tsitalopraam | N06AB04 | CITALEC 10 tablett 10 mg N30 | Leciva a.s. | 50% | |||||||
| 1083563 | tsitalopraam | N06AB04 | CITALEC 20 tablett 20 mg N30 | Leciva a.s. | 50% | |||||||
| 1112937 | tsitalopraam | N06AB04 | CIRAL 20 tablett 20 mg N28 | Hexal AG | 50% | |||||||
| 1106772 | tsitalopraam | N06AB04 | CIRAL 30 tablett 30 mg N28 | Hexal AG | 50% | |||||||
| 1106806 | tsitalopraam | N06AB04 | CIRAL 40 tablett 40 mg N28 | Hexal AG | 50% | |||||||
| 1138698 | tsitalopraam | N06AB04 | CIRAL 60 tablett 60 mg N14 | Hexal AG | 50% | |||||||
| 1105759 | tsitalopraam | N06AB04 | CITALOPRAM ALPHARMA TABLETS 20MG tablett 20 mg N30 | Alpharma Limited | 50% | |||||||
| 1109551 | tsitalopraam | N06AB04 | PRAM 10 MG tablett 10 mg N28 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1109517 | tsitalopraam | N06AB04 | PRAM 20 MG tablett 20 mg N28 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1109472 | tsitalopraam | N06AB04 | PRAM 40 MG tablett 40 mg N28 | LANNACHER HEILMITTEL GmbH | 50% | |||||||
| 1152874 | tsitalopraam | N06AB04 | ZYLORAM 10 MG TABLETS kaetud tabletid 10 mg N28 | Ranbaxy UK Ltd | 50% | |||||||
| 1152986 | tsitalopraam | N06AB04 | ZYLORAM 20 MG TABLETS kaetud tabletid 20 mg N28 | Ranbaxy UK Ltd | 50% | |||||||
| 1153088 | tsitalopraam | N06AB04 | ZYLORAM 40 MG TABLETS kaetud tabletid 40 mg N28 | Ranbaxy UK Ltd | 50% | |||||||
| 1151851 | tsitalopraam | N06AB04 | CITALON kaetud tabletid 40 mg N28 | Sandoz GmbH | 50% | |||||||
| 7000175 | tsitrulliin | V06CA80 | L-CITRULLINE 100 g | SHS International | 50% | |||||||
| M05; M06; | ||||||||||||
| 1021790 | tsüklofosfamiid | L01AA01 | ENDOXAN kaetud tablett 50mg N50 | Baxter Oncology GmbH | 50% | 75% | M08; (M30- M33); M35; M45; M46; (N00- N08)* | rv reumatoloogil ja pediaatril; *rv nefroloogil ja pediaatril | 100% | (C00-D48)* | *rv onkoloogil, hematoloogil ja pediaatril | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1001608 | tsüklofosfamiid | L01AA01 | SYKLOFOSFAMID tablett 50mg N100 | ORION CORPORATION ORION PHARMA | 50% | 75% | M05; M06; M08; (M30- M33); M35; M45; M46; (N00- N08)* | rv reumatoloogil ja pediaatril; *rv nefroloogil ja pediaatril | 100% | (C00-D48)* | *rv onkoloogil, hematoloogil ja pediaatril | |
| 1123760 | tsüklopentolaat | S01FA04 | CYCLOGYL silmatilgad 1% 15ml N1 | s.a. ALCON- COUVREUR n.v. | 50% | |||||||
| 1008559 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | SANDIMMUN NEORAL kapsel 100mg N50 | Novartis Finland OY | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1008526 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | SANDIMMUN NEORAL kapsel 25mg N50 | Novartis Finland OY | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1008548 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | SANDIMMUN NEORAL kapsel 50mg N50 | Novartis Finland OY | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1008504 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | SANDIMMUN NEORAL suukaudne lahus 100mg/ml 50ml N1 | Novartis Finland OY | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1098828 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | EQUORAL 25 MG kapsel 25 mg N50 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1098839 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | EQUORAL 50 MG kapsel 50 mg N50 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1098840 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | EQUORAL 100 MG kapsel 100 mg N50 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1113231 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | CICLOHEXAL 25 kapsel 25 mg N50 | Hexal AG | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1113253 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | CICLOHEXAL 50 kapsel 50 mg N50 | Hexal AG | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1113264 [RTL 2006, 26, 482 – jõust. 1.04.2006] | tsüklosporiin | L04AA01 | CICLOHEXAL 100 kapsel 100 mg N50 | Hexal AG | 50% | 75% | L40; M05; M06; M07; M08; (M30- M33); M35; M45; M46** | rv dermatoveneroloogil, reumatoloogil ja pediaatril, *rv reumatoloogil ja pediaatril | 100% | (D60- D64)*; T86 | *rv hematoloogil ja pediaatril | |
| 1117628 [Kehtetu - RTL 2006, 26, 482 – jõust. 1.04.2006] | ||||||||||||
| 1064124 | tsüproteroon | G03HA01 | ANDROCUR 50 tablett 50mg N50 | Schering AG | 50% | 100% | (C00-D48)* | *rv hematoloogil, onkoloogil ja uroloogil | ||||
| 1018370 | tsüproteroon+östrogeen | G03HB01 | CLIMEN tablett 1 mg+2 mg N10; 2 mg N11 | Schering AG | 50% | |||||||
| 1014488 | tsüproteroon+östrogeen | G03HB01 | DIANE-35 tablett 2mg+0,035mg N21 | Schering AG | 50% | |||||||
| 1122084 | tsüproteroon+östrogeen | G03HB01 | FEMINA-35 tablett 2 mg+35 mcg N21 | Nycomed Sefa AS | 50% | |||||||
| 1040779 | Tõrvade segu | D05AA84 | POLYTAR LIQUID paikne lahus 1% 150ml N1 | Stiefel Laboratoires UK Ltd | 50% | 75% | L40; M07 | |||||
| 1040768 | Tõrvade segu+tsinkpüritioon | D05AA82 | FONGITAR shampoon 1%+1% 150ml N1 | Stiefel Laboratoires UK Ltd | 50% | 75% | L40; M07 | |||||
| 1069477 | uratsiil+tegafuur | L01BC80 | UFT kapsel 224mg N120 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1027156 | uratsiil+tegafuur | L01BC80 | UFT kapsel 224mg N28 | Bristol-Myers Squibb Eesti AS | 50% | |||||||
| 1063101 | ursodeoksühoolhape | A05AA02 | URSOFALK CAPSULES kapsel 250mg N100 | Dr. Falk Pharma GmbH | 50% | 75% | K73; K74 | *rv gastroenteroloogil ja pediaatril | ||||
| 1044818 | ursodeoksühoolhape | A05AA02 | URSOFALK CAPSULES kapsel 250mg N50 | Dr. Falk Pharma GmbH | 50% | 75% | K73; K74 | *rv gastroenteroloogil ja pediaatril | ||||
| 1088489 | ursodeoksühoolhape | A05AA02 | URSOSAN kapsel 250mg N10 | PRO. MED. CS. PRAHA a.s. | 50% | 75% | K73; K74 | *rv gastroenteroloogil ja pediaatril | ||||
| 1016985 | ursodeoksühoolhape | A05AA02 | URSOSAN kapsel 250mg N50 | PRO. MED. CS. PRAHA a.s. | 50% | 75% | K73; K74 | *rv gastroenteroloogil ja pediaatril | ||||
| 1012532 | valatsükloviir | J05AB11 | VALTREX tablett 250mg N60 | Glaxo Wellcome Operations | 50% | |||||||
| 1016301 | valatsükloviir | J05AB11 | VALTREX tablett 500mg N10 | Glaxo Wellcome Operations | 50% | |||||||
| 1086555 | valproehape | N03AG01 | DEPAKINE CHRONO 300 retardtablett 300mg N100 | SANOFI- SYNTHELABO FRANCE | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1086544 | valproehape | N03AG01 | DEPAKINE CHRONO 500 retardtablett 500mg N30 | SANOFI- SYNTHELABO FRANCE | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| (F00-F09)*; (F10-F19.4- | ||||||||||||
| 1108246 | valproehape | N03AG01 | ORFIRIL 150 gastroresistentne tablett 150mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40** | rev psühhiaatril; *rev neuroloogil | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1108257 | valproehape | N03AG01 | ORFIRIL 300 gastroresistentne tablett 300mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1108268 | valproehape | N03AG01 | ORFIRIL 600 gastroresistentne tablett 600mg N50 | Desitin Arzneimittel GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1078185 | valproehape | N03AG01 | ORFIRIL LONG 1000 MG prolong gran 1000mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1076419 | valproehape | N03AG01 | ORFIRIL LONG 150 MG prolong kapsel 150mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1077308 | valproehape | N03AG01 | ORFIRIL LONG 300 MG prolong kapsel 300mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1076341 | valproehape | N03AG01 | ORFIRIL LONG 500 MG prolong gran 500mg N100 | Desitin Arzneimittel GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1025536 | valproehape | N03AG01 | ORFIRIL SAFT 60mg/ml 250ml N1 | Desitin Arzneimittel GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1043592 | valproehape | N03AG01 | CONVULEX kapslid 150 mg | Gerot Pharmazeutika | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); | rev psühhiaatril; *rev | ||||
| N100 | GmbH | (F32/33.2- 3); F60.3; (F70-79); G40* | neuroloogil | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |
| 1043604 | valproehape | N03AG01 | CONVULEX kapslid 300 mg N100 | Gerot Pharmazeutika GmbH | 50% | 100% | (F00-F09); (F10-F19.4- 7); (F20- F29); (F30-F31); (F32/33.2- 3); F60.3; (F70-79); G40* | rev psühhiaatril; *rev neuroloogil | ||||
| 1113017 | valproehape | N03AG01 | DEPAKINE siirup 50 mg/ml 150 ml | SANOFI- SYNTHELABO FRANCE | 50% | 100% | G40** | **rev neuroloogil | ||||
| 1092844 | valsartaan | C09CA03 | DIOVAN kaetud tablett 160mg N28 | Novartis Finland OY | 50% | |||||||
| 1092877 | valsartaan | C09CA03 | DIOVAN kaetud tablett 80mg N28 | Novartis Finland OY | 50% | |||||||
| 1086027 | valsartaan+hüdroklorotiasiid | C09DA03 | CO-DIOVAN tablett 160mg+12,5mg N28 | Novartis Finland OY | 50% | |||||||
| 1086072 | valsartaan+hüdroklorotiasiid | C09DA03 | CO-DIOVAN tablett 160mg+25mg N28 | Novartis Finland OY | 50% | |||||||
| 1031342 | valsartaan+hüdroklorotiasiid | C09DA03 | CO-DIOVAN kaetud tablett 80mg+12,5mg N28 | Novartis Finland OY | 50% | |||||||
| 1008368 | varfariin | B01AA03 | MAREVAN FORTE tablett 5mg N100 | ORION CORPORATION ORION PHARMA | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | 100% | I26; T82 | ||
| 1008335 | varfariin | B01AA03 | MAREVAN tablett 3mg N100 | ORION CORPORATION ORION PHARMA | 50% | 75% | (I47-I49)* | *rev kardioloogil ja pediaatril | 100% | I26; T82 | ||
| 1027741 | venlafaksiin | N06AX16 | EFEXOR 37,5 MG tablett 37,5mg N28 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1111004 | venlafaksiin | N06AX16 | EFEXOR 37,5 MG tablett 37,5mg N30 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1111015 | venlafaksiin | N06AX16 | EFEXOR 37,5 MG tablett 37,5mg N56 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1111026 | venlafaksiin | N06AX16 | EFEXOR 37,5 MG tablett 37,5mg N60 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1044661 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 150mg N14 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1068791 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 150mg N28 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1068803 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 150mg N98 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1011519 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 37,5mg N30 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1068780 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 37,5mg N60 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1044650 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 75mg N14 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1068858 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 75mg N28 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1068869 | venlafaksiin | N06AX16 | EFEXOR XR retardkapsel 75mg N98 | WYETH LEDERLE PHARMA GmbH | 50% | |||||||
| 1073157 | verapamiil | C08DA01 | ISOPTIN RETARD 120 MG retardtablett 120mg N100 | Abbott GmbH & Co. KG | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1017267 | verapamiil | C08DA01 | ISOPTIN RETARD 120 MG retardtablett 120mg N20 | Abbott GmbH & Co. KG | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1073146 | verapamiil | C08DA01 | ISOPTIN RETARD 120 MG retardtablett 120mg N50 | Abbott GmbH & Co. KG | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1073180 | verapamiil | C08DA01 | ISOPTIN RETARD retardtablett 240mg N100 | Abbott GmbH & Co. KG | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1017278 | verapamiil | C08DA01 | ISOPTIN RETARD retardtablett 240mg N20 | Abbott GmbH & Co. KG | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1073179 | verapamiil | C08DA01 | ISOPTIN RETARD retardtablett 240mg N50 | Abbott GmbH & Co. KG | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1073203 | verapamiil | C08DA01 | ISOPTIN tablett 40mg N100 | Abbott GmbH & Co. KG | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1017245 | verapamiil | C08DA01 | ISOPTIN tablett 40mg N20 | Abbott GmbH & Co. KG | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1073191 | verapamiil | C08DA01 | ISOPTIN tablett 40mg N50 | Abbott GmbH & Co. KG | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||
| 1073225 | verapamiil | C08DA01 | ISOPTIN tablett 80mg N100 | Abbott GmbH & Co. KG | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1017256 | verapamiil | C08DA01 | ISOPTIN tablett 80mg N20 | Abbott GmbH & Co. KG | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1073214 | verapamiil | C08DA01 | ISOPTIN tablett 80mg N50 | Abbott GmbH & Co. KG | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1073405 | verapamiil | C08DA01 | VERAPAMIL- RATIOPHARM N 80 tablett 80mg N50 | ratiopharm GmbH | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1002182 | verapamiil | C08DA01 | VERAPAMIL-RATIOPHARM N 40 tablett 40mg N20 | ratiopharm GmbH | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1073427 | verapamiil | C08DA01 | VERAPAMIL-RATIOPHARM N 40 tablett 40mg N50 | ratiopharm GmbH | 50% | 75% | (I47-I49)* | *rev kardioloogil | ||||
| 1073090 | verapamiil | C08DA01 | VEROGALID ER 240 MG retardtablett 240mg N100 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1009550 | verapamiil | C08DA01 | VEROGALID ER 240 MG retardtablett 240mg N30 | IVAX Pharmaceuticals s.r.o. | 50% | 75% | (I10-I13); I15; (I47- I49)* | *rev kardioloogil | ||||
| 1074675 | verapamiil+trandolapriil | C08DA80 | TARKA retardkapsel 180mg+2mg N14 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074686 | verapamiil+trandolapriil | C08DA80 | TARKA retardkapsel 180mg+2mg N28 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074697 | verapamiil+trandolapriil | C08DA80 | TARKA retardkapsel 180mg+2mg N30 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074709 | verapamiil+trandolapriil | C08DA80 | TARKA retardkapsel 180mg+2mg N50 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074710 | verapamiil+trandolapriil | C08DA80 | TARKA retardkapsel 180mg+2mg N56 | Abbott GmbH & Co. KG | 50% | |||||||
| 1074721 | verapamiil+trandolapriil | C08DA80 | TARKA retardkapsel 180mg+2mg N98 | Abbott GmbH & Co. KG | 50% | |||||||
| 1075159 | vismutsubtsitraat | A02BX05 | DE-NOL tablett 120mg N120 | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1020687 | vismutsubtsitraat | A02BX05 | DE-NOL tablett 120mg N40 | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1075148 | vismutsubtsitraat | A02BX05 | DE-NOL tablett 120mg N60 | YAMANOUCHI EUROPE B.V. | 50% | |||||||
| 1063437 | östradiool | G03CA03 | CLIMARA TTS 3,9mg N12 | Schering AG | 50% | |||||||
| 1026672 | östradiool | G03CA03 | CLIMARA TTS 3,9mg N4 | Schering AG | 50% | |||||||
| 1029068 | östradiool | G03CA03 | DERMESTRIL 50 TTS 4 mg (50 mcg/24h) N8 | ROTTAPHARM S.r.I | 50% | |||||||
| 1030510 | östradiool | G03CA03 | DIVIGEL geel 1mg/g 0.5g N28 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1063415 | östradiool | G03CA03 | DIVIGEL geel 1mg/g 1g N28 | ORION CORPORATION ORION PHARMA | 50% | |||||||
| 1002328 | östradiool | G03CA03 | ESTRADERM TTS 100 TTS 100mcg 24h N6 | Novartis Finland OY | 50% | |||||||
| 1143728 | östradiool | G03CA03 | ESTRADERM TTS 25 TTS 25mcg 24h N6 | Novartis Finland OY | 50% | |||||||
| 1002407 | östradiool | G03CA03 | ESTRADERM TTS 50 TTS 50mcg 24h N6 | Novartis Finland OY | 50% | |||||||
| 1089154 | östradiool | G03CA03 | ESTRIMAX tablett 2 mg N28 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1089165 | östradiool | G03CA03 | ESTRIMAX tablett 2 mg N28x3 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1030442 | östradiool | G03CA03 | ESTROFEM tablett 1mg N28 | Novo Nordisk A/S | 50% | |||||||
| 1030431 | östradiool | G03CA03 | ESTROFEM tablett 2mg N28 | Novo Nordisk A/S | 50% | |||||||
| 1000102 | östradiool | G03CA03 | ESTROGEL geel 0,06% 80g N1 | Leiras OY | 50% | |||||||
| 1063460 | östradiool | G03CA03 | LINOLADIOL N kreem 0,01%/g 100g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1031746 | östradiool | G03CA03 | LINOLADIOL N kreem 0,01%/g 25g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1063459 | östradiool | G03CA03 | LINOLADIOL N kreem 0,01%/g 50g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1035896 | östradiool | G03CA03 | VAGIFEM vagin. tablett 25mcg N5x3 | Novo Nordisk A/S | 50% | |||||||
| 1105928 | östradiool+noretisteroon | G03FB05 | TRIAKLIM tablett 2mg N12; 2mg+1mg N10; 1mg N6 (N28) | GEDEON RICHTER Ltd. | 50% | |||||||
| 1105939 | östradiool+noretisteroon | G03FB05 | TRIAKLIM tablett 2mg N12; 2mg+1mg N10; 1mg N6 N28x3 | GEDEON RICHTER Ltd. | 50% | |||||||
| 1030453 | östradiool+noretisteroon | G03FB05 | TRISEQUENS tablett 2 mg+1mg N10; 1mg N6; 2mg N12 | Novo Nordisk A/S | 50% | |||||||
| 1116560 | östradiool+noretisteroon | G03FB05 | NOVOFEM tablett (1mg+1mg N12; 1mg N16) N28 | Novo Nordisk A/S | 50% | |||||||
| LINOLADIOL-H N kreem | DR.AUGUST WOLFF | |||||||||||
| 1031735 | östradiool+prednisoloon | G03CA80 | 0,005%+0,4% 25g N1 | GmbH & Co. | 50% | 95 | ||||||
| --- | --- | --- | --- | --- | --- | --- | ||||||
| 1083170 | östradiool+prednisoloon | G03CA80 | LINOLADIOL-H N kreem 0,005%+0,4% 50g N1 | DR.AUGUST WOLFF GmbH & Co. | 50% | |||||||
| 1021161 | östramustiin | L01XX11 | ESTRACYT kapsel 140mg N100 | Pfizer Enterprises Sarl | 50% | |||||||
| 1022566 | östriool | G03CA04 | OVESTIN vaginaalkreem 1mg/g 15g | N.V. ORGANON | 50% | |||||||
| 1022634 | östriool | G03CA04 | OVESTIN vaginaalsupposiit 0,5mg N15 | N.V. ORGANON | 50% | |||||||
| 1063538 | östriool | G03CA04 | OVESTIN vaginaalsuposiit 0,5mg N30 | N.V. ORGANON | 50% |